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Abstract 
Diabetes is a metabolic disorder dysregulating glucose homeostasis. The role of 
astrocytes in central glucose sensing is poorly understood. But it is recognised they 
take part in whole-body energy homeostasis, specifically as glucose sensors 
necessary for the counterregulatory response (CRR) to hypoglycaemia. Iatrogenic 
hypoglycaemia is the limiting factor to glycaemic control in people with type 1 or type 
2 diabetes. Severe hypoglycaemia occurs approximately once per year, whereas, 
the incidence of minor hypoglycaemia is much greater. Hypoglycaemia impairs 
awareness of future hypoglycaemia and blunts the CRR, eventually causing 
hypoglycaemia-associated autonomic failure. The mechanisms of this process are 
poorly understood. 
This thesis utilised isolated human astrocytes exposed to acute or recurrent low 
glucose (RLG) in vitro to mimic glucose variation in diabetes. Cellular responses 
were characterised of three key astrocyte functions. Firstly, is astrocyte metabolism 
altered by acute and RLG treatment? Secondly, do isolated human astrocytes 
become activated by low glucose treatment, and is this affected by RLG? Thirdly, are 
astrocytic inflammatory pathways altered by acute or RLG? 
The key findings from this thesis shows for the first time that astrocytic mitochondrial 
oxidation is increased following RLG, with a concurrent increase in fatty acid 
dependency but decreased coupling efficiency; glycolytic function is also enhanced. 
Together, this indicates that astrocytes successfully adapt to low glucose to sustain 
intracellular nucleotide ratios. Contrary to previous work, these human astrocytes do 
not respond to low glucose by Ca2+-dependent activation. However, the astrocytes 
do increase inflammatory cytokine release following acute and RLG. Lastly, for the 
first time an RNA-sequencing approach has been used to identify low glucose-
induced differential gene expression. Together these findings support the argument 
that astrocytes are sensitive to low glucose and may be important in glucose 
sensation and the CRR. 
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HERPUD1 Homocysteine inducible ER protein with ubiquitin like domain 1 
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KI Knock-in 
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T2DM Type 2 diabetes mellitus 
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WHO World health organisation 
XBP1 X-box binding protein 1 
ZnT8 Zinc transporter 8 protein 
 
 
26 
 
 
Chapter 1 
 
 
 
Introduction 
  
27 
1.1 Diabetes mellitus 
Diabetes mellitus is an umbrella term used to describe a range of metabolic 
disorders that are characterised by faulty nutrient metabolism and insulin action. 
Diabetes is defined by hyperglycaemia, or high blood glucose levels. The threshold 
for hyperglycaemia is a fasted plasma glucose ≥7.0 mmol/l, or a 2-hour plasma 
glucose concentration after 75 g anhydrous glucose in an oral glucose tolerance test 
of ≥11.1mmol/l, or a random plasma glucose concentration of ≥11.1 mmol/l (Alberti 
et al. 1998). Hyperglycaemia also results in the classical symptoms of diabetes; 
polydipsia, polyuria, vision impairment, fatigue and nausea, as well as other severe 
symptoms (Alberti et al. 1998). Globally, diabetes prevalence in adults was 
estimated to be 8.8% in 2015 (Ogurtsova et al. 2017). The incidence of diabetes, 
globally, is predicted to increase to an estimated 10.4% in 2040 (Ogurtsova et al. 
2017). In the United Kingdom, diabetes affects approximately 10% of adults, with an 
estimated cost of £23.7 billion, in 2011 (Hex et al. 2012). With a further 17% 
estimated increase by 2036 with associated costs of £22.9 billion (Hex et al. 2012). 
Diabetes is commonly thought of as including type 1 diabetes mellitus (T1DM), type 
2 diabetes mellitus (T2DM) and gestational diabetes mellitus (GDM). However, an 
international committee of experts solidified the definitions of the subtypes of the 
diabetes syndrome (ADA 2014). T1DM, T2DM and GDM are listed as polygenic 
disorders; where environmental factors are involved in disease pathogenesis. 
However, a fourth group contains “other specific types” of diabetes that includes 8 
sub-categories within which are several members (ADA 2014). These other specific 
types include monogenic triggered diabetes, known as maturity onset diabetes of the 
young (MODY), as well as drug-induced pancreatic damage resulting in diabetes. 
T2DM is the most common subtype accounting for 90.4% of cases, whereas T1DM 
and other specific types account for 8.5% and 1.2% respectively, in the UK (Holman 
et al. 2015). 
1.1.1 Type 2 diabetes mellitus 
The pathogenesis of T2DM is principally characterised by insulin resistance resulting 
in an inability to reduce blood glucose levels. Insulin is released from the β-cell found 
in the islets of Langerhans within the pancreas (Hoang Do et al. 2015). Insulin is 
released in response to high glucose (mechanisms discussed in section 1.3.1). Once 
released, insulin binds to insulin receptors found in the muscle, liver, adipose tissue, 
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and the brain among others to increase glucose uptake, glycogen synthesis, and 
lipogenesis; and to decrease food intake, gluconeogenesis and lipolysis (Taniguchi 
et al. 2006). In T2DM, insulin sensitivity is lost resulting in reduced glucose uptake by 
the muscle and suppression of glucose production particularly in the liver (Stumvoll 
et al. 2005). 
While the precise mechanisms of insulin resistance remain unknown, obesity 
correlates with the onset of insulin resistance and subsequent T2DM (Bastard et al. 
2006). Obesity is a condition where the body has large fat deposits due to excess 
caloric intake relative to energy expenditure. Lipids are primarily stored in adipocytes 
of white adipocyte tissue (WAT) as triglycerides (Trayhurn 2007). In the absence of 
food intake the triglycerides are metabolised and released as fatty acids which can 
be an energy substrate for other cells. However, this occurs in excess during obesity. 
The release of fatty acids, the most common being palmitate, has been shown to 
impair insulin sensitivity (Vessby et al. 1994) and decrease insulin-stimulated 
glucose uptake in skeletal muscle (Roden et al. 1996) and liver (Boden 1997). Aside 
from subcutaneous adiposity, ectopic fat storage is also important for insulin 
resistance (Danforth Jr 2000). Both intramyocellular (Machann et al. 2004) and 
intrahepatic (Seppälä-Lindroos et al. 2002, Bajaj et al. 2003) lipids are associated 
with insulin resistance. 
To compensate for a lack of insulin action, insulin secretion from β-cells increases to 
compensate (Wilcox 2005). Prolonged hyperglycaemia results in β-cell hyperplasia 
increasing the β-cell mass and therefore increasing the insulin producing capacity of 
the pancreas (Bonner-Weir et al. 1989). While this initial compensatory 
hyperinsulinaemia compensates for insulin insensitivity, β-cell dysfunction eventually 
occurs. People with a family history of diabetes sometimes fail to display this initial β-
cell compensatory response to the onset of insulin resistance (Elbein et al. 2000). 
This highlights that while lifestyle and environmental factors are triggering 
pathogenic drivers, genetic factors also impact the likelihood of diabetes. Indeed, 
monozygotic and dizygotic twin studies have been used to demonstrate a heritable 
genetic risk for diabetes (Stumvoll et al. 2005). 
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1.1.2 Type 1 diabetes mellitus 
While T1DM also results in hyperglycaemia, like T2DM, this is due to an absolute 
lack of insulin production rather than action. T1DM is an autoimmune disorder 
characterised by the destruction of the pancreatic β-cell, thus ablating insulin 
production. The resulting failure to suppress gluconeogenesis and increase glucose 
uptake results in fasted hyperglycaemia. At disease onset, auto-reactive T cells 
mediate the destruction of β-cells (Tsai et al. 2008, Willcox et al. 2009). Indeed, islet-
cell auto-antibodies are present and are a positive indicator of T1DM risk (Pihoker et 
al. 2005). Glutamic acid decarboxylase (GAD), islet antigen 2 (IA-2), insulin, and zinc 
transporter 8 protein (ZnT8) are the four most commonly found auto-antibodies at 
disease onset (Atkinson et al. 2001). 
Despite the understanding that, predominantly, T-cells mediate β-cell destruction, the 
precise triggers remain unknown. In 1866, it was first suggested that T1DM may be 
hereditary (Harley 1866). This observation is confirmed by genome wide association 
studies (GWAS) that show many genes to increase risk of T1DM (Jerram et al. 
2017), many of which are linked to immune function (Mehers et al. 2008). 
While T1DM susceptibility is influenced by genetic factors, there is only a 50% 
concordance between monozygotic twins in developing T1DM (Metcalfe et al. 2001). 
Therefore, environmental factors must be involved in initiating disease onset. One 
such factor may be enteroviral infection which was found in 61% of recently 
diagnosed T1DM patients (Richardson et al. 2009). Other factors proposed include 
changes in gut health and microbiota (Vaarala et al. 2008, Knip et al. 2012), as well 
as vitamin D deficiency (Cantorna et al. 2004). While there are multiple factors 
involved it remains unclear the relative importance of each in influencing disease 
aetiology. Therefore, genetic risk factors remain most important in predicting onset of 
T1DM (Concannon et al. 2009). 
1.2 Pancreas 
All forms of diabetes result in the same endpoint; hyperglycaemia and associated 
complications. While there are different triggers and mechanisms involved in 
diabetes they revolve around glucose homeostasis dysregulation. Therefore, an 
improved understanding of glucose homeostasis and the cells, tissues, organs and 
organ systems involved is required for the better therapies and potential cures. 
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The pancreas is both an endo- and exocrine organ surrounded by multiple major 
blood vessels that distribute the signalling molecules released (Jouvet et al. 2017). 
Approximately 98% of pancreatic mass is made up of acinar cells which release 
digestive enzymes into the duodenum (Husain et al. 2009). The remaining 2% is 
comprised of the α-, β-, δ-, ε- and PP-cells (Jouvet et al. 2017). In diabetes these are 
of the most importance as the β- and α-cells release the endocrine hormones insulin 
and glucagon respectively. δ-cells are also found in other organs, i.e. the stomach, 
and secrete somatostatin which suppresses insulin and glucagon release (Sacks et 
al. 1977, van der Meulen et al. 2015). ε-cells secrete ghrelin which mediates food 
intake, fat deposition and growth hormone release (Pradhan et al. 2013). Finally, the 
PP-cells release pancreatic polypeptide which autoregulates endocrine function as 
well as gastrointestinal secretion (Kojima et al. 2007). 
1.3 Glucose homeostasis 
Glucose homeostasis is tightly controlled in a healthy person even in states of 
extreme energy expenditure and excess. To mediate glucose homeostasis the 
pancreas releases the hormones insulin and glucagon to decrease or increase blood 
glucose respectively. However, additional neuronal mechanisms exist which regulate 
body weight, metabolism and food intake (Schwartz et al. 2005, Prodi et al. 2006). 
Furthermore, while classically thought of an energy store, adipose tissue is being 
recognised as a regulator of metabolism (Rosen et al. 2006). For example, 
adipocytes release leptin which decreases food intake and enhances energy 
expenditure. A principle target site of leptin function are the leptin receptors found in 
the brain in the mediobasal hypothalamus where it supresses orexigenic and 
activates anorexigenic pathways (Rosen et al. 2006). Lastly, the gastrointestinal tract 
and gut hormones regulates glucose homeostasis as well (Drucker 2007). For 
example, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like 
peptide-1 (GLP1), released from the gut, modulate meal-stimulated insulin secretion 
from β cells in a glucose dependent manner (Drucker et al. 2006). 
While there are several excellent overviews of glucose homeostasis and how it is 
altered by diabetes, (Rosen et al. 2006, Marty et al. 2007, Watts et al. 2010, Jouvet 
et al. 2017), due to the breadth and depth of the literature, a fully comprehensive 
review is not within the scope of this thesis. Instead the following brief review 
presents an outline of peripheral glucose homeostatic mechanisms and focuses 
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more closely on neural regulation of glucose homeostasis. The role of astrocytes and 
their impact on glucose homeostasis will be discussed in detail. 
1.3.1 Glucose homeostasis: insulin release and action 
The release of insulin from β-cells is dependent on sensing elevated glucose 
concentrations. In a healthy human β-cell glucose is uptaken via glucose transporter 
1 (Glut1) and Glut3 (McCulloch et al. 2011). Glucose is metabolised through 
glycolysis and further metabolised by the mitochondria to generate ATP. This 
increases the ATP/ADP ratio in the β-cell. The KATP channel is closed by this 
elevation of ATP depolarising the cell membrane which opens the voltage-gated 
calcium channels (VGCC) allowing the influx of Ca2+ and thus increasing [Ca2+]i. This 
promotes the fusion of insulin granules with the cell membrane and the release of 
the insulin contained within (Orci et al. 1973, Komatsu et al. 2013). 
β-cell insulin release is also modulated by fatty acids and amino acids. For example, 
L-glutamate, in isolation, does not alter insulin release, but enhances insulin 
secretion in the presence of L-leucine (Newsholme et al. 2006, Newsholme et al. 
2014). Fatty acids can regulate insulin release from β-cells in three known distinct 
pathways. Firstly, fatty acid metabolism contributes to ATP production, through 
mitochondrial metabolism, closing KATP channels (Prentki et al. 2013). Secondly, 
long-chain fatty acids (LCFA) can directly activated the G-protein coupled receptor 
(GPCR) 40 (GPCR40), found in β-cells, to increase insulin release (Mancini et al. 
2013). Lastly, during fatty acid metabolism, monoacylglycerol (MAG) is produced 
with activates Munc13-1, an insulin granule exocytosis activator [14]. 
Non-pancreas derived hormones such as the incretins regulate β-cell metabolism. 
Incretins include GLP-1, and GIP, secreted by K and L cells respectively in the gut 
(Meier et al. 2005). While GLP-1 augments insulin secretion, and suppresses 
glucagon secretion from α-cells, GIP increases glucagon secretion (Meier et al. 
2003). 
Released insulin acts across the body to enhance energy consumption and suppress 
energy production. Insulin receptors are found throughout the body, including the 
brain, liver, adipose, and muscle (Ullrich et al. 1985). When insulin binds to the 
receptor, the α-subunit conformationally changes allowing for β-subunit auto-
phosphorylation and phosphorylation of insulin receptor substrates (IRS). Once the 
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α-subunit of the β-subunit auto-phosphorylates and further phosphorylates IRS. This 
activates mitogen-activated protein (MAP) kinase signalling pathway as well as the 
phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB) signalling pathway 
which regulates cell growth, gene expression, lipogenesis, glycogenesis and glucose 
uptake (Frasca et al. 2008). 
Insulin also decreases blood glucose by increasing glycogen storage in a process 
known as glycogenesis. Upon binding to the insulin receptor, the subsequent 
activation of protein kinase C (PKC) disinhibits glycogen synthase by inhibiting its 
phosphorylation by glycogen synthase kinase 3-β (GSK3-β) (Lochhead et al. 2001). 
The principle sites of glycogen storage are in the liver and muscle (Wasserman 
2009). However, glycogen stores are also found in the brain in astrocytes (Brown 
2004). These small cerebral stores of glycogen can also be increased by insulin 
stimulation (Muhič et al. 2015). It is generally considered that insulin enters the brain 
from the periphery and originates from the pancreas via insulin-receptor mediated 
active transport (Schwartz et al. 1992, Baura et al. 1993, Woods et al. 2003, Banks 
2004). However, based on analysis of cultured rodent neurons (Devaskar et al. 
1994), and in situ hybridisation techniques showing the expression of insulin and 
preproinsulin mRNA in the rodent brain (Schechter et al. 1996) indicates that the 
brain may also produce some portion of this insulin (Gerozissis 2008). Insulin binds 
to insulin receptors found on the neurons and glia in networks associated with 
feeding, reproduction or cognition (Baskin et al. 1983, Brüning et al. 2000, Gerozissis 
2003). The intact hypothalamic insulin signalling mechanisms are required for the full 
systemic effect of insulin on reducing endogenous glucose production (Obici et al. 
2002b, Prodi et al. 2006). For example, central insulin action can stimulate muscle 
glycogen synthesis (Perrin et al. 2004). 
Insulin upregulates lipogenic gene expression by activating sterol regulatory 
element-binding protein 1 (SREBP-1) (Lane et al. 1990, Assimacopoulos-Jeannet et 
al. 1995, Nakae et al. 1999), and also increases leptin release from adipocytes by 
increasing gene expression (Malmstrom et al. 1996, Koopmans et al. 1998, Saad et 
al. 1998). Leptin is a satiety hormone that correlates strongly with BMI and fat mass 
(Considine et al. 1996, Dagogo-Jack et al. 1996). While leptin binds to type 1 
cytokine receptors found throughout the body (Cirillo et al. 2008), it mainly acts on 
the hypothalamus to both inhibit neuropeptide Y and stimulate satiety (Elias et al. 
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1999, Elmquist et al. 1999, Fekete et al. 2000). Therefore, suppressing food intake 
and increasing anabolic processes. 
1.3.2 Glucose homeostasis: glucagon release and action 
Glucagon contradicts the actions of insulin by increasing endogenous glucose 
production, glycolysis and lipolysis. Glucagon, released from the α-cells of the 
pancreas, binds to the glucagon receptor, a GPCR found throughout the body; liver, 
pancreas, brain, heart, adrenal glands, thyroid and skeletal muscle (Hansen et al. 
1995, Brubaker et al. 2002). Once activated the glucagon receptor stimulates 
adenylate cyclase to increase [cAMP]i, activating protein kinase A (PKA), which 
phosphorylates and activates glycogen phosphorylase (Exton 1987, Johnson 1997) 
and catalyses the breakdown of glycogen to generate glucose-6-phosphate. Glucose 
exits myocytes and hepatocytes via Glut2 to raise blood glucose levels (Nordlie et al. 
1999). Additionally, glucagon increases blood glucose by inhibiting glucose storage. 
Glucagon inhibits glycogen synthase activity (via PKA activation) which also 
activates glycogen phosphorylase  (Ciudad et al. 1984, Roach 1990). Glucagon also 
inhibits glycolysis in the liver by inhibiting phosphofructokinase-1 (PFK1) (Pilkis et al. 
1991, Okar et al. 1999). Glucagon can stimulate hepatic gluconeogenesis via 
phosphoenolpyruvate carboxykinase (PEPCK) and the activation of cAMP-response 
element binding protein (CREB) via PKA. CREB activation increases gene 
transcription of, for example, PEPCK (Herzig et al. 2001, Yoon et al. 2001). 
1.4 Central regulation of glucose homeostasis 
The sensitivity of the brain to low glucose was identified in the 1950s (Mayer 1953). 
The brain can control glucose homeostasis, by altering glucose production and 
utilisation, and food intake. The hypothalamus is the centre of glucose homeostasis, 
feeding and energy expenditure in the brain (Schwartz et al. 2000, Spiegelman et al. 
2001, Flier 2004, Schwartz et al. 2005, Stanley et al. 2005), with the action of 
glucose sensing neurons being identified in the 1960s by Oomura et al (Oomura et 
al. 1969). It is optimally located at a part of the blood-brain barrier (BBB) that is more 
permeable to nutrients and is located close to the Willis polygon making the 
hypothalamus one of the first brain areas to be supplied with arterial blood (Leloup et 
al. 2016). To facilitate the increased permeability of the BBB in this area the 
capillaries are specialised with semi-permeable endothelial cells unlike normal blood 
vessels (Rodriguez et al. 2010). The hypothalamus is comprised of distinct nuclei 
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that coordinate energy balance: arcuate nucleus, ventromedial nucleus (VMN) and 
the paraventricular nucleus (PVN). Additionally the hindbrain is also involved in 
regulating energy balance, including the  nucleus of the tractus solaris (NTS; nucleus 
of the solitary tract) and the dorsal motor nucleus of the vagus (DMV) (Grill et al. 
2012). Together these nuclei integrate neuronal (e.g. vagal nerve), hormonal (e.g. 
leptin, ghrelin, and insulin) (Baskin et al. 1999, Beverly et al. 2000, Bellinger et al. 
2002), and nutritional inputs (e.g. glucose (Beverly et al. 2000, Routh et al. 2014), 
fatty acids (Obici et al. 2002a, Lam et al. 2005a), and amino acids (Su et al. 2012)) 
to modulate food intake, energy expenditure, and fat deposition (Morton et al. 2006). 
1.4.1 Metabolism sensing neurons 
The detection of energy state within the brain depends on neuronal signalling from 
glucose excited (GE) and glucose inhibited (GI) neurons (Song et al. 2001, Levin et 
al. 2004). The current understanding of hypothalamic glucose-excited (GE) neurons 
sensing stems from the “β-cell model” of glucose sensing (described in 1.3.1). 
Briefly, in the β-cells of the pancreas, glucose is taken up by Glut-2 and metabolised 
by hexokinase-4 (HK-4; glucokinase). In a dose-dependent manner, glucose uptake 
increases the ratio of ATP:ADP within the cell. This closes the KATP channels 
depolarising the cell with further Ca2+ influx. Conversely, in low glucose the KATP 
channel is open and hyperpolarises the cell preventing firing. Glucose-inhibited (GI) 
neurons, on the other hand, are hyperpolarised by high glucose levels and 
depolarised by low glucose (Routh 2002). The key molecule mediating glucose 
sensing in these cells is AMP-activated protein kinase (AMPK) (Murphy et al. 2009). 
AMPK acts as an intracellular ‘fuel-gauge’ (McCrimmon 2008), which is activated by 
the relative abundance of AMP, which displaces ATP and prevents 
dephosphorylation of AMPK. Once activated, AMPK blocks the cystic fibrosis 
transmembrane regulator (CFTR) Cl- ion channel (Murphy et al. 2009), thus 
activating voltage dependent calcium channels (VDCC) which depolarises the cell 
and stimulates neurotransmitter release (Beall et al. 2012b). Other evidence 
suggests that tandem-pore K+ channels (K2P) mediates orexin GI neuronal firing 
(Burdakov et al. 2006). Additionally, in orexin GI neurons the intracellular supply of 
glucose or ATP, and preventing Ca2+ influx did not inhibit their firing suggesting that 
the glucose-sensing mechanism required extracellular signalling to alter firing rates 
(Burdakov et al. 2006). 
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In addition to glucose, neurons also sense changes in other nutrients, including fatty 
acids and amino acids, which can be modulated by hormones (insulin, leptin, ghrelin) 
and neurotransmitters (5HT, NA) to moderate feeding and energy balance (Watts et 
al. 2010, Toda et al. 2017). Pro-opiomelanocortin (POMC) neurons, for example, 
release POMC to regulate metabolism (Parton et al. 2007). This can be cleaved to 
produce α-melanocyte stimulating hormone (α-MSH; involved in satiety (Varela et al. 
2012)), adrenocorticotropic hormone (ACTH; regulating glucocorticoid secretion 
(Bornstein et al. 2008)), β-endorphin, and opioid peptides (Smith et al. 1988). POMC 
mutations result in an obese phenotype, indicating its role in metabolism (Coll et al. 
2004). POMC neurons are found within the hypothalamus, in the arcuate nucleus 
(ARC), and the hindbrain, in the NTS. Low glucose attenuates POMC neuron firing 
rates in ex vivo slices from mice (Parton et al. 2007), similar to a glucose excited cell 
phenotype (Ibrahim et al. 2003). This is mediated by the KATP channel (Parton et al. 
2007) where, as glucose levels decrease, the ATP:AMP ratio decreases which 
opens the KATP channel increasing hyperpolarisation. POMC neurons are also 
activated by leptin, endocannabinoids, nicotine, serotonin, fatty acids and amino 
acids, and inhibited by ghrelin and glucocorticoids (Toda et al. 2017). Interestingly, 
insulin has been reported to both suppress (Plum et al. 2006, Williams et al. 2010) 
and activate (Qiu et al. 2014) POMC neurons. 
Neuropeptide Y (NPY)/ agouti-related peptide (AGRP) neurons are similarly found in 
ARC and the hindbrain (Akabayashi et al. 1993, Akabayashi et al. 1994, Sergeyev et 
al. 2000, Elmquist 2001, Fraley et al. 2003, Li et al. 2004, Li et al. 2006). However, 
NPY/AGRP neurons are a population of orexigenic neurons that stimulate feeding 
behaviour (Gropp et al. 2005, Wu et al. 2009), unlike the anorexigenic POMC 
neurons (Sohn 2015). For example, NPY/AGRP pharmacogenetic or optogenetic 
activation increases food intake in mice (Aponte et al. 2011, Krashes et al. 2011). 
Ghrelin and glutamate released from excitatory neurons increase the firing rate of 
NPY/AGRP neurons (Enriori et al. 2007, Sohn 2015). NPY/AGRP neurons primarily 
release γ-aminobutyric acid (GABA) (Krashes et al. 2013) which suppresses POMC 
neurons (Cowley et al. 2001). The inhibitory function of the NPY/AGRP neurons 
suggests their role as inhibitors of the anorexigenic centres of the CNS. 
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1.4.2 Glucose sensing networks 
The schema by which sensory input is integrated and actioned upon by the brain is 
achieved via the basic principle of sensory motor integration first proposed by 
Sherrington  (Sherrington 1906). Firstly, sensory neurons, i.e. GE or GI neurons, 
centrally or peripherally, detect an initial stimulus. Secondly, this is relayed and 
processed by integrative networks for higher level processing, or directly to pre-
motor control neurons which directly project to defined motor neurons allowing for 
reflexive responses. Lastly, the motor neurons, that mediate the output from the 
brain to effector cells (i.e. pancreatic α- and β- cells). 
1.4.2.1 Glucose sensing networks: glucose sensors 
Glucose sensing cells can be found centrally, in the hypothalamus (Oomura et al. 
1969), hindbrain (Adachi et al. 1984), and in the periphery, in the hepatic portal 
mesenteric vein (PMV), gut and oral cavity (Niijima 1989, Thorens et al. 2004, Fujita 
et al. 2005) and in the pancreatic β-cells (MacDonald Patrick et al. 2005). 
Interestingly, many of the glucose-sensitive cells in the hypothalamus (Shimizu et al. 
1983) and hindbrain (Adachi et al. 1984) respond to changes in glucose within the 
PMV via vagal afferents. Indeed, hindbrain hypoglycaemia-induced FOS activation is 
greatly reduced by chemically preventing neurotransmission from the PMV (Bohland 
et al. 2014). In the hindbrain there several glucose sensing areas (Lynch et al. 2000, 
Andrew et al. 2007) including the area postrema (Funahashi et al. 1993), nucleus of 
the tractus solaris (NTS) and the dorsal nucleus of vagus nerve (DMX) (Mizuno et al. 
1984, Balfour et al. 2006). Within the hypothalamus, glucose-sensing areas include 
the lateral hypothalamus (Oomura et al. 1964), and the ventromedial hypothalamus 
including the ventromedial nucleus of the hypothalamus (VMN), arcuate nucleus 
(Arc), paraventricular nucleus (PVN), tuberal nucleus (TU), and lateral hypothalamus 
all of which are critical for counterregulatory responses (CRR) to 
hypoglycaemia  (Borg et al. 1995, Borg et al. 1997, Beverly et al. 2000, Song et al. 
2001, Chan et al. 2006, Chan et al. 2008). 
1.4.2.2 Pre-motor control and their targets 
The pre-motor neurons project directly to their respective neuroendocrine and pre-
autonomic neurons within the hypothalamus, hindbrain and spinal cord. Viral tracer 
studies in the pancreas, and adrenal gland identified regions of the hypothalamus 
(Jansen et al. 1997, Buijs et al. 2001) and hindbrain (Kerman et al. 2003, Kerman et 
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al. 2006, Kerman et al. 2007) as containing pre-motor neurons. Within the hindbrain 
several regions have been identified, including the NTS, locus coeruleus and A5 
catecholamine cell group. These groups then activate pre-autonomic 
parasympathetic (e.g. the NTS activating the pancreas), or both the parasympathetic 
and sympathetic networks (Watts et al. 2010).  
Regions of the hypothalamus project into the hindbrain and spinal cord (Saper et al. 
1976, Swanson et al. 1980) which can regulate CRR (Motawei et al. 1999). 
Specifically, the PVN, lateral hypothalamus, and retrochiasmatic area contribute to 
CRR by pre-autonomic control of the pancreas and adrenal gland (Watts et al. 
2010). Injections of noradrenaline, opiate agonists or neuropeptide Y into the PVN 
increased plasma adrenaline and glucose levels (Kiritsy-Roy et al. 1986, Leibowitz et 
al. 1988), demonstrating the role of the PVN to regulate glucose concentrations. The 
PVN integrates signals from the ARC (Sawchenko et al. 1983, Broberger et al. 
1998b), lateral hypothalamus (Watts et al. 1999) and dorsal-medial hypothalamus 
(Thompson et al. 1996). The corticotropin-releasing hormone pre-motor neurons of 
the PVN trigger the release of adrenocorticotropic hormone (ACTH) which stimulates 
the synthesis and release of glucocorticoids which are important for 
counterregulation (Cryer 1997a). Glucocorticoids, including cortisol, stimulate 
gluconeogenesis in the liver, reduce glucose uptake and stimulate lipolysis (Munck 
1971, Exton et al. 1972). The lateral hypothalamus projects to the spinal cord and 
hindbrain (Saper et al. 1976), as well as the pancreas adrenal gland (Jansen et al. 
1997, Buijs et al. 2001, Kerman et al. 2006), and liver (Yi et al. 2010). Furthermore, 
the lateral hypothalamus projects to other hypothalamic regions involved in CRR, 
including the VMN (Canteras et al. 1994), ARC (Broberger et al. 1998a, Broberger et 
al. 1998b), and PVN (Sawchenko et al. 1983, Watts et al. 1999). Lastly, the 
retrochiasmatic area projects to the pancreas and adrenal gland. But it is unknown 
the extent of its role in CRR.  
1.4.2.3 Integrative networks of glucose regulation 
There is a good comprehension of the general mechanisms of glucose sensing and 
that central networks mediate glucose homeostasis (Ritter et al. 2003, Saberi et al. 
2008). For example, the hindbrain contains all the necessary components for 
glucose homeostasis as sympathoadrenal responses remain following decerebration 
and 2-DG-glucoprivation in rats (DiRocco et al. 1979). Additionally, specific 
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glucoprivation within the hindbrain triggers counterregulatory responses (Cechetto et 
al. 1988, Cardin et al. 2001). Within the hindbrain chatecholaminergic (adrenaline or 
NA releasing cells) widely innervate the CNS (Ungerstedt 1971) including the 
hypothalamus and spinal cord (Watts et al. 2010, Ritter et al. 2011) and vice versa. 
The hypothalamus is well known for its control of metabolism (Bellinger et al. 2002, 
Evans et al. 2004b). The VMN, alongside metabolism, also integrates sexual 
behaviour and territoriality (Yang et al. 2013). The dendrites extend beyond its 
nuclear borders, which likely contributes to its diverse functions (Millhouse 1973). 
However, retrograde viral tracer studies have failed to demonstrate the VMN as 
innervating the liver, pancreas or adrenal gland directly (Jansen et al. 1997, Buijs et 
al. 2001). These studies utilised pseudorabies viral tracer techniques where the 
neurotropic virus can propagate from an initial injection site along neurons; 
afterwards the pseudorabies virus presence in neurons is identified 
immunohistochemically. However, it does interact with pre-autonomic hypothalamic 
neurons in the lateral hypothalamus and PVN (Sawchenko et al. 1983, Canteras et 
al. 1994, Watts et al. 2010). Furthermore, retrograde viral studies in the pancreas 
showed first order neurons in the hindbrain, second order neurons locus coeruleus 
as well as the paraventricular nucleus of the hypothalamus (PVN), and lastly third-
order neurons in the VMN and Arc indicating their role in the glucose regulatory 
network (Buijs et al. 2001). This signifies the importance of the VMN in regulating the 
pancreas indirectly via pre-autonomic neurons. 
The Arc is another region that is part of the greater integrative network of glucose 
homeostasis (Watts et al. 2010). Being a small region there are few tracing studies 
of its projections, however it does contain NPY/AGRP and POMC neurons. These 
neurons project to the telencephalon and other nuclei within the hypothalamus 
(Broberger et al. 1998b, Haskell-Luevano et al. 1999). Within the hypothalamus, Arc 
neurons project to the lateral hypothalamus and the PVN which directly links the Arc 
with pre-autonomic control networks (Sawchenko et al. 1983, Broberger et al. 
1998a). These neurons are also found in the dorsomedial hypothalamus (DMH) 
(Broberger et al. 1998b, Haskell-Luevano et al. 1999), and the hindbrain (Kenny 
2011, Blevins et al. 2013). 
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Together these networks, both central and peripheral, interact to provide a complex 
and integrative system for regulating glucose homeostasis (figure 1.1). These 
networks allow for autonomic responses to changes in glucose, but also allow for 
modulatory input from other brain regions (Loewy 1991, Saper 2002). However, as 
the hindbrain can regulate glucose homeostasis without forebrain input (DiRocco et 
al. 1979) this suggests some hierarchical structure to the overall central 
glucoregulatory network. 
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1.5 Complications of diabetes 
Effective glucose homeostasis in diabetes fails primarily due to the loss of insulin 
action either by the loss of production or insulin sensitivity. The negative 
consequences of diabetes and faulty glucose homeostasis are of both short- and 
long-term significance. Hyperglycaemia leads to the classical symptoms previously 
mentioned: ketoacidosis, nonketotic hyperosmolar syndrome, polyuria, polydipsia, 
and blurred vision (Association 2012). Longer-term sequelae of hyperglycaemia 
have been thoroughly reviewed and are not the focus of this introduction. For 
interest, the reader is directed to these reviews: (Brownlee 2001, Brownlee 2005, 
Forbes et al. 2013). Briefly, these may include neuropathy, with risks ulceration; 
nephropathy, leading to renal failure; Charcot joints; autonomic dysfunction; and 
increased risks of cardiovascular, peripheral vascular and cerebrovascular diseases 
(Alberti et al. 1998, Association 2012). This thesis and introduction focus on the 
effects of hypoglycaemia, specifically those affecting the central nervous system 
(CNS), which will be reviewed in detail below. 
1.5.1 Management of hyperglycaemia in diabetes 
To counteract hyperglycaemia caused by the loss of insulin action (through depletion 
or insensitivity) either exogenous insulin is supplied or other glucose lowering 
agents. Sulfonylureas, for example stimulate insulin release by blocking KATP 
channels on β-cells (Madison et al. 1959, Ashcroft 1996). Metformin, another 
common drug used in the treatment of diabetes reduces endogenous glucose 
production and improves hepatic insulin sensitivity (Hundal et al. 2000, Moghetti et 
al. 2000, Zhou et al. 2001).  
A side effect of anti-hyperglycaemic medicine usage is iatrogenic hypoglycaemia, 
particularly in patients treated with intensive insulin therapy. Indeed, iatrogenic 
hypoglycaemia is major barrier to effective glycaemic control (Cryer 2008). Patients 
often fear hypoglycaemia, and deliberately allow their blood glucose levels to be high 
to avoid hypoglycaemia, despite the known consequences of this action (Driscoll et 
al. 2016). 
1.5.2 Acute effects of hypoglycaemia 
Hypoglycaemia is defined by blood glucose levels of <4 mmol/l amount. A single 
episode of hypoglycaemia can induce a range of symptoms including, tremor, 
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anxiety, sweating, tiredness, hunger and paraesthesia, and cognitive symptoms: 
behavioural changes, cognitive dysfunction, seizures and coma. If untreated, 
hypoglycaemia can result in severe brain damage or death. An estimated 2-4% of 
deaths in those with T1DM have been caused by hypoglycaemia (Cryer 1997b, 
Laing et al. 1999). Additionally, inpatients’ with diabetes that experience 
hypoglycaemia during their stay increases the length of hospitalisation and cost of 
stay (McEwan et al. 2015). 
1.5.3 Frequency of hypoglycaemia in T1DM and T2DM 
The awareness of hypoglycaemia is often lost following repeated episodes. This 
leads to the clinically recognised condition of impaired hypoglycaemia awareness, 
which increases the likelihood of hypoglycaemia occurrence. Iatrogenic 
hypoglycaemia is more common in those with T1DM, who will experience mild 
hypoglycaemia twice a week and one severe episode, requiring medical attention, 
per year (Donnelly et al. 2005). This equates to a rate of 0.62-1.70 hypoglycaemic 
episodes per year in T1DM (Reichard et al. 1991, MacLeod et al. 1993, Group 
1998), compared to 0.03-0.73 episodes per year in those with T2DM (Reichard et al. 
1991, Abraira et al. 1995, Saudek et al. 1996). 
1.6 Counterregulatory response 
To restore euglycaemia multiple mechanisms converge to raise blood glucose 
concentrations in a process known as the CRR. Firstly, insulin production, from β-
cells is reduced as glucose drops below 4.6 mmol/l. Secondly, counterregulatory 
hormones like glucagon, adrenaline and noradrenaline are released when glucose 
drops below 3.8 mmol/l. Thirdly, if glucose concentrations fall below 3.2 mmol/l, the 
onset of neurological symptoms occurs, i.e. confusion and anxiety (Zammitt et al. 
2005). The brain will increase sympathoadrenal outflow activating pre-autonomic 
nerve fibres which activates the adrenal medulla to release adrenaline and 
noradrenaline (Strack et al. 1989, Buijs et al. 1999). Neuroglycopenia will also induce 
hypothalamic-pituitary-adrenal activation releasing growth hormones, cortisol and 
glucocorticoids. In combination, these responses to falling glucose levels increase 
glucose production, decrease glucose clearance, increase the release of 
gluconeogenic precursors, such as lactate, and increase appetite (Mastorakos et al. 
1993, de Guia et al. 2014). However, in those with diabetes this process is 
fundamentally altered. 
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1.6.1 Perturbations of counterregulatory response in diabetes 
The first aspect of counterregulation, modulation of endogenous insulin levels, is lost 
in T1DM and advanced T2DM where an individual has become insulin dependent. 
Secondly, after approximately 5 years of diabetes disease duration glucagon 
production is lost in response to hypoglycaemia in T1DM (Bolli et al. 1983, Cryer et 
al. 2003) and in advanced T2DM as well (Gerich et al. 1973, Segel et al. 2002, 
Drucker et al. 2006). Interestingly, this is not due to a lack of α-cells as they are 
present in normal numbers and are functional in other scenarios, such as exercise 
(Wali et al. 2015). Given that glucagon production is possible the α-cells have not 
lost the ability to synthesis and secrete glucagon, instead there is a loss of the 
signals that trigger this event. One proposed explanation is that the loss of 
endogenous β-cells prevents the α-cells’ responses to falling insulin levels, 
especially in the context of the inhibitory effect of exogenously supplied insulin 
(Taborsky et al. 1998).  
Glucagon stimulates the breakdown of hepatic glycogen stores to produce glucose 
and increases glucose levels (Drucker et al. 2006). The release of glucagon from α-
cells relies on signalling from other cells within the pancreatic islet and CNS inputs 
(Taborsky et al. 1998). For example, α-cells are suppressed by insulin and specific 
KO of the insulin receptor on α-cells results in hyperglucagonaemia (Kawamori et al. 
2009). Additionally, central input from the hypothalamus and hindbrain increase 
glucagon secretion (Tong et al. 2007, Fan et al. 2009). 
Catecholamines, adrenaline and noradrenaline are released during CRR from the 
adrenal gland (DeRosa et al. 2004), which act on adrenergic receptors in the liver to 
enhance hepatic glucose output (Exton 1987). However, in both T1DM and 
advanced T2DM the magnitude of the adrenaline response is diminished and begins 
at a lower glucose concentration (Segel et al. 2002). The adrenal response to 
hypoglycaemia is primarily mediated by central hypoglycaemia detection and 
autonomic outflow activating adrenaline and noradrenaline release (McCorry 2007). 
See figure 1.2 for an outline of these processes. 
1.6.2 Recurrent hypoglycaemia counterregulation 
In addition to pathological changes to the glucoregulatory systems induced by 
diabetes, antecedent hypoglycaemia in healthy humans reduces CRR to subsequent 
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hypoglycaemia (Davis et al. 1997, Davis et al. 2000). This increases the likelihood of 
future hypoglycaemia as the awareness of hypoglycaemia is impaired leading to 
hypoglycaemia-associated autonomic failure (HAAF) (Cryer 2005). Repeated 
antecedent hypoglycaemia results in an acute reduction of adrenalin, pancreatic 
polypeptide (a marker of parasympathetic nervous system activity), and muscle 
sympathetic nerve activity (a direct marker of sympathetic nerve system activation) in 
humans with T1DM, T2DM and healthy controls (Cryer 2008). Fortunately, 
hypoglycaemia awareness can be regained with strict glycaemic control and 
hypoglycaemia avoidance in some patients (Cranston et al. 1994). Nevertheless, the 
mechanisms by which blunted CRR occurs are not completely understood and as 
such, hypoglycaemia remains a limiting factor in maintaining euglycaemia in 
diabetes (Cryer 2004).  
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1.6.2.1 Glycogen supercompensation 
As mentioned previously glycogen is a carbohydrate store that is readily broken 
down as glucose levels fall and increased during high blood glucose states. 
Glycogen, in the brain, is mostly stored in astrocytes (Brown 2004). Astrocyte 
glycogen content is modulated by many signals including noradrenaline and 
serotonin, insulin, and blood glucose concentrations (Magistretti et al. 1993, Gruetter 
2003). During hypoglycaemia in humans (Oz et al. 2009) and rodents (Choi et al. 
2003) glycogen is broken down within astrocytes to provide energy for neurons in the 
form of lactate according to the astrocyte-neuron lactate shuttle hypothesis (ANLS) 
(Pellerin et al. 2012). When lactate is provided exogenously, in the presence of 
peripheral hypoglycaemia, CRR is blunted (Borg et al. 2003), therefore, glucose 
sensing neurons may not detect the energy deficit when lactate is provided by 
astrocytes. It was originally hypothesised by Choi and Gruetter (Choi et al. 2003) that 
following hypoglycaemia astrocytic glycogen stores may increase in size to pre-empt 
future metabolic stress. This hypothesis is supported by evidence that in rats 
glycogen levels are elevated 20 hours after glucopaenia in the hypothalamus 
(Alquier et al. 2007), or following an episode of hypoglycaemia (Choi et al. 2003). 
However, other groups have found that glycogen supercompensation did not occur 
in rats following acute or recurrent hypoglycaemia, even though a faulty CRR was 
detected (Herzog et al. 2008). Furthermore, hypoglycaemia awareness and brain 
glycogen content in the brain are not correlated in humans with T1DM diabetes (Öz 
et al. 2012). While the discrepancies in the literature have not been resolved, it is 
more important to know whether or not manipulation of glycogen levels will provide a 
therapeutic benefit to people. For example, would increasing brain glycogen stores 
protect neural function or prevent the detection of hypoglycaemia? 
1.6.2.2 Blunting of AMPK activation 
AMPK is expressed in both neurons and astrocyte populations (Turnley et al. 1999), 
and is involved in energy homeostasis and CRR (McCrimmon 2008). For example, 
the use of the AMPK activator AICAR stimulates VMN GI neurons, similarly to a low 
glucose treatment, even in 2.5 mM glucose (euglycaemia) (Canabal et al. 2007). GI 
neurons also produce nitric oxide during low glucose stimulation which is attenuated 
by AMPK inhibition (Canabal et al. 2007). Nitric oxide signalling is required for the 
closing of the CFTR and is therefore necessary for GI neuron function (Murphy et al. 
47 
2009). Interestingly, AMPK activation during acute hypoglycaemia in the VMN 
enhanced CRR and improved CRR in rats with blunted CRR (McCrimmon et al. 
2006a). Similarly, AMPK inhibition by siRNA prevents CRR to hypoglycaemia 
(Mccrimmon et al. 2006b). Furthermore, the selective KO of the active AMPK subunit 
(α-1) prevented glucose sensitivity in POMC and AGRP neurons (Claret et al. 2007). 
Normal AMPK activity is suppressed by repeated neuroglycopenia, 
intracerebroventricular 2-DG injections over 4 days in vivo (Alquier et al. 2007). 
Interestingly, activation of AMPK in CRR-blunted rats can improve counterregulatory 
responses to future hypoglycaemia (McCrimmon et al. 2006a, Alquier et al. 
2007). Furthermore, recent work shows that recurrent insulin-induced hypoglycaemia 
(RIIH) increases AMPK protein expression in several hypothalamic nuclei while the 
normal increase in AMPK phosphorylation was lost (Mandal et al. 2017). Taken 
together these data indicate AMPK activity is suppressed following RIIH or repeated 
neuroglycopenia suggesting a failure of glucose sensing activity. While this likely 
contributes to blunted CRR, given AMPK activation improves CRR (McCrimmon et 
al. 2006a, Alquier et al. 2007), the mechanisms by which AMPK phosphorylation is 
diminished remains unclear. One potential explanation could be glycogen 
supercompensation (as described above) (Alquier et al. 2007) may delay the onset 
of AMPK activation enhancing short-term energy supplies from glycogenolysis and 
glycolysis (Pellerin et al. 2012). 
1.6.2.3 Alterations in brain glucose uptake 
The brain utilises approximately 20% of a human body’s total caloric intake (Rolfe et 
al. 1997). Most of this comes from the metabolism of carbohydrates of which the 
brain preferentially uses (Benarroch 2014). The source of glucose for the brain is 
from the vasculature supplying the brain. Glucose is transported across the blood 
brain barrier (BBB) via Glut-1 which then directly enters the neuron via Glut-3 or is 
indirectly transported into astrocytes by Glut-1 and metabolised to lactate; which is 
transported to neurons by monocarboxylate transporter 1 (MCT1) and MCT2 
(Benarroch 2014). 
Glucose uptake is reduced during acute hypoglycaemia. However, recurrent, long 
duration, hypoglycaemia in humans prevented this reduction in a future 
hypoglycaemic clamp study (Boyle et al. 1994). An additional study showed brain 
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glucose uptake was unchanged during hypoglycaemia in patients with T1DM who 
also had low glycosylated haemoglobin (HbA1c), impaired hypoglycaemia 
awareness, and blunted CRR, compared to patients with T1DM and higher HbA1C 
values (Boyle et al. 1995). This has also been investigated in rodent models where 
sustained, but not acute, hypoglycaemia reversibly increased glucose uptake into the 
brain during hypoglycaemia (McCall et al. 1986). Indeed cerebral glucose levels are 
maintained in humans with T1DM and IHA (Criego et al. 2004). Together this 
suggests glucose uptake into the brain is enhanced, which may explain the 
maintenance of cognitive function and absence of hypoglycaemia-associated 
symptoms. A rodent study of chronic hypoglycaemia demonstrated that the 
increased brain glucose uptake may be due to increased Glut-1 mRNA expression 
and BBB permeability-surface area (Kumagai et al. 1995). 
1.6.2.4 Altered neuronal transmission 
Within the VMN, glucose sensing can be directly manipulated by the addition of 
glucose or 2-DG which inhibit or enhance CRR (Borg et al. 1995, Borg et al. 1997). It 
has been suggested that blunted CRR may be partly due to a failure in the sensitivity 
of GE and GI neurons to glucose (Parekh 2009). KATP channels are a necessary part 
of GE neuron glucose detection (Parton et al. 2007) and modulate GABA levels. KATP 
channel blockers decrease CRR to both central and systemic hypoglycaemia 
through increasing GABAergic inhibitory tone (Evans et al. 2004a, Chan et al. 2007). 
Conversely, KATP channel openers improve CRR in hypoglycaemia naïve rats and 
those with blunted CRR by attenuating GABA levels (McCrimmon et al. 2005, Chan 
et al. 2007). 
1.6.2.5 GABA and glutamate signalling 
As mentioned previously, GABA is an important inhibitory neurotransmitter in the 
brain with importance in the energy balance centres of the brain (Cowley et al. 
2001). For example, inhibition and activation of GABA receptors in the VMN 
amplifies and suppresses CRR respectively (Chan et al. 2006). Additionally, GABA 
levels are suppressed by KATP activation with a corresponding increase in glucagon 
and adrenaline responses to hypoglycaemia (Chan et al. 2007). During 
hypoglycaemia, GABAergic inhibitory tone within the VMN decreases but is 
increased by RH (Chan et al. 2008). Conversely, glutamatergic neurotransmission is 
increased by acute hypoglycaemia, but diminished by RH (Chowdhury et al. 2017). 
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Glutamatergic neurotransmission is necessary for glucagon release and avoidance 
of hypoglycaemia (Tong et al. 2007). Furthermore, in people with T1DM and HAAF, 
glutamate concentrations do not decline as expected during hypoglycaemia in the 
occipital lobe (Terpstra et al. 2014). While the precise mechanisms remain unclear, 
the interplay between GABA and glutamatergic neurotransmission is altered by RH. 
Together, failure in each system results in diminished CRR (Tong et al. 2007, 
Potapenko et al. 2012). 
1.7 Astrocytes 
While much of the literature discussed so far focusses primarily on neurons, 
astrocytes have also been shown to sense metabolic hormones and nutritional state 
(Chowen et al. 1999, Cheunsuang et al. 2005, Marty et al. 2005, McDougal et al. 
2013a, McDougal et al. 2013b, Angelova et al. 2015, Chen et al. 2016, García-
Cáceres et al. 2016, Rogers et al. 2016, Turovsky et al. 2016). 
Astrocytes are non-electrically excitable neural cells which have a supporting role in 
the brain. They are a part of the tripartite synapse, where their fine processes 
ensheaths the synaptic cleft to regulate neurotransmission (Papouin et al. 2017). 
However, the number of synapses in intimate association with astrocytes varies 
within the rodent brain between an estimated 30-90% depending on the brain region 
(Papouin et al. 2017) indicating a wide range of uses in the CNS. Additionally, 
astrocytes have a heterogeneous morphological structure which can define different 
subtypes of glia. Protoplasmic, fibrous, surface-associated, gomori, perivascular and 
marginal, and radial astrocytes are the major sub-classifications of astrocytes 
(Verkhratsky et al. 2017). Even within each subtype astrocytes can have 
heterogeneous functions. Within the hippocampus, for example, there are 
protoplasmic GluR and GluT astrocytes; GluR astrocytes express ionotropic 
glutamate receptors whereas GluT astrocytes lack the receptors but express 
glutamate transporters (Matthias et al. 2003). Dissimilarly, perivascular astrocytes do 
not commonly interact with neurons, instead they interact with the cerebral 
vasculature through their end-feet which form a part of the blood brain barrier (Liu et 
al. 2013). Lastly, gomori astrocytes, found in the hypothalamus and hippocampus, 
highly express Glut2 allowing for rapid uptake of glucose which may contribute to 
metabolic sensing of the hypothalamus (Young et al. 2004). Astrocytes also have 
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important roles in ion, water and pH homeostasis, and inflammation (Verkhratsky et 
al. 2017). 
1.7.1 Astrocyte calcium signalling 
Astrocytic activation is fundamentally linked to the flow of Ca2+ ions. The generation 
of a high to low calcium gradient is essential for calcium signalling which occurs both 
extracellularly to cytoplasm, as well as between intracellular compartments, i.e. the 
endoplasmic reticulum (ER), and the cytoplasm (Verkhratsky et al. 2012). The 
cellular machinery which enables gradient formation can include Ca2+ channels, 
buffers, pumps and exchangers (Verkhratsky et al. 2012). Ca2+ influx can be both 
compartmentalised into microdomains or apply to a broader whole cell response 
(Berridge 2006, Verkhratsky et al. 2012). For example, influx of Ca2+ into the 
cytoplasm from the extracellular space or from internal stores can be highly spatially 
restricted or cascade on to the rest of the cell. Alternatively, after increased [Ca2+]i, 
secondary downstream signalling occurs leading to changes in gene transcription 
(Fields et al. 2005), metabolism (Denton et al. 1972, Hubbard et al. 1996, Territo et 
al. 2000), and propagation to other cells (Verkhratsky 2006, Verkhratsky et al. 2006). 
Aside from Ca2+ influx, metabotropic GPCRs induce the production of inositol 
triphosphate (IP3) which triggers IP3-induced Ca
2+ release from the ER (Hamilton et 
al. 2008). The increase in intracellular IP3 can also be propagated intercellularly via 
gap-junctions to stimulate long-range calcium waves (Cornell-Bell et al. 1990). IP3-
induced Ca2+ release is important in the exocytosis of vesicles from astrocytes as an 
ER calcium inhibitor prevented the calcium dependent release of glutamate from 
astrocytes (Innocenti et al. 2000, Jeremic et al. 2001). Astrocytes propagate calcium 
signalling through the glial syncytium through calcium waves enabling the 
dissemination of a signal from an initial stimulus to other astrocytes (Scemes et al. 
2006). 
1.7.2 Gliotransmission 
The release of neurotransmitters such as glutamate was thought to be the exclusive 
role of neurons. However, astrocytes also release neurotransmitters in response to 
stimuli in a Ca2+-dependent manner (Zhang et al. 2005a, Savtchouk et al. 2018). In 
vitro studies first demonstrated Ca2+-dependent astrocytic exocytosis of 
neurotransmitters (Parpura et al. 1994, Parpura et al. 1995, Araque et al. 1998a, 
Araque et al. 1998b, Araque et al. 1999, Araque et al. 2000, Parpura et al. 2000, 
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Araque et al. 2001). This expanded to the use of pharmacological activation of 
endogenous receptors that activate Gq-GPCRs to increase [Ca2+]i from intracellular 
stores (Parpura et al. 1994, Jeftinija et al. 1996, Montana et al. 2006). While debate 
remains (see Savtchouk and Volterra arguing for (Savtchouk et al. 2018) and Fiacco 
and McCarthy arguing against (Fiacco et al. 2018)), glutamate, D-serine, purines are 
proposed to be released during gliotransmission (Haydon et al. 2006, Di Castro et al. 
2011, Harada et al. 2015). 
Exocytotic release of stored vesicles in astrocytes, as in other cells, requires Ca2+-
sensitive machinery such as the soluble N-ethyl maleimide-sensitive fusion protein 
attachment protein receptor (SNARE) complex (Montana et al. 2006). Inhibition of 
this process prevents the release of glutamate from astrocytes (Montana et al. 
2006). 
It is well established that astrocytes recycle glutamate (Danbolt 2001, Oliet et al. 
2001) known as the glutamate-glutamine cycle. Briefly, astrocytes uptake glutamate, 
convert it to glutamine by glutamine synthetase, and export it to neurons where it is 
converted back to glutamate by glutaminase (Rudy et al. 2015). Importantly, neurons 
lack the machinery to synthesise glutamate or GABA directly from glucose (Hertz et 
al. 1999), thus require astrocytes to perform this function. Astrocytes can also 
release glutamate directly in a Ca2+-dependent fashion. Importantly, failure of the 
glutamate-glutamine cycle leads to excitotoxicity (Halassa et al. 2007). 
D-serine is amino acid proposed to be released from astrocytes that co-agonises 
NMDA receptors (Mothet et al. 2005, D’Ascenzo et al. 2014, Paul et al. 2014). 
However, recent evidence suggests that this is not the case and serine racemase, 
which synthesises D-serine, is almost exclusively found in neurons and not 
astrocytes (Miya et al. 2008, Benneyworth et al. 2012). Furthermore, while 
astrocytes in vitro release D-serine, this has been attributed to changes in 
expression resulting in non-physiological serine racemase expression (Wolosker et 
al. 2016). Instead it is proposed that astrocytes produce L-serine, the precursor to D-
serine, which is shuttled to neurons which subsequently synthesise D-serine 
(Wolosker et al. 2016). 
Lastly, purines, including ATP, ADP, and adenosine have long been known to be 
neurotransmitters and act through a process known as purinergic signalling 
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(Burnstock 1972, Burnstock 2016). Aside from being the energy currency of the cell, 
ATP acts as a signalling molecule often regarded as a danger signal (Trautmann 
2009). Extracellular ATP, or following hydrolysis by ectonucleotidases, ADP and 
adenosine bind to purinergic receptors. Briefly, these are categorised into P2X, 
ionotropic, P2Y metabotropic receptors. A specific class of adenosine sensitive 
receptors are called P1 or adenoreceptors (Burnstock 2016). Together these 
modulate [Ca2+]i by direct influx of ions opening voltage dependent calcium channels, 
or through Gq-GPCRs which trigger calcium release from intracellular stores (Tomic 
et al. 1996). Astrocytes release ATP from vesicles (Zhang et al. 2007b, Abbracchio 
et al. 2009), pannexin hemi-channels (Bao et al. 2004) and P2X7 receptors 
(Suadicani et al. 2006). 
As gliotransmission is calcium dependent, systems that modulate astrocytic calcium 
can affect gliotransmitter release. Circulating hormones can directly affect 
gliotransmission; for example, insulin receptor KO in astrocytes in mice caused 
anxiety, obesity (Brüning et al. 2000, Fisher et al. 2005) and a decrease in ATP 
exocytosis (Cai et al. 2018). Additionally, other factors like pH, O2/CO2, and 
metabolic availability increase astrocytic [Ca2+]i which could then influence 
gliotransmission (Verkhratsky et al. 2017). For example, hypoxia/hypoglycaemia 
triggers the release of adenosine in the CNS including astrocytes (Ciccarelli et al. 
1999). Furthermore, adenosine receptor antagonists, i.e. caffeine, can prevent 
normal CRR in response to 2-DG glucoprivation (Minor et al. 2001) and prevent 
hypoglycaemia-induced neuronal death (Turner et al. 2004). 
1.7.3 Astrocyte and neuronal metabolism 
Neurotransmission is an energetically costly process (Laughlin et al. 1998, Attwell et 
al. 2001). In neurons glucose is completely metabolised by oxidative phosphorylation 
in the mitochondria (Waagepetersen et al. 1998, Bouzier‐Sore et al. 2006). Kety and 
Schmidt noted, however, there was a discrepancy between estimated and actual 
glucose utilisation rates by the brain; glucose utilisation exceeded oxygen 
consumption (Kety et al. 1948). Therefore, glucose was being used partly in an 
oxygen independent manner, i.e. glycolysis. This has been largely attributed to 
astrocytes which are more glycolytic than neurons (Bélanger et al. 2011, Pellerin et 
al. 2012). Astrocytic involvement in neurotransmission incurs metabolic costs; when 
glutamate is released from neurons some of this is uptaken by astrocytes and this 
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stimulates lactate release and increases glucose utilisation (Pellerin et al. 1994, 
Sibson et al. 1998, Schurr et al. 1999, Voutsinos-Porche et al. 2003). Despite high 
metabolic demands, astrocytes are more glycolytic in comparison to neurons. This is 
partly due to their expression of 6-phosphofructo-2-kinase type 3 (PFKFB3) which is 
almost absent in neurons (Herrero-Mendez et al. 2009). This enzyme generates 
fructose-2,6-bisphosphate which activates phosphofructokinase-1 (PFK) accelerating 
glycolysis. Interestingly, forced increases in neuronal glycolysis via PFKFB3 
overexpression causes increased ROS, which was attributed to decreased pentose 
phosphate pathway (PPP) mediated anti-ROS defence (Herrero-Mendez et al. 
2009). Astrocytes also contain glycogen stores, unlike neurons, which can be utilised 
in the absence of glucose to maintain glycolysis (Wender et al. 2000, Brown 2004). 
Pyruvate is the end-product of glycolysis which enters the mitochondria for complete 
oxidation. Alternatively, lactate dehydrogenase (LDH) converts pyruvate to lactate. In 
astrocytes, thanks to LDH5 isoform, the majority of pyruvate is converted to lactate 
(Bittar et al. 1996); which can then be exported via monocarboxylate transporters 
(MCT) 1 and 4 to supply neurons with lactate as a metabolic substrate (Steinman et 
al. 2016). Neurons express LDH1 which favours the conversion of lactate into 
pyruvate (Bittar et al. 1996) which can then be completely oxidised in the 
mitochondria. 
1.7.4 Astrocyte-neuron lactate shuttle hypothesis 
The supply of lactate to neurons is a part of the astrocyte-neuron lactate shuttle 
(ANLS), proposed by Pellerin and Magistretti (Pellerin et al. 1994). The ANLS 
hypothesises that neuronal activity results in a corresponding increase in astrocytic 
glycolysis to provide lactate to neurons as a metabolic substrate (Pellerin et al. 1994, 
Pellerin et al. 2012). This was demonstrated, initially, by glutamate stimulating 
astrocytic metabolism due to co-transport of Na+ ions activating the Na+/K+-ATPase 
using ATP. The resulting increased glucose uptake produces lactate which is 
transported to and metabolised in neurons (Pellerin et al. 1994, Pellerin et al. 2012). 
Interestingly, in streptozotocin-induced diabetes in rats MCT 1 and 2 expression 
increased and even more so following RH, increasing brain lactate uptake (Aveseh 
et al. 2014). Additionally, in humans with T1DM compared to healthy controls lactate 
uptake into the brain is similarly increased (Mason et al. 2006, De Feyter et al. 
2013). Together these data suggest an enhanced ANLS induced by diabetes and/or 
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RH. For example, RH blunts the CRR (Aveseh et al. 2014) and direct infusion of 
lactate into the hypothalamus also blunts the CRR during systemic hypoglycaemia 
(Borg et al. 2003) then is it plausible that enhanced lactate production and/or 
utilisation may be blunting of CRR following RH. 
1.7.5 Glucose sensing role of astrocytes 
While CNS glucose sensing has been known for over 60 years, this has mostly been 
attributed as a function of neurons (Mayer 1953, Oomura et al. 1969, Watts et al. 
2010). Nonetheless, relatively recently, astrocytes are being recognised as sensors 
of metabolic hormones, local energy balance, and glucose (Marty et al. 2005, 
McDougal et al. 2013a, McDougal et al. 2013b, Chen et al. 2016, Rogers et al. 
2018). Marty et al, were the first group to identify astrocytes as being important low 
glucose sensors (Marty et al. 2005). Their work studied a mouse Glut2 KO model 
and found extrapancreatic Glut2 glucose-sensing mechanism to be important in 
hypoglycaemia-induced glucagon secretion. 2-DG-induced glucoprivation increased 
c-FOS activation in the NTS in control but not Glut2 KO mice and selective re-
expression of Glut2 in GFAP expressing cells rescued the Glut2 KO phenotype. 
More recently, McDougal et al, demonstrated that isolated NTS-astrocytes in vitro 
respond to glucose withdrawal and 2-DG glucoprivation (McDougal et al. 2013a). 
Furthermore, inhibition of astrocytes using fluorocitrate, an astrocyte anti-metabolite, 
prevented gastric motility in response to glucoprivation (McDougal et al. 2013b). 
Furthermore, activation or inhibition of GFAP-expressing glia in the ARC increases 
and suppresses food intake, respectively (Chen et al. 2016). This was shown to be 
dependent on NPY/AgRP but not POMC neurons, as specific inhibition of the 
NPY/AgRP neurons prevented increased food intake (Chen et al. 2016). 
Furthermore, astrocytes were necessary for hindbrain-derived CRR which was 
blocked by the addition of fluorocitrate (Rogers et al. 2016). The addition of 
adenosine receptor, blockers also prevented CRR suggesting that purinergic 
gliotransmission is also necessary for CRR (Rogers et al. 2016). Purinergic 
gliotransmission was also required for activation of glucose-sensing neurons in ex 
vivo mouse hindbrain slices containing the NTS (Rogers et al. 2018). Again, 
inhibition of astrocytes with fluorocitrate inhibited the activation of these neurons 
(Rogers et al. 2018). Importantly, upon glucoprivation, astrocytes Ca2+ increase 
occurred approximately 40 seconds before neurons suggesting they are the initiators 
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of glucose detection. Together these seminal studies demonstrate the necessity of 
astrocytes in glucose sensing and counterregulation. 
1.8 Inflammation 
Inflammation is an integral aspect of both T1DM and T2DM (Wellen et al. 2005). It is 
well established that inflammatory responses require metabolic involvement; for 
example, mobilisation of lipid stores are necessary for acute-phase responses 
(Khovidhunkit et al. 2004). Furthermore, malnutrition, both over- and under-nutrition 
negatively affects inflammation. People in starvation, for example, have immune 
suppression (Chandra 1996, Blackburn 2001, Khovidhunkit et al. 2004). The modern 
epidemic of obesity is also resulting in a rise of inflammatory diseases, including 
T2DM diabetes (Heilbronn et al. 2008). 
Although both T1DM and T2DM both involve inflammatory pathways, they are 
fundamentally different in aetiology. T1DM is an auto-immune response where the 
body fails to recognise “self” antigens, leading to the selective destruction of the 
pancreatic β-cells. This is thought to stem from both genetic (Habib et al. 2012) and 
environmental factors (Cantorna et al. 2004, Knip et al. 2012, Ghazarian et al. 2013) 
involving failures in the gut (Vaarala et al. 2008), thymus (Geenen 2012), and lymph 
nodes (Yip et al. 2014). Conversely, T2DM strongly correlates with obesity which is 
characterised by chronic low grade inflammation (Heilbronn et al. 2008). A key 
inflammatory-obesity mediator is the cytokine TNF-α which is overexpressed in 
adipose and muscle tissue in obesity (Hotamisligil et al. 1993, Hotamisligil et al. 
1995, Saghizadeh et al. 1996, Sethi et al. 1999). Interestingly, TNF-α treatment in 
vitro or in vivo impairs insulin action which can be reversed by disruption of TNF-α or 
its receptor (Hotamisligil et al. 1993, Uysal et al. 1997). For example, the incubation 
of murine adipocytes with TNF-α decreased expression of Glut1 and Glut2 reducing 
glucose uptake, and blocking TNF-α receptor activity increased insulin-stimulated 
glucose utilisation in mice (Hotamisligil et al. 1993). 
1.8.1 Peripheral and central inflammatory processes 
In the periphery the immune response is mediated by dedicated immune cells; 
natural killer cells, lymphocytes, T cells, and B cells. While historically the brain has 
been regarded as an immunoprivileged site, absent of peripheral immune cells, it is 
now understood that T-cells, for example cross the BBB into the CNS (Louveau et al. 
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2015). Within the CNS glial cells, astrocytes and microglia, are the first responders to 
a CNS insult (Gadani et al. 2015). Both astrocytes and microglia are activated by 
ATP which triggers the release of cytokines (Panenka et al. 2001, Kataoka et al. 
2008) as well as ATP-induced ATP release from astrocytes (Davalos et al. 2005, 
Roth et al. 2013). 
1.8.2 Hypoglycaemia as an inflammatory stimulus 
As previously mentioned, undernutrition can alter the immune system (Chandra 
1996, Blackburn 2001, Khovidhunkit et al. 2004), and hypoglycaemia can stimulate 
the release of proinflammatory, prothrombotic and pro-atherogenic cytokines in man 
(Gogitidze Joy et al. 2010, Wright et al. 2010). Interestingly, non-esterified fatty acids 
are released during hypoglycaemia and can induce vascular inflammation (REF). 
Typically RH blunts normal responses to acute hypoglycaemia; however, RH 
appears to exacerbate cytokine release (Joy et al. 2015). RH also stimulates 
microglial activation in diabetic rats (Won et al. 2012). In acute glucose/oxygen 
deprivation astrocytes suppressed the release of interferon-γ, an inflammatory 
cytokine, from microglia (Kim et al. 2010). Given the metabolic expense of 
inflammatory processes (Romanyukha et al. 2006), it is plausible this suppression of 
inflammation is to conserve energy. 
1.8.3 Inflammatory modulation of the hypothalamus 
A high-fat diet (HFD) for 20 weeks in rats increases CNS inflammation via increased 
NF-κB signalling and reactive oxygen species (ROS) production (Zhang et al. 
2005b). In the hypothalamus, 16 weeks of HFD upregulates the release of 
inflammatory cytokines TNF-α, IL-1β and IL-6 in rats (De Souza et al. 2005). 
Conversely, blockade of hypothalamic NF-κB signalling reduces insulin resistance in 
a mouse diet-induced obesity model (Zhang et al. 2008). This implicates 
hypothalamic inflammation as a central mediator of obesity and regulation of food 
intake more generally. Indeed, cytokines including TNF-α, IL-1β and IL-6 also 
stimulate the hypothalamic-pituitary-adrenal axis (Chrousos 1995, Tsigos et al. 
1997). IL-6, for example, is released during hypoglycaemia in healthy humans 
(Dotson et al. 2008), but also in obesity (Park et al. 2010). Additionally, IL-6 
administration also stimulates ACTH release and hypothalamic-pituitary-adrenal axis 
activation (Naitoh et al. 1988, Späth-Schwalbe et al. 1994). Given that hypothalamic-
pituitary-adrenal axis increases plasma glucose concentrations, IL-6 is an important 
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factor in CRR and obesity-related elevated blood glucose. Interestingly, the largest 
source of IL-6 in the CNS are astrocytes (Van Wagoner et al. 1999). Therefore, 
astrocytes may be contributing to restoring glucose levels through activation of the 
hypothalamic-pituitary-adrenal axis. 
1.8.4 Astrogliosis 
Astrogliosis is a defence mechanism in response to noxious stimuli like trauma or 
ischaemia (Burda et al. 2014). This typically involves changes to astrocyte 
morphology (Sofroniew 2009) and an alteration to gene expression (Zamanian et al. 
2012). Typical markers of astrocytes, glial fibrillary acid protein (GFAP) and vimentin 
have increased expression which corresponds to morphology becoming more 
ramified. Additionally, cytokine release, including IL-6, TNF-α, and IFN-γ increases 
with the magnitude of astrogliosis (Kıray et al. 2016). Importantly, astrogliosis is 
stimulus specific and not a homogenous response. In one study, while approximately 
50% of astrogliosis-induced gene expression was the same, the remaining 50% 
differed depending on whether astrogliosis was induced by ischaemia or 
lipopolysaccharide (LPS) injection (Zamanian et al. 2012), highlighting the adaptive 
capabilities of astrocytes.  
While neuronal NF-κB signalling disruption can protect against hypothalamic 
inflammation caused by HFD, a similar result can be found in astrocytes (Buckman 
et al. 2015, Douglass et al. 2017). Interestingly, fasting also triggers astrogliosis and 
activation (Daumas‐Meyer et al. 2018). Inflammation has a metabolic demand 
(Romanyukha et al. 2006) which in astrocytes is met by adaptive metabolic 
responses (Iglesias et al. 2017). For example, glucose/oxygen deprivation of in vitro 
primary rat astrocytes increases both glycolysis and lactate production by >50% 
(Amaral et al. 2010), which may be due to increased Glut1 expression (Vannucci et 
al. 1998). Additional glycolytic upregulation is reported to come from increased 
PFKFB3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Mazzola et al. 
2001, El Kadmiri et al. 2014, Fu et al. 2015). 
Inflammatory stimuli like HFD (Zhang et al. 2005b) and hypoglycaemia (McGowan et 
al. 2006) increase ROS production. This can lead to DNA damage (Singh et al. 
2004) and mitochondrial dysfunction (Lin et al. 2006). A major anti-oxidant defence 
mechanism is the pentose phosphate pathway (PPP) which diverts glucose-6-
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phosphate out of glycolysis to generate NADPH and ribose-5-phosphate (R5P) 
(Stincone et al. 2015). The NADPH is used to generate reduced glutathione (GSH) 
which is neutralises ROS (Winterbourn et al. 1994). Astrocytes increase PPP activity 
in response to traumatic brain injury (Bartnik et al. 2005). As glucose is required for 
the PPP the upregulation of glucose uptake transporters, like Glut1 (Vannucci et al. 
1998), may be required. Indeed, reactive gliosis also upregulates the expression of 
metabolic related genes which may address the increased metabolic demands of 
their inflammatory response. With the aforementioned roles of inflammation 
modulating energy-homeostasis in the body and the CNS, astrocytes could be 
important and under-appreciated mediators of these processes that have not been 
fully investigated. 
1.9 Summary and project aims 
Astrocytes are no longer seen as passive bystanders in the functions of the CNS.  
Previously it was known astrocytes are important in sensing circulating metabolic 
hormones, such as leptin (Cheunsuang et al. 2005) and insulin (García-Cáceres et 
al. 2016), as well as oxygen (Angelova et al. 2015) and carbon dioxide (Turovsky et 
al. 2016). However, important gaps in the knowledge remain. In the following 
chapters the work presented aims to characterise the responses of isolated human 
astrocytes to physiologically and pathophysiologically relevant glucose 
concentrations. To investigate the effects of acute or recurrent low glucose (RLG) 
human primary astrocytes (HPA) and U373 human astrocytoma cell lines were used. 
The overarching hypothesis was that astrocytic function would be altered by glucose 
variation. Specifically, the aims of this thesis were; firstly, to test whether human 
astrocytes respond to low glucose in an AMPK dependent manner and how this is 
affected by RLG. Secondly, to test whether astrocytic mitochondrial and glycolytic 
metabolism enhanced to compensate for low glucose availability. Thirdly, to test 
whether isolated human astrocytes are activated by low glucose exposure and how 
this is affected by RLG. Lastly, to investigate if astrocytic cytokine release is 
differentially regulated by RLG treatment.  
59 
 
 
Chapter 2 
 
 
 
Materials and Methods 
  
60 
2.1 Materials 
2.1.1 Chemicals 
 
Table 2.1 
Chemical Supplier 
Catalogue 
number 
0.05% (w/v) Trypsin-EDTA Fisher 25300-062 
100% ethanol (for RNA extraction) Thermo Fisher E/0650DF/17 
6-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino-
6-Deoxyglucose  (6-NBDG) 
Cayman 
Chemical 
CAY13961-5 
A438079 Biotechne 2972 
Adenosine diphosphate (ADP) Sigma-Aldrich A2754 
Adenosine triphosphate (ATP) Sigma-Aldrich A9187 
Ammonium persulfate Sigma-Aldrich A3678 
ATP:ADP ratio kit Sigma-Aldrich MAK135 
ATPlite luminescence assay system PerkinElmer 6016947 
Benzamidine Sigma-Aldrich 12072 
Bio-Rad protein assay dye reagent Bio-Rad 500-0006 
BioTrace Nitrocellulose membrane VWR 732-3031 
Bovine serum albumin Sigma-Aldrich A2153 
Bromophenol blue sodium salt Sigma-Aldrich B5525 
DAPI Molecular Probes D1306 
Dimethyl Sulfoxide HYBRI-MAX (DMSO) Sigma-Aldrich 
D2650-
5X5ML 
Direct-zolTM RNA MiniPrep kit Zymo Research R2050 
D-mannitol Sigma-Aldrich M4125 
DMEM glucose free Fisher 11966 
DMEM high glucose Sigma-Aldrich D5671 
DMEM low glucose  Sigma-Aldrich 31885 
DMEM, no glucose or phenol red Fisher 12307263 
EGTA Melford e1102 
Ethylenediaminetetraacetic acid disodium salt 
(EDTA) 
Sigma-Aldrich E1644 
Fluo-4 direct calcium assay reagent Life Technologies F10471 
Foetal bovine serum (FBS) Gibco 11573397 
Fura-2 AM Life Technologies F1221 
Gentamicin Thermo Fisher 15750060 
Glucose Sigma-Aldrich G7021 
Gluteraldehyde Thermo 11423488 
Glycerol Sigma-Aldrich 49767 
Glycine Melford G0709 
Glycogen kit (fluorometric) Cell Biolabs, Inc MET-5023 
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Grade 3MM Chr blotting paper Fisher 11330744 
HEPES Sigma-Aldrich H0877 
Human cytokine array panel A R&D systems ARY005 
Interleukin-13 (IL-13) ELISA Biotechne DY213-05 
Lactate dehydrogenase (LDH) Sigma-Aldrich L1254 
L-glutamine Fisher 25030-024 
L-lysine Thermo 10016203 
Macrophage migration inhibitory factor (MIF) 
ELISA 
RayBiotech ELH-MIF-1 
Methanol Sigma-Aldrich 34860-2.5L-R 
Mito fuel flex test kit Agilent 103260-100 
Mito stress test kit Agilent 103015-100 
MitoTracker Red CMXRos Molecular Probes M7512 
N,N,N′,N′-Tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich T7024 
NaCl Sodium Chloride Sigma-Aldrich S7653 
NaF Sodium Fluoride Sigma-Aldrich S7920 
NaVO4 Sodium Orthovanodate Sigma-Aldrich S6508 
Noradrenaline Abcam ab120717 
Normal donkey serum Sigma-Aldrich S30-100ML 
Paraformaldehyde Sigma-Aldrich P6148-1KG 
Penicillin-streptomycin Fisher 15070-063 
Phenylmethanesulfonyl fluoride (PMSF) Sigma-Aldrich P7626 
Phosphate buffered saline (PBS) tablets Fisher 10209252 
Plasminogen activator inhibitor-1 (PAI-1) ELISA Sigma-Aldrich RAB0429 
Poly-L-lysine hydrobromide Sigma-Aldrich P1274 
Pyridoxalphosphate-6-azophenyl-2',4'-disulfonic 
acid tetrasodium salt (PPADs) 
BioTechne 625 
ProtoGel (30% w/v) acrylamide 
Scientific 
Laboratory 
Supplies 
NAT1260 
SeeBlue plus 2 pre-stained protein standard Life Technologies LC5925 
Semicarbazied hydrochloride Sigma-Aldrich S2201 
Serotonin hydrochloride (5HT) 
Cambridge 
Bioscience 
CAY14332 
Skimmed milk powder Oxoid LP0031 
Sodium dodecyl sulphate (SDS) Melford B2008 
Sucrose Melford S0809 
Tris Melford B2005 
Triton X100 VWR M143-1L 
TRIzol Invitrogen 15596026 
Tween-20 Sigma-Aldrich P2287 
β-mercaptoethanol (BME) Sigma-Aldrich M3148 
β-Nicotinamide adenine dinucleotide sodium 
salt 
Sigma-Aldrich N0632 
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2.1.2 Equipment 
Table 2.2 Equipment 
Equipment Supplier 
PHERAstar® FS microplate reader BMG Labtech 
Seahorse XFe96 bioanalyser Agilent 
DM4000 B LED Fluorescent microscope Leica 
DMi8 confocal microscope Leica 
Odyssey® CLx Licor 
Mini-PROTEAN® Tetra system Bio-Rad 
TC20TM Automated Cell Counter Bio-Rad 
Eclipse TE 2000-S Nikon 
79000 Series Filter Set Chroma 
ORCA-ER Digital Camera Hamamatsu 
Lambda DG4 Sutter Instrument Company 
2200 Tapestation Agilent 
HiSeq 2500 Illumina 
 
Table 2.3 Cell culture materials 
Equipment and apparatus Supplier Catalogue number 
96-Well Microplate, Round Wells, 
Flat Bottom, PS (Sterile) 
Starlab E2996-1600 
FluoroNunc F96-MicroWell Plate, 
with lid, sterile (50 pack) 
VWR 732-2699 
Greiner 96-well plate TC treated 
with lid clear sterile 
Scientific Laboratory 
Supplies 
G655180 
T25 Starstedt 83.3911.001 
T75 Starstedt 83.3911.002 
T175 Starstedt 83.3912 
35 mm dish Thermo Fisher 150318 
60 mm dish Starstedt 83.3901 
10 cm dish Starstedt 83.3902 
12 well plate Starstedt 83.3921 
24 well plate Starstedt 83.3922 
 
2.1.3 Primary antibodies 
Table 2.4 Primary Antibodies 
Primary antibodies Supplier Catalogue number 
CPT1-a 
Cell Signalling 
technologies (CST) 
15184-1-AP 
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EAAT1 St John's Laboratory STJ92813 
FAS CST 3180S 
G6PD Source Bioscience GTX101212S 
GFAP Dako z0334 
Glut-1 Millipore 07-1401 
HK1 CST 2024 
HK2 CST 2867 
HK3 Abcam ab126217 
pSer79 ACC CST 3661 
pThr172 AMPK CST 2535 
PDHe1 CST 3205P 
PFKP CST 5412 
PGC1-a CST 2178S 
PKM2 CST 4053P 
SDHa CST 11998 
VDAC CST 4661S 
Vimentin Sigma-Aldrich V6630 
β-actin Biotechne NB600-501 
 
2.1.4 Secondary antibodies 
Table 2.5 Secondary antibodies 
Primary antibodies Supplier Catalogue number 
Alexa fluorTM 680 goat anti-
mouse IgG 
Invitrogen A21057 
Anti-mouse Alexa fluor 568 Invitrogen A10037 
Anti-IgG (Rabbit) Goat 
Polyclonal Antibody 
VWR ROCK611-132-122 
Anti-rabbit Alexa fluor 488 Invitrogen A21206 
 
2.2 Methods 
2.2.1 Cell culture 
Cells were cultured using aseptic technique to avoid contamination and incubated at 
37°C in a humidified atmosphere containing 95% air and 5% CO2. Human 
astrocytoma U373 cells were obtained from the European Collection of 
Authenticated Cell Cultures (EACC), human neuroblastoma SH-SY5Y cells were 
gifted by Professor Rory McCrimmon of the University of Dundee, and mouse 
hypothalamic immortalised neuronal GT1-7 cells were gifted by Dr Pamela Mellon of 
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the University of San Diego. Human primary astrocytes (HPA) were gifted by Dr 
Janet Holley and Professor Nicholas Gutowski from the University of Exeter. HPA 
cells were originally isolated from normal subventricular deep white matter blocks 
immediately post-mortem following consent from next-of-kin and with ethical 
approval from the North and East Devon Research Ethics Committee from a 17-year 
old male (Holley et al. 2005). Astrocytes were isolated from approximately 2 cm3 
tissue blocks modifying methods previously used (McCarthy et al. 1980, Noble et al. 
1984a, Noble et al. 1984b). Media components for each cell type are listed in table 
2.6: 
Table 2.6 Media components 
Cell type Medium name Medium constituents 
HPA Stock 
Sigma DMEM (31885), 10 % (v/v) Sigma Foetal 
Bovine Serum (FBS, 11573397), 2 mM L-
glutamine, and 25 ug/ml gentamicin. Contains 5.5 
mM glucose. 
HPA 
2.5 mM 
glucose 
Sigma DMEM (11966) and 2.5 mM glucose. 
HPA 
0.1 mM 
glucose 
Sigma DMEM (11966) and 0.1 mM glucose. 
HPA 
2.5 mM 
glucose with 
serum 
Sigma DMEM (11966), 1% (v/v) Sigma FBS 
(11573397), 22.5 mM mannitol, and 2.5 mM 
glucose. 
HPA 
0.1 mM 
glucose with 
serum 
Sigma DMEM (11966), 1% (v/v) Sigma FBS 
(11573397), 24.9 mM Mannitol, and 0.1 mM 
glucose. 
U373, SH-
SY5Y and 
GT1-7 
Stock 
Sigma DMEM (D5671), 10 % (v/v) Sigma FBS, 
4% (v/v) L-glutamine, and 2% PenStrep. Contains 
25 mM glucose. 
U373, SH-
SY5Y and 
GT1-7 
7.5 mM 
glucose 
Sigma DMEM (11966), 10 % (v/v) Sigma FBS 
11573397), 2% penStrep, and 2% (v/v) L-
glutamine. 
U373, SH-
SY5Y and 
GT1-7 
2.5 mM 
glucose 
Sigma DMEM (11966), and 2.5 mM glucose. 
U373, SH-
SY5Y and 
GT1-7 
0.1 mM 
glucose 
Sigma DMEM (11966), and 0.1 mM glucose. 
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U373 cells were passaged every 3-7 days and maintained at 50-85% confluency in 
T-75 flasks. HPA cultures were passaged weekly to fortnightly and kept between 70-
100% confluency in T-175 flasks. To aid with adhesion, plastic ware used to culture 
HPAs was coated with poly-L-lysine (PLL) used at 4 mg/ml for >30 minutes. Cell 
cultures were passaged by removal of media, gentle washing with warm PBS, 
incubating with 0.05% Trypsin-EDTA (3-5 ml for T-75s and 7-10 ml for T-175s) for 3-
5 minutes at 37 °C, trypsinisation was ceased with the addition of stock medium (5ml 
for T-75s and 10ml for T-175s) to the flask. Cells were pelleted by centrifugation at 
1000 rpm for 5 minutes. The pellet was resuspended in 1 ml of medium and then a 
further 2-5 ml. For U373 cultures, 1 ml of cell-suspension would then be added to a 
new T-75 and 9 ml of stock medium added. For HPA cultures, 1x106 cells were 
counted using the TC20TM Automated Cell Counter (Bio-Rad) and topped up to a 
total of 25 ml of stock media. Stock flasks were given fresh media every 48-72 hours 
to maintain nutrient supply. For experiments, U373 cultures were incubated in 7.5 
mM glucose containing media, HPAs were plated in stock medium the night before 
experimentation. To ensure a suitable and consistent confluency, cells were seeded 
at the densities found in table 2.6. 
Table 2.7 Seeding densities 
Cell type Culture vessel Cells seeded 
HPA 96 well plate 2 x104 
HPA 24 well plate 5 x104 
HPA 60 mm dish 
2.5 x105 for 4 day RLG. 
4.5 x105 for next day 
treatment and collection 
U373 60 mm dish 
4.5 x105 for next day 
treatment and collection  
2.5 x105 for 4 day RLG 
HPA 10 cm dish 
6.5 x105 for next day 
treatment and collection 
1 x106 for 4 day RLG 
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HPA T75 
1 x106 for stock or 4 day 
RLG or 7.5x105 for RLG 
plus recovery 
U373 T75 1:3-1:5 from previous flask 
HPA T175 1 x106 for stock culturing 
SH-SY5Y T75 1 x106 for stock culturing 
SH-SY5Y 60 mm dish 
4.5 x105 for next day 
treatment and collection 
GT1-7 T75 1 x106 for stock culturing 
GT1-7 96 well plate 5 x104 
When suitable confluency was attained cell cultures were split and used within a 
range of passage numbers: HPA cells p7-20, U373 cells p16-p30, SH-SY5Y cells 
p10-20, and GT1-7 cells p50-56. 
2.2.2 Glucose variation treatments 
2.2.2.1 Acute low glucose 
Cells were seeded the day before experiments and incubated overnight; HPA in 
stock medium and U373 in 7.5 mM glucose containing medium. On the day of 
experimentation the overnight media was aspirated and cells washed with warm 
PBS and replaced with 2.5 mM glucose containing DMEM 11966 media. During the 
characterisation of AMPK pathway activation by low glucose in HPA cells it was 
noted that cellular morphology was altered by the withdrawal of FBS, therefore, in 
experiments HPA media was supplemented with 1% serum, and 22.5 or 24.9 mM 
mannitol for 2.5 and 0.1 mM glucose concentrations respectively, to reduce osmotic 
stress. The cells were incubated for 2-hours before washing with warm PBS and 
replaced with either 2.5 or 0.1 mM glucose containing DMEM 11966 media. Cells 
were then cultured for 30 or 180 minutes. For experiments including the addition of 
noradrenaline (NA) and serotonin (5HT) a final concentration of 50 µM was added 
from a stock of 100 mM and 50 mM (vehicle was H2O) respectively into the treatment 
media. Cells were incubated for 30 minutes before termination of the treatment. In all 
instances, following treatments conditioned media and cell lysates were collected 
(see 2.2.2.4). 
67 
2.2.2.1.1 Repeated sampling of U373 cells exposed to acute low glucose 
U373 cells were seeded the day before experimentation into 60 mm dishes and 
incubated in medium containing 7.5 mM glucose. On the day of experimentation 
media was aspirated and the cells washed with 1.5 ml of warmed PBS and replaced 
with 1.5ml 2.5 mM glucose containing media with 22.5 mM mannitol and incubated 
for 2 hours at 37°C. Medium was aspirated; cells washed with 1.5 ml of warmed PBS 
and incubated for 3 hours in 1.5 ml 2.5 mM glucose with 22.5 mM mannitol 
containing media at 37°C. After this first, baseline, period 1 ml of conditioned media 
was collected and frozen at -20°C. The rest of the medium was aspirated and the 
cells washed with 1.5 ml warmed PBS. The cells were then incubated in 1.5 ml of 2.5 
or 0.1 mM glucose with 22.5 or 24.9 mM mannitol containing media respectively at 
37°C for 3 hours. 1 ml of conditioned media was collected from both control (2.5 mM 
glucose) and low glucose (0.1 mM glucose) treated cells and frozen. The remaining 
media was aspirated and the cells washed with 1.5 ml warmed PBS. There was then 
a final 3 hour incubation of cells in 1.5 ml 2.5 mM glucose, 22.5 mM mannitol 
containing media at 37°C. 1 ml of conditioned media was then collected and frozen, 
the remaining medium aspirated and the cells lysed and collected using 65 µl of lysis 
buffer. Cell samples were frozen and stored until protein quantification. Conditioned 
media samples were stored frozen until a human MIF ELISA was performed. 
2.2.2.2 Recurrent low glucose 
Each day cells were exposed to 2 hours of media containing 2.5 mM glucose then 3 
hours of medium containing 2.5 or 0.1 mM before being recovered in stock medium 
or 7.5 mM glucose containing medium overnight for HPA and U373 respectively. The 
control and acute low glucose groups were treated with media containing 2.5 mM 
glucose, whereas, the antecedent RLG and RLG treated groups received 0.1 mM 
glucose media for 3 hours each day for the first three days. On the fourth day control 
and antecedent RLG were treated with 2.5 mM glucose media, whereas, acute low 
glucose and RLG were treated with 0.1 mM glucose media. See figure 2.1A for a 
depiction of the treatments.  The treatment period on the last day varied between 15, 
30 or 180 minutes depending on the experiment performed. At the end of treatment 
conditioned media and cell lysates were then collected. 
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2.2.2.2.1 Antecedent recurrent low glucose for Seahorse analysis 
For analysis of cellular metabolism using the Seahorse XFe96 HPA and U373 cells 
were seeded into T75 flasks 3 days, and the day before glucose variation, 
respectively. Control and RLG cells were treated with 2.5 mM glucose for 2 hours 
and then medium containing 2.5 or 0.1 mM glucose for 3 hours. Each night cells 
were recovered in stock medium or medium containing 7.5 mM glucose for HPA and 
U373 cells respectively. On the fourth day of this treatment cells were recovered for 
2 hours and then split and seeded at 2x104 cells per well into a Seahorse 96-well 
microplate and incubated overnight in stock medium or medium containing 7.5 mM 
for HPA and U373 cells respectively. 
2.2.2.2.2 Recurrent low glucose treatment of HPA for RNA extraction 
HPA samples generated for RNA extraction were cultured in 60 mm dishes and 
treated to control, acute low glucose, antecedent RLG, or RLG as previously 
described. At the end of the treatment period, cells were trypsinised at 37°C and 
centrifuged for 5 minutes at 1x103 RPM to pellet the cells. Supernatant was then 
removed and cells resuspended in PBS. One half of the cell suspension was 
transferred to a new tube where an additional 250 µl of TRIzolTM was added. The 
other half was kept for analysis of DNA at a later date. Samples were then stored at -
80°C until DNA and RNA extraction took place. 
2.2.2.3 Recurrent low glucose with recovery 
HPA cells were seeded at 7.5x105 cells per T75 flask and incubated overnight in 
stock media. For the next 7 days control, RLG and RLG plus recovery treatment 
groups were treated with media containing 2.5 mM glucose for 2 hours, 3 hours of 
treatment media, and recovered overnight in stock media. On days 1-4, control and 
RLG cells were treated with medium containing 2.5 mM glucose for 3 hours and RLG 
plus recovery were treated with medium containing 0.1 mM glucose. On days 5-8, 
control and RLG + recovery cells were treated with medium containing 2.5 mM 
glucose and RLG cells were treated with medium containing 0.1 mM glucose. On 
day 8, after the final treatment, conditioned media and cell lysates were collected. 
For assessment of cellular metabolism, cells were recovered for 2 hours in stock 
media before being split and seeded into Seahorse 96 well plates at 2x104 cells per 
well and incubated overnight in stock medium. See figure 2.1B for a depiction of the 
cell treatment protocol. 
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2.2.2.4 Preparation of cell lysates 
Lysis buffer contained EDTA and EGTA to chelate Mg2+ and Ca2+ ions, removing an 
essential cofactor for many protein kinases. Ca2+ chelation also inhibits calcium-
dependent proteases, phosphatases, and kinases. To inhibit serine/threonine protein 
kinases sodium fluoride and sodium pyrophosphate were used. Tyrosine 
phosphatases were inhibited by sodium orthovanadate. Furthermore, benzamidine 
and phenylmethylsulfonyl fluoride (PMSF) was added to inhibit other protease 
activity. The complete lysis buffer constituents were: 25 mM Tris HCl (pH 7.4), 0.5 M 
NaF, 0.1 M NaCl, 1 mM EDTA (pH 8), 5 mM EGTA (pH 8), 1% (v/v) Triton X100, 10 
mM NaPPi, 269 mM sucrose, 1 µl/ml β-Mercaptoethanol (BME), 1 mM NaVO4, 1 mM 
benzamidine, and 0.1 mM PMSF. 
After experimental conditions were completed media samples were collected and 
immediately cooled in wet ice or snap frozen with dry ice. Cells culture vessels were 
placed on top of a bed of ice to keep them cold, and ice cold lysis buffer added. Lysis 
was further aided by mechanical disruption of the cells using scraping. Sample lysate 
was then collected and retained in a 1.5 ml Eppendorf tube and cooled in wet ice or 
snap frozen in dry ice. Cell lysates were frozen and thawed before they were 
centrifuged at 1.48 x104 rpm for 15 minutes at 4°C to removed insoluble material. 
Supernatants were transferred to fresh 1.5 ml Eppendorf tubes and protein content 
quantified by the Bradford method. 
2.2.2.5 Determination of protein content 
Protein concentration was determined using the Bradford method (Bradford 1976). 
Briefly, 1 µl of sample was added in triplicate in a 96 well plate and 200 µl of 1 in 5 
diluted Bradford reagent (BioRad) was added. The resulting solution was mixed by 
orbital shaking at 500 rpm for 5 minutes prior to measurement. Measurement was 
achieved by measuring absorbance at 595 nm was measured using the 
PHERAstar® FS. Samples were compared to a standard curve generated from 
known concentrations of bovine serum albumin (BSA). 
2.2.3 SDS-PAGE separation of proteins 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to separate proteins of different molecular weights in a sample. Proteins were 
linearised and a negative charge applied using SDS, allowing for their 
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electromagnetic attraction to an anode. An electrical current was applied to the 
samples and pulled the sample through the poly-acrylamide gel. By varying the 
concentration of acrylamide in the gel (table 2.7), different matrix sizes could be 
created. Gels containing a higher percentage of polyacrylamide, with small matrix 
sizes, allowed for optimal resolution of smaller molecular weight proteins and the 
inverse is also true. 
2.2.3.1 Preparation of hand cast gels 
Table 2.8 Hand cast gel compositions 
  4% 7% 10% 12% 
ddH2O 1.4 ml 2.64 ml 2.075 ml 1.71 ml 
1.5 M Tris - 1.575 ml 1.575 ml 1.575 ml 
0.5 M tris 0.625 ml - - - 
30% Acrylamide 0.425 ml 1.315 ml 1.875 ml 2.24 ml 
10% SDS 25 µl 55 µl 55 µl 55 µl 
20% APS 25 µl 27.7 µl 27.7 µl 27.7 µl 
TEMED 2.675 µl 5.5 µl 5.5 µl 5.5 µl 
 
Hand cast gels were made using mini-PROTEAN® Tetra equipment supplied by Bio-
Rad. TEMED and 20% ammonium persulfate (APS) were added in quick succession 
last to initiate acrylamide polymerisation. Before the gel had polymerised the 
resolving (7-12% mixtures) gel was poured and a layer of water added to level out 
the gel. Once the resolving gel had set the water was removed and the stacking 
(4%) gel was added and well combs put in place. 
Wells were loaded at 10 µg of sample protein in sample buffer. Once loaded the gels 
were run at 90 V for 15 minutes, until the samples had passed through the stacking 
gel. The gels were then exposed to 150 V for 1 hour and 30 minutes to 2 hours 
depending on the molecular weight of the protein of interest. 
Table 2.9 SDS-PAGE buffers 
Buffer Recipe 
Sample buffer Immediately prior to use 1 µl/ml of BME was added to 4x sample 
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buffer which was then added to make a 1x final solution with 
samples diluted to a desired concentration of protein. 125 mM 
Tris/HCl (pH 6.8), 0.4 ml/ml 10% SDS, 0.2 ml/ml glycerol, and a 
small amount of bromophenol blue, made up in ddH2O. 
Running buffer 
A 10x stock was diluted to 1x before use. 10 x stocks were made 
with 250 mM Tris, 1.9 M glycine, and 34.7 mM SDS made up in 
ddH2O. 
Transfer buffer 
0.2 ml/ml methanol, 48 mM tris, and 39 mM glycine was made up 
in ddH2O 
Tris-buffered 
saline with 
tween 20 (TBS-
T) 
20mM Tris/HCl (pH 7.4),  152 mM NaCl, 0.05% v/v Tween-20 
made up in ddH2O 
 
2.2.3.2 Transfer of proteins to nitrocellulose membranes 
Upon completion of SDS-PAGE protein was transferred to nitrocellulose membranes 
by electrotransfer. A nitrocellulose membrane was placed onto the gel and 
sandwiched by filter paper and fibre pads on both sides. To electrotransfer the 
proteins in the gel onto the membrane, the membrane was placed between the gel 
and an anode whilst bathed with transfer buffer. Similarly to SDS-PAGE, an electrical 
current, 100 V for 1 hour and 15 minutes, was applied to attract the still negatively 
charged proteins towards the anode. 
2.2.3.3 Immunodetection 
Following the completion of electrotransfer membranes were incubated in 5% (w/v) 
dried milk or 5% (w/v) BSA in TBS-T for 1 hour at room temperature with gentle 
rocking. This allowed for all the nitrocellulose membrane’s free protein binding sites 
to be bound and prevent non-specific binding of the antibodies used. Primary 
antibodies were then incubated using the specific protocols as outlined in table 2.9. 
After these protocols were completed primary antibodies were removed and the 
membranes washed for 6 x 5 minute washes in TBS-T to remove remaining un-
bound primary antibody. Membranes were then incubated in TBS-T containing 
IRDye secondary antibodies for 1 hour at room temperature. Following the 
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incubation membranes were washed with TBS-T for 6 x 10 minutes. To visualise the 
Immunodetection the Odyssey® CLx (Licor) was used to scan the blots. 
Table 2.10 Antibody protocols: 
Antibody Dilution Solution Source 
pAMPK 1:1000 2.5% (w/v) BSA in TBS-T Rabbit 
pACC 1:1000 2.5% (w/v) BSA in TBS-T Rabbit 
HK1 1:1000 2.5% (w/v) BSA in TBS-T Rabbit 
HK2 1:1000 2.5% (w/v) BSA in TBS-T Rabbit 
HK3 1:1000 2.5% (w/v) BSA in TBS-T Rabbit 
PFKP 1:1000 2.5% (w/v) BSA in TBS-T Rabbit 
VDAC 1:1000 2.5% (w/v) BSA in TBS-T Rabbit 
SDHa 1:1000 2.5% (w/v) BSA in TBS-T Rabbit 
PGC1-a 1:1000 2.5% (w/v) BSA in TBS-T Rabbit 
Glut-1 1:1000 5% (w/v) BSA in TBS-T Rabbit 
PDHe1 1:1000 5% (w/v) BSA in TBS-T Rabbit 
PKM2 1:1000 5% (w/v) BSA in TBS-T Rabbit 
CPT1-a 1:1000 2.5% (w/v) BSA in TBS-T Rabbit 
Vimentin 1:1000 2.5% (w/v) BSA in TBS-T Mouse 
FAS 1:1000 2% (w/v) Milk in TBS-T Rabbit 
G6PD 1:1000 2.5% (w/v) BSA in TBS-T Rabbit 
EAAT1 1:1000 2.5% (w/v) BSA in TBS-T Rabbit 
β-actin 1:10000 2.5% (w/v) BSA in TBS-T Mouse 
Anti-Rabbit  1:10000 TBS-T Goat 
Anti-mouse 1:10000 TBS-T Goat 
 
2.2.3.4 Analysis of western blots 
Densitometric analysis was done using Image Studio™ Lite; regions of interest were 
drawn around the detected bands, including regions for background signal detection, 
and the signal measured using pixel intensity. For all proteins of interest signal was 
normalised to the loading control, β-actin. The β-actin was used to account for errors 
in protein quantification and sample loading. Samples were then normalised to the 
control, which was designated as 1, and relative levels of protein or phosphorylated 
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protein were analysed using one-sample T-tests. Statistical significance was 
determined if the P<0.05. 
2.2.4 Extracellular flux analysis 
2.2.4.1 Seahorse XFe96 
The Seahorse XFe96 measures in real time oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) of live cells in a 96 well plate. OCR is a 
measure of mitochondrial respiration whereas ECAR is a measure of glycolysis. 
OCR is generated by the use of oxygen in the electron transport chain within the 
mitochondria. ECAR is generated by the production of lactate and H+ by glycolytic 
processes. HPA or U373 cells were seeded at 2x104 cells per well at least 16-24 
hours before the assay was performed. The assay began, after pre-treatments when 
needed, by replacing the medium with low buffered Seahorse basal medium with an 
additional 2.5 mM glucose, 2 mM L-glutamine, and 2.5 mM pyruvate. Note that in the 
case of the glucose dose response experiments, the cells were cultured with no 
glucose in the Seahorse media, which was then injected back in during the 
experiment. The low buffered medium allows for the unregulated change of pH in the 
medium which can be measured by the Seahorse probes. Once the medium was 
replaced, the cells were incubated at 37°C for 1 hour in atmospheric oxygen and 
CO2 conditions to further reduce the buffering capacity of the medium by eliminating 
CO2 mediated buffering. During this de-gassing process a Seahorse cartridge was 
loaded with any compounds that were to be injected during flux analysis. Once 
completely loaded the cartridge was placed in the Seahorse machine and an 
equilibration and calibration process was performed. After de-gassing, equilibration 
and calibration the cells were loaded and OCR and ECAR flux was measured. 3 
minute mix and 3 minute measure cycles were used during the assay. Prior to any 
injections 3-4 baseline measurements were taken to ensure stability. Following 
assay completion the plate was removed and the medium aspirated. The cells were 
lysed with 100 µl of 50 mM NaOH and the protein content of the wells was quantified 
by the Bradford method as previously described. OCR and ECAR measurements 
were normalised to well protein content. 
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2.2.4.2 Mitochondrial stress test 
The Mito Stress test was performed using the manufacturer’s instructions (Agilent). 
The Mito Stress test is performed by the sequential addition of mitochondrial 
inhibitors to test different mitochondrial parameters. Following measurement of basal 
OCR, oligomycin, an ATP-synthase inhibitor, was injected at 10 µM. The resulting 
decrease in OCR was a measure of ATP-production-associated OCR. After 4 mix 
and measure cycles carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), 
an ionophore that transports H+ through the inner mitochondrial membrane, 
uncoupling respiration driving maximal oxygen consumption, was added at a final 
concentration of 5 µM. The increase in OCR gave a measure of maximal respiration, 
and when basal respiration was subtracted gave a measure of spare respiratory 
capacity. After a further 4 mix and measure cycles rotenone and antimycin A were 
added at 5 µM each. These are complex 1 and 3 inhibitors respectively, which 
ablates the remaining function of the electron transport chain, thus eliminating 
mitochondrial oxygen consumption, allowing the measurement of non-mitochondrial 
OCR. Cytoplasmic oxygenases are the principle source of non-mitochondrial oxygen 
consumption. When non-mitochondrial OCR is subtracted from basal OCR it reveals 
the mitochondrial component of OCR. One can further calculate other mitochondrial 
parameters including proton leak and coupling efficiency. See table 2.10 for a list of 
measurable parameters and their calculations. The basal ECAR readings can also 
be of value, showing at baseline differences in glycolytic activity. 
Table 2.11 Cellular metabolic parameter calculations 
Parameter Equation 
Non-mitochondrial OCR 
Minimum rate after rotenone and 
antimycin A injection 
Basal Respiration 
(last rate measurement before first 
injection) – (non-mitochondrial 
respiration rate) 
Maximal respiration 
(maximum rate measurement after 
FCCP injection) – (non-mitochondrial 
respiration rate) 
H+ (proton) leak (minimum rate measurement after 
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oligomycin injection) – (non-
mitochondrial respiration rate) 
ATP-production-associated OCR 
(last rate measurement before 
oligomycin injection) – (minimum rate 
measurement after oligomycin 
injection) 
Spare respiratory capacity 
(maximal respiration) – (basal 
respiration) 
Spare respiratory capacity as a % 
(maximal respiration) / (basal 
respiration) x 100 
Coupling efficiency 
(ATP production rate) / (basal 
respiration rate) x 100 
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2.2.4.3 Mitochondrial fuel flex test 
The Mitochondrial Fuel Flex test was carried out following the manufacturer’s 
instructions (Agilent). The Mitochondrial Fuel Flex test allows measurement of 
differential fuel usage by mitochondria; pyruvate, glutamine, and long-chain fatty 
acids (LCFAs). The test elucidates the fuel specific dependency, capacity and 
flexibility by the sequential inhibition of either the pathway of interest or the other two 
pathways. To inhibit glucose fuel utilisation UK5099 was added at a final 
concentration of 2 µM which blocks the transport of pyruvate into the mitochondria 
via mitochondrial pyruvate carrier. Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-
yl)ethyl sulphide (BPTES) was used at 3 µM to inhibit glutamine oxidation via 
allosteric inhibitor of glutaminase, which converts glutamine to glutamate which is 
subsequently converted to α-ketoglutarate and oxidised by the TCA cycle. Etomoxir 
was used at 4 µM to inhibit LCFA usage by inhibiting carnitine palmitoyl-transferase 
1A (CPT1A), the rate limiting enzyme in the uptake of LCFAs into the mitochondria. 
To calculate dependency the pathway of interest is inhibited and OCR was allowed 
to stabilise before inhibition of the remaining two pathways. The decrease in OCR is 
indicative of the inability of mitochondria to compensate for the loss of this substrate 
therefore a measure the mitochondria’s dependency on that substrate. A cell’s 
capacity to use a fuel can be calculated by inhibiting the two alternative pathways 
leaving the cells to use the remaining fuel pathway at their maximal rate. Fuel 
flexibility can be calculated by subtracting the fuel dependency from fuel capacity. To 
carry out the test on HPA and U373 cells, they were exposed to RLG using the 
protocol previously described. On the day before experimentation split and seeded 
into Seahorse 96 well plate and cultured overnight in stock medium for the HPAs and 
medium containing 7.5 mM glucose for the U373 cells. 
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2.2.4.4 Glucose dose response 
To study the effect of reintroduction of glucose following RLG HPA and U373 cells 
were exposed to the RLG model previously described and the day before 
experimentation seeded into the Seahorse 96 well plate and incubated in stock or 
medium containing 7.5 mM glucose respectively. On the day of experiment, the 
medium of the de-gas step, which normally containing 2.5 mM glucose, 2.5 mM 
pyruvate and 2 mM L-glutamine, contained no glucose. The cells were incubated for 
60 minutes outside of the Seahorse XFe96 before being put in and baseline 
measurements were taken for a further 20 minutes before glucose was injected into 
the wells. The glucose injections were 0.5, 2.5 and 5.5 mM glucose. OCR and 
EFCAR were continually measured a further 60 minutes. 
2.2.4.5 Inhibition of the pentose phosphate pathway (PPP) using 6-
aminonicotinamide (6-AN) 
The PPP runs in parallel to glycolysis and produces CO2 as a by-product during the 
synthesis of NADPH and ribulose-5-phosphate (Stincone et al. 2015). CO2 is 
released from the cell and this contributes to ECAR (Mookerjee et al. 2015). The rate 
limiting step of the PPP is the conversion of glucose-6-phosphate to 
phosphogluconolactone by glucose-6-phosphate dehydrogenase (G6PD). 
To study the impact of the PPP on cellular metabolism, HPA cells were exposed to 
control and RLG as previously described. Two hours after the cells had been seeded 
into the Seahorse 96 well plate, and 15 hours before analysis in the Seahorse XFe96 
analyser vehicle containing DMSO (0.01%), and 250 or 500 µM 6-aminonicotinamide 
(6-AN) were added into the wells. 6-AN is a selective inhibitor of G6PD and therefore 
inhibits the PPP. The inhibition of the PPP should result in a decrease in CO2 
production and therefore a decrease in ECAR. If there is a large decrease in ECAR it 
would suggest that there is a lot of PPP activity and vice versa. Therefore, changes 
to ECAR induced by 6-AN can be used as a preliminary method for the estimation of 
PPP activity. 
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2.2.5 Immunocyctochemistry 
2.2.5.1 GFAP and vimentin 
For experiments resulting in fluorescent imaging, cells were cultured on 13 mm 
round glass coverslips. Adhesion of HPA cells was aided by the addition of poly-L-
lysine. Following treatment, cells were fixed by methanol. Medium was aspirated and 
immediately replaced with methanol kept at -20°C and incubated for 90 seconds. 
The methanol was then aspirated and cells were washed with PBS. Cells were 
permeabilised with lysine buffer (PBS, 10% normal donkey serum, 50 mM L-lysine, 
0.2% Triton X-100). Cells were incubated overnight at 4°C with primary antibodies, 
anti-vimentin (Sigma, V6630, #102M4831 1:500 in lysine buffer), or anti-GFAP 
(Dako, z0334, #20035994, 1:100 in lysine buffer). The following day, primary 
antibodies were washed off with PBS and secondary anti-mouse (Alexa fluor 568, 
Invitrogen, A10037, #1827879 1:500 in PBS for vimentin) or anti-rabbit (Alexa fluor 
488, Invitrogen, A21206, #1927937 1:500 in PBS for GFAP) were added to the cells 
for 1 hour at room temperature. The anti-body containing solution was washed off 
briefly with PBS and cells were co-stained with DAPI. Coverslips were mounted in 
fluoroshield mounting medium, dried, and imaged by fluorescence microscopy (Leica 
DM4000 B LED; x40). 
2.2.5.2 Measurement of mitochondrial morphology with MitoTracker Red 
CMXRos 
HPAs were cultured on 13 mm round glass coverslips coated with poly-L-lysine in 24 
well plates for 4 days, seeded at 5x104 cells per well and exposed to the RLG model 
previously described. On the fourth day of RLG treatment during the initial incubation 
of the cells for 2 hours in medium containing 2.5 mM glucose was modified so that 
the first 15 minutes contained MitoTracker Red CMXRos (50 nM; Molecular Probes, 
M7512, #1785958). After 15 minutes the medium was aspirated, the cells washed 
with 500 µl PBS and replaced with medium containing 2.5 mM for a further 1 hour 
and 45 minutes. After 3 hours 2.5 or 0.1 mM glucose treated cells were fixed with 4% 
PFA and 0.25% glutaraldehyde solution for 20 minutes. Cells were permeabilised 
with lysine buffer and stained with DAPI nuclear stain (Molecular Probes, D1306, 
0.2mg/mL in PBS). Coverslips were briefly submersed in water and excess liquid 
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removed prior to mounting in fluoroshield mounting medium (Abcam, ab104135, 
#GR311329-1). Note that the fourth day of RLG, addition of MitoTracker Red 
CMXRos, fixing and staining of the cells was carried out by Josephine Robb and 
included here for completeness. Confocal microscopy (Leica DMi8; x63/oil 
immersion lens) was used to obtain Z-stacks of cells. After maximum projections 
were generated using LAS X software (v1.9.0.13747), images were thresholded, 
mean, median, and the total number of objects per image was calculated using a 
custom MatLab script (work carried out by Dr Jon Chilton, but included here for 
completeness). Data from the script were analysed using one-way ANOVA with post-
hoc Bonferroni multiple comparisons tests in GraphPad Prism (v5.01). 
2.2.6 Measurement of intracellular nucleotides 
2.2.6.1 Total ATP levels 
Total ATP levels were measured using ATPlite (Perkin Elmer, #6016941) with minor 
modifications as previously described (Vlachaki Walker et al. 2017). Briefly, this 
assay uses a luciferase assay that luminesces based on ATP content in the sample. 
Media samples were taken from the 60 mm dishes and 100 µl of this was loaded in 
triplicate into the wells of a black walled 96 well plate (VWR). To generate a standard 
curve fresh medium was added to the standard wells and known amounts of ATP 
added ranging from 0.01 to 10 µM. Mammalian cell lysis solution was added to all 
wells, and the plate shaken for 5 minutes. ATP substrate solution was then added to 
all wells and shaken for a further 5 minutes. The plate was dark adapted for 10 
minutes to reduce auto-luminescence of the plate prior to measuring luminescence. 
2.2.6.2 ATP:ADP ratios 
ATP:ADP ratios were calculated using a luminescence assay (Sigma; #MAK135). 
Briefly, 1x103 cells were seeded into black walled 96 well plates and exposed to 2.5 
mM or 0.1 mM glucose levels for 15-180 minutes and nucleotide ratios assayed as 
per manufacturer’s instructions. The assay is performed using two steps. Firstly, 
cells are lysed releasing ATP and ADP. The luciferase, ATP and substrate react to 
produce light which is a direct measure of [ATP]i. The second step converts ADP to 
ATP through an enzymatic reaction which then reacts with the luciferase and 
substrate to emit light. 
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2.2.7 Measurement of extracellular lactate 
Quantification of lactate in the conditioned media of HPA, U373 and SH-SY5Y 
neuroblastoma cells was carried out using an absorbance based plate assay. 
Following cell treatments supernatant was collected and frozen. Samples were 
defrosted on ice and centrifuged for 5 minutes at 1x103 RPM. Supernatants were 
moved to fresh 1.5 ml Eppendorf tubes and 100 µl of sample was aliquoted, in 
triplicate, into a clear bottomed 96 well plate. A standard of known lactate 
concentrations was also loaded into the plate in triplicate. 100 µl of reaction buffer 
was added to each well and incubated for 1 hour at 37°C with intermittent shaking. 
Absorbance was read at 340 nm and the concentration in samples was determined 
by comparison against the standard. 
The reaction buffer contained lactate dehydrogenase (LDH) and NAD+. LDH 
converts lactate to pyruvate and NADH which can be detected by a change in 
absorbance at 340 nm. The recipe for the reaction buffer is as follows: 0.2 M glycine, 
0.2 M semicarbazide hydrochloride. The pH of the solution was adjusted to 10 using 
10N NaOH. On the day of assay, 2.5 U/ml LDH, and 3 mM NAD+ are added just prior 
to use. 
2.2.8 Calcium imaging 
2.2.8.1 Fluo-4 Direct™ 
Fold changes in intracellular calcium were measured using the cell-permeable Ca2+ 
sensitive dye fluo-4 Direct™ (Thermo Fisher) as previously described (Vlachaki 
Walker et al. 2017). Cells were incubated in medium containing 2.5 or 0.1 mM 
glucose for 2 hours and then loaded with 1 x Fluo-4 Direct™ for 1 hour in phenol red 
free DMEM (Fisher) medium containing 2.5 or 0.1 mM glucose supplemented with 5 
mM L-glutamine. After the 1 hour loading period the plate was loaded into the 
PHERAstar® FS microplate reader. Fluorescence was measured with excitation at 
485 nm and emission at 520 nm. Measurements were taken every 0.2 seconds with 
vehicle (phenol red free DMEM with 25 mM HEPES), or drug injections occurring at 
30 seconds, and continually measured for an additional 95 seconds. Compounds 
injected and the concentrations used are listed in table 2.11. Changes to Ca2+-
dependent fluorescence were normalised to the first measurement set to a value of 
85 
1. For analysis the peak fold-change response was used to measure the magnitude 
of change in [Ca2+]i. 
Table 2.12 Compounds used during Fluo-4 experiments 
Compound Treated cell lines Concentrations used (µM) 
ATP HPA, U373, GT1-7 5, 10, 20, 50, 100 
ADP U373 5, 10, 20 
Noradrenaline (NA) HPA, U373 10, 50 and 100 
 
2.2.8.2 Fura-2 AM 
To measure [Ca2+]i in single cells, the cell permeable ratiometric calcium sensitive 
dye Fura-2 AM was used as previously described (Vlachaki Walker et al. 2017). 
Briefly, cells were loaded with Fura-2 AM (2 µM) for 60 minutes. The dye was 
washed off using NaCl HEPES based normal saline containing 2.5 or 0.1 mM 
glucose. During imaging cells were continuously perfused in a low volume chamber 
with NaCl HEPES based normal saline with either 2.5 or 0.1 mM glucose, and/or 
supplemented with ATP. Ratiometric calcium imaging was carried out by alternating 
exposures of excitation at 340 and 380 nm and emission at 510 nm. This was 
performed on the TE 2000-S Eclipse microscope (Nikon), using the 79001-ET Fura2 
filter set (Chroma), the lamda DG4 light source (Sutter Instrument Company), and an 
ORCA-ER digital camera (Hamamatsu). Images were analysed using Volocity 
software (v5.5). 
The recipe for NaCl HEPES based normal saline is as follows: NaCl 135 mM, KCl 5 
mM, HEPES 10 mM, MgCl2 1 mM, CaCl2 2 mM, glucose 2.5 or 0.1 mM dissolved in 
double distilled H2O and the pH adjusted to 7.4 using 1 M NaOH. 
2.2.9 Measurement of 6-NBDG uptake 
6-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino-6-Deoxyglucose (6-NBDG) is a non-
hydrolysable fluorescent glucose analogue that is transported into cells by GLUT-1. 
Once inside the cell fluorescence the dye can be excited by 485 nm of light and 
emission of 520 nm measured. To measure its uptake by HPA cells, following control 
or RLG treatment 6-NBDG was added at 600 µM for 15 minutes in 2.5 mM glucose 
before being washed off and fluorescence measured. 
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2.2.10 Measurement of glycogen 
Glycogen content of HPA and U373 cells exposed to control or RLG was measured 
using a fluorometric kit (Cell Biolabs, Inc.) as per manufacturer’s instructions. Briefly 
samples were compared against a standard curve of known glycogen content. HPA 
cells were exposed to control or RLG treatments; after the last 3 hour glucose 
exposure the cells were washed with ice cold PBS and, scraped and collected with 
ice cold PBS and snap frozen in dry ice. Samples were sonicated and centrifuged for 
10 minutes at 1x104 g for 10 minutes at 4°C. Samples were then loaded into a 
colourless 96 well plate in triplicate. Separate wells were exposed to 
amyloglucosidease and the other half were not, to measure endogenous 
background. This converts glycogen to glucose which is converted to D-gluconic acid 
by glucose oxidase releasing H2O2 which can be measured by a fluorometric probe. 
2.2.11 Measurement of cytokines in conditioned media 
Assessment of extracellular cytokines was achieved using the human cytokine array 
panel A (R&D Systems, ARY005) under the manufacturer’s instructions. HPA cells 
were exposed to control or RLG conditions as previously described, without the 
addition of 1% serum and mannitol to the treatment media. Briefly, conditioned 
media from the cells was collected and incubated on the membranes supplied by the 
kit with bound anti-bodies specific for 36 different human cytokines. Membranes 
were washed and signal developed using horseradish peroxidase conjugated 
secondary antibodies on X-ray film. Densitometric analysis was carried out using 
Image Studio Lite (v5.2, Li-cor). 
2.2.12 Quantifying cytokines in conditioned media using enzyme-linked 
immunosorbent assays (ELISAs) 
To quantify IL-13, PAI-1 and MIF concentrations in conditioned media a targeted 
ELISA was used under manufacturer’s instructions (Biotechne, Sigma-Aldrich and 
RayBiotech respectively). All kits used a sandwich ELISA methodology. The PAI-1 
and MIF ELISA plates were pre-coated with a capture antibody, the IL-13 kit required 
the overnight incubation of the plate coated with a supplied capture antibody. 
Unknown samples and standards of known concentration were loaded into the wells 
and incubated for a specific amount of time. Following this, unbound antigens were 
washed out of the wells and a specific biotinylated anti-target antibody was added to 
the well. Following an incubation period, unbound primary antibody was washed 
87 
from the well. A conjugated streptavidin-horse radish peroxidase (HRP) secondary 
antibody was added. Following incubation, unbound enzyme-antibody-antibody 
conjugates were washed off the plate. 3,3,5,5'-tetramethylbenzidine (TMB) substrate 
reagent was added to each well and incubated to generate a reaction product. Upon 
the addition of an acidic stop solution, 0.2 M sulphuric acid, the reaction product 
becomes yellow in colour with a peak absorbance at 450 nm. The absorbance of 
light at 450 nm was immediately read in each well using the PHERAstar® FS 
microplate reader. 
Mean absorbance values were calculated across technical replicates from each 
ELISA and the average zero standard was subtracted from each. A standard curve 
was produced by fitting a model curve to standard data, which was then used to 
predict the concentrations of the unknown samples. The model curve fitting was 
achieved using a four parameter logistic regression model. To see example standard 
curves for each ELISA please see appendix C. 
2.2.13 RNA-sequencing 
RNA-sequencing is a technique being increasingly used to measure the entire 
transcriptome of biological samples (Kukurba et al. 2015). This improves on 
quantitative PCR and microarray techniques that are comparatively slower. An 
overview of the RNA-sequencing pipeline is given in figure 2.5, and discussed in 
detail in the sections below. 
2.2.13.1 Isolation of RNA 
RNA extraction was completed by Samuel Washer and included here for 
completeness. Total RNA extraction was completed using the Direct-zolTM RNA 
MiniPrep kit (Zymo Research, California, USA). Prior to RNA extraction, RNA 
PreWash, and RNA wash buffer were prepared by adding 10 ml and 48 ml of 100 % 
ethanol (Thermo Fisher) respectively. 
Samples generated from 2.2.2.2.2, containing TRIzol, were thawed on ice and 
homogenised by trituration. 250 µl of 100% ethanol was added to each sample, 
mixed and then transferred to a Zymo-SpinTM IIC Column in a collection tube and 
centrifuged at 1.2x104 g for 30 seconds. Any flow-through was discarded and the 
spin column moved to a new collection tube. 400 µl of RNA Wash Buffer was added 
and the column centrifuged, as before, and flow-through discarded. To remove any 
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DNA contamination DNase I and DNA digestion buffer were added to each spin 
column and incubated for 15 minutes at room temperature. RNA PreWash was 
added, and the tubes centrifuged at 1.2x104 g for 30 seconds and the flow through 
discarded. This was done a second time. RNA wash buffer was added, and the 
tubes centrifuged at 1.2x104 g for 2 minutes to completely remove any wash buffer. 
To elute the RNA, DNase and RNase-free water was added to the column and 
centrifuged for 30 seconds at 1.2x104 g. RNA quantity and quality was checked 
using the 2200 TapeStation (Agilent Technologies) and samples stored at -80°C until 
further use. 
2.2.13.2 RNA-sequencing by the Exeter sequencing service 
RNA library preparation and sequencing was performed by the Exeter Sequencing 
Service and Computational core facilities at the University of Exeter. Prior to RNA 
sequencing libraries were enriched for mRNA using poly-A isolation. Once prepared 
RNA was sequenced using the HiSeq 2500 (Illumina, Cambridge, UK) This facility 
was funded by the Medical Research Council Clinical Infrastructure award 
(MR/M008924/1), Wellcome Trust Institutional Strategic Support Fund 
(WT097835MF), Wellcome Trust Multi User Equipment Award (WT101650MA) and 
BBSRC LOLA award (BB/K003240/1). The author thanks the generous support from 
the aforementioned funders and the service provided by the sequencing service. 
2.2.13.3 Quality control 
Raw data quality control was performed by the Exeter Sequencing Service using 
FastQC. This determines a Phred score which is a metric for the quality of base 
identification during the sequencing procedure (Ewing et al. 1998a, Ewing et al. 
1998b). The Phred score is logarithmically linked to error probabilities (Ewing et al. 
1998a), meaning a Phred score of 10, 20, and 30 has a base call accuracy of 90, 99 
and 99.9% respectively. All samples had a Phred score of >30. 
2.2.13.4 Spliced transcripts alignment to a reference (STAR) alignment 
To align the reads generated from RNA sequencing to the human genome (Homo 
sapiens GRCh38, STAR alignment software (v2.4.0.1) was used (Dobin et al. 2013, 
Dobin et al. 2015). STAR is comprised of two principle phases, seed searching, and 
clustering, stitching and scoring. Seed searching involves sequentially searching for 
a maximal mappable prefix. 
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Once aligned to a reference genome, STAR clusters, stitches and scores the seeds 
generated from the first step. Firstly, STAR clusters seeds by proximity to ‘anchor’ 
seeds. The reads that are successfully mapped are stitched together. The stitching 
process is guided by a local alignment scoring system where the highest scoring 
stitched combination is reported as the best alignment for a read. 
The success of read mapping can be measured as the percentage of uniquely 
mapped reads, which is the percentage of reads successfully mapped reads 
compared to the total number of reads input into the software. A score of >80% is 
considered good (Dobin et al. 2015). 
2.2.13.5 Read summarisation by featureCounts 
Once reads have been successfully aligned to the reference genome, the number of 
reads mapping to a genome feature, i.e. a gene, can be counted by a process known 
as read summarisation, using featureCounts software (v1.6.1) (Liao et al. 2014). The 
featureCounts algorithm works by firstly overlapping reads with predefined genomic 
features. Any reads that overlap multiple features are removed. A hash table of the 
reference sequence names is generated allowing for reference sequence names to 
be found quickly within the input files. After hashing, a two-level hierarchy of genomic 
bins and features is derived that allows for a quick comparison of query reads 
against. The read counts generated from this procedure provides a summary of 
overall expression level of a gene. Note that this method does not distinguish 
between different isoforms of the same gene due to high genomic overlap. 
2.2.13.6 DESeq2 
Once the abundance of reads has been calculated differential gene expression 
analysis was performed using DESeq2 software (1.16.1). The original authors of the 
software Love et. al., 2014  give a full explanation of DESeq2 in their original paper 
(Love et al. 2014). Briefly, genes with low read counts, due to stochastic changes in 
read counts, can have large variance and give false positives with little physiological 
significance. Therefore, genes with <5 reads across each sample were excluded 
from further analysis. Raw read count data is input into DESeq2 software which 
internally corrects and normalises for library size. A series of contrasts were 
performed between groups of interest using wald-tests that determine whether or not 
the log2 fold-change is significantly different between groups from 0. These contrasts 
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were performed between the following groups: cells treated with 0.1 versus 2.5 mM 
glucose on the last day (i.e. control and antecedent RLG versus low glucose and 
RLG), cells treated with control and RLG prior to the last day of study (i.e. control 
and acute low glucose versus antecedent RLG and RLG), as well as individual 
groups control versus low glucose, control versus antecedent RLG, control versus 
RLG, low glucose versus antecedent RLG, low glucose versus RLG, and antecedent 
RLG versus RLG. The false discovery rates within each contrast were controlled for 
using Benjamini-Hochberg corrections (Benjamini et al. 1995). These analyses gave 
lists of differentially expressed genes that were subsequently analysed. 
2.2.13.7 Gene ontology analysis 
Differentially expressed genes were further analysed using the web-based 
enrichment analysis software Enrichr (Chen et al. 2013, Kuleshov et al. 2016). This 
software uses a Fisher exact test to measure overlap between genes of interest 
input by the user and known gene ontologies derived from data bases such as the 
Gene Ontology Consortium (The Gene Ontology et al. 2000, 
The Gene Ontology Consortium 2017) or the Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) (Kanehisa et al. 2000, Kanehisa et al. 2016, Kanehisa et al. 
2017). These multiple comparisons performed in this process are corrected for using 
Benjamini-Hochberg corrections (Chen et al. 2013, Kuleshov et al. 2016). In this 
thesis differentially expressed gene lists derived from DESeq2 were input as a crisp 
data set rather than a fuzzy data set (i.e. one that includes membership weightings). 
Fuzzy data sets require further computational analysis to generate and only slightly 
improve enrichment scores (Kuleshov et al. 2016). Therefore in the interests of first-
pass analysis crisp data sets were used. 
2.2.14 Statistical analysis 
Excluding the data generated by RNA-sequencing, which is discussed above, 
statistical analysis was carried out using GraphPad Prism v7.03. For the comparison 
of two groups unpaired two-tailed student’s t-tests were used. For the comparison of 
three or more groups one-way ANOVA tests were used with post hoc Bonferonni 
multiple comparisons test to determine confidence intervals between groups. To 
compare groups to a hypothetical mean (i.e. fold-change or baseline) one-sample t-
tests were used set to the appropriate hypothetical value. In all instances p values 
were determined as significant by an α level of 0.05.  
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and glycolytic rates following recurrent glucose 
variation in vitro 
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Introduction 
Hypoglycaemia in T1DM is a major barrier to glycaemic control and still a significant 
concern for those affected. Acutely, hypoglycaemia is dangerous and can result in 
coma, seizures and death if left untreated; also known as ‘dead-in-bed’ syndrome 
accounting for approximately 6% of deaths in people under 40 years of age with 
T1DM (Secrest et al. 2011). However, more insidious risks are an increase in 
cardiovascular events (Robinson et al. 2004, Chow et al. 2014a) and dementia 
(Mancardi et al. 1983, Renkawek et al. 1999, Booth et al. 2017). Moreover, 
hypoglycaemia blunts the counterregulatory response to future hypoglycaemia 
(Heller et al. 1991, Segel et al. 2002). This can lead to reduced symptom awareness 
resulting in deeper, more frequent hypoglycaemia; causing IHA. However, strict 
avoidance of hypoglycaemia can improve hypoglycaemia awareness to some extent 
(Fanelli et al. 1993, Cranston et al. 1994, Dagogo-Jack et al. 1994, Fritsche et al. 
2001). 
The principal site of counterregulation is in the central nervous system (CNS), in 
particular the cells of the ventromedial nucleus of the hypothalamus (VMN) (Borg et 
al. 1995), the arcuate nucleus of the hypothalamus (ARC) (Wang et al. 2004), and 
the dorsal vagal complex (Filippi et al. 2012). Pharmacological (Muller et al. 1972) or 
chemical (Shor-Posner et al. 1986, Lu et al. 1993) inhibition of adrenergic hindbrain 
neurons impairs or ablates the normal responses to neuroglycopenia. The 
hypothalamus also detects glucose directly; hypothalamic glucose transporter 
inhibition induces hyperphagia in rats (Glick et al. 1968). More recently, Levin et. al., 
demonstrated the chemical and genetic manipulation of glucose-sensing neurons in 
the VMN alters the CRR to insulin-induced hypoglycaemia (Levin et al. 2008). In the 
ARC there are neuropeptide Y (NPY) and pro-opiomelanocortin (POMC) neurons, 
which have opposite effects on energy metabolism. NPY neurons are orexigenic and 
increase food intake and reduce energy consumption (Shintani et al. 2001), 
whereas, POMC neurons are anorexigenic, decreasing food intake and increasing 
energy expenditure (Cowley et al. 2001). Glucose-sensing neurons can be classified 
as glucose excited (GE) or glucose inhibited (GI). Populations of POMC neurons are 
GE and increase firing in response to high interstitial glucose (Ibrahim et al. 2003). 
Populations of NPY neurons, conversely, are GI and activated by low glucose 
(Mountjoy et al. 2007). Synaptic glutamate release from neurons of the VMN is 
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necessary for CRR to insulin-induced hypoglycaemia (Tong et al. 2007). Astrocytes 
have also been demonstrated to be important in glucose-sensing and the CRR. For 
example, astrocyte activation can be induced by glucoprivic stimuli, such as 2-
deoxyglucose (2-DG), where consequent neuronal modulation increases gastric 
emptying (McDougal et al. 2013b). Moreover, in a global KO of glucose transporter 2 
(Glut-2), the selective re-expression of Glut-2 in astrocytes, but not neurons, restored 
CRR in rodents (Marty et al. 2005). Lastly, using chemogenetic manipulation of 
astrocytes Chen et al, were able to bi-directionally control food intake, highlighting 
the importance of astrocytes in whole-body energy homeostasis (Chen et al. 2016). 
The ability to sense low glucose is mediated in part by the activation of AMP-
activated protein kinase (AMPK) (McCrimmon et al. 2006a). AMPK, found in many 
tissues, is a cellular fuel-gauge which when activated increases catabolism and 
decreases anabolism. As AMP and ADP increase within a cell AMPK is activated 
and phosphorylated at threonine 172. AMPK is phosphorylated at this site by at least 
three kinases liver kinase B1 (LKB1), Ca2+/calmodulin-dependent protein kinase II 
(CaMKK2) and TGFβ-activated kinase 1 (TAK1) (Hardie et al. 2012). ATP 
allosterically inhibits AMPK activation forming a negative feedback loop as 
intracellular ‘energy’ levels increase. ATP blocks the action of upstream kinases and 
permits access to phosphatases, protein phosphatase 2C (PP2C) and Mg2+-/Mn2+-
dependent protein phosphatase 1E (PPM1E), that dephosphorylate threonine 172. 
When AMP and ADP reach high concentrations, they displace ATP and block the 
action of phosphatases, thus activating AMPK during low energy situations. While 
AMPK is known to be important in glucose-sensing neurons (McCrimmon et al. 
2006a), it remains unclear the extent to which it is involved in astrocyte glucose-
sensing. 
AMPK is necessary for normal cellular function during increased energy demands. 
During energetic stress, according to the astrocyte-neuron lactate shuttle hypothesis, 
astrocytes are able to provide metabolic support to neurons in the form of lactate via 
monocarboxylate transporter 1 (MCT1) and MCT4 on astrocytes, and MCT2 on 
neurons (Pellerin et al. 1994, Pellerin et al. 1998, Pellerin 2003, Bergersen 2007). 
However, there is some disagreement in the literature concerning the extent of this 
phenomenon and whether it occurs in physiological and/or pathological 
circumstances (Chih et al. 2003, Mangia et al. 2009, Figley 2011). Importantly, 
95 
astrocytes can store small amounts of glycogen, which have been shown to be 
broken down in ex vivo brain slices in response glucose withdrawal in order to 
bolster energy supplies; some of which may be provided to neurons via lactate 
(Wender et al. 2000, Brown et al. 2005). Astrocytes also line the blood-brain barrier 
(BBB), in combination with pericytes and endothelial cells, and therefore may be 
exposed to glucose changes before neurons, perhaps being first to act to falling 
glucose levels (Virgintino et al. 1997). Indeed, astrocytes have been shown to 
mediate glucose uptake from microvessels, demonstrating a regulatory role (Maxwell 
et al. 1989). In vitro cultures of brain endothelial cells the uptake of glucose can be 
upregulated by the release of gliotransmitters which may couple astrocyte sensing of 
neuronal activity and the increased supply of glucose at the BBB (Braet et al. 2004, 
Leybaert et al. 2004, Leybaert 2005). Furthermore, the release of these factors from 
astrocytes may be triggered by hypoglycaemia which may serve as a mechanism to 
sustain neuronal energy supply (Régina et al. 2001). 
Astrocyte and neuronal metabolism are markedly different. Neurons utilise primarily, 
the more efficient, oxidative phosphorylation to generate ATP, whereas, astrocytes 
can rapidly increase glycolytic rates (Bélanger et al. 2011). This is partly due to a 
higher expression of 6-phosphofructo-2-kinase type 3 (PFKFB3), which can enhance 
glycolysis (Almeida et al. 2004, Snyder et al. 2004). Glycolysis in astrocytes is also 
more likely to result in lactate production rather than pyruvate (Walz et al. 1988, 
Peng et al. 1994) due to the presence of lactate dehydrogenase (LDH) isoform 5 
(LDH5), which has a higher affinity for pyruvate resulting in net lactate production 
(Bittar et al. 1996). This contrasts with neurons, which only have LDH1 (also found in 
astrocytes) which favours lactate catabolism (Bittar et al. 1996). The increased 
metabolic flexibility of astrocytes makes them highly adaptable to different nutrient 
states and able to react to increased energy demands associated with 
neurotransmission (Pellerin et al. 1994, Fray et al. 1996). 
A consequence of oxidative phosphorylation is the generation of reactive oxygen 
species (ROS) (Murphy 2009). While neurons have an increased reliance on 
mitochondrial respiration, they are more sensitive to oxidative stress-induced cell 
death (Bolanos et al. 1997). A significant cytosolic mechanism for ameliorating ROS 
is the pentose phosphate pathway (PPP) (Stincone et al. 2015). In neurons, the PPP 
accounts for ~5% of glucose metabolism compared to ~60-70% in astrocytes 
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(Allaman et al. 2010, Takahashi et al. 2012). The PPP operates in parallel to 
glycolysis, diverging when glucose-6-phosphate (G6P) is converted by the rate-
limiting enzyme G6P dehydrogenase (G6PDH) to phosphogluconolactone (Glaser et 
al. 1955). The PPP is composed of the oxidative phase and the non-oxidative phase 
(Stincone et al. 2015). The oxidative phase consists of phosphogluconolactone being 
further broken down to 6-phosphogluconate and onto ribose-5-phosphate (R5P), 
contributing to DNA and RNA synthesis (Stincone et al. 2015). During the conversion 
of G6P to R5P, two nicotinamide adenine dinucleotide phosphate (NADPH) 
molecules are produced which is the major source of NADPH within the cell (Dickens 
et al. 1951). This also produces CO2 which contributes to extracellular acidification 
rates (ECAR), detectable by the Seahorse XFe96 extracellular flux analyser 
(Mookerjee et al. 2015). The PPP can also re-join glycolysis, via the production of 
fructose-6-phosphate and glyceraldehyde-3-phosphate, allowing for further 
contributions to ECAR. In theory, the glucose shunted away from glycolysis would be 
prevented from undergoing complete oxidation by the mitochondria and, therefore, 
detectable by changes to OCR also. 
The NADPH produced by the PPP is used as a reducing agent involved in fatty acid 
synthesis and production of reduced glutathione (GSH) from glutathione disulphide 
(GSSG) (Panday et al. 2014).  GSH is a major cellular antioxidant which converts 
H2O2 to GSSG and water by GSH peroxidase (Stincone et al. 2015). It is known that 
the PPP is upregulated as a part of the oxidative stress response (Stincone et al. 
2015). For example, high-glucose-induced stress in astrocytes in vitro leads to an 
elevation in PPP activity (Takahashi et al. 2012). The PPP requires glucose, 
therefore in hypoglycaemia PPP may not be as active leading to a decrease in ROS 
defence. Indeed, hypoglycaemia (McGowan et al. 2006), and glucose deprivation 
(Rose et al. 1998) have been shown to increase oxidative stress in the brain. AMPK 
is activated by hypoglycaemia (McCrimmon et al. 2004) which in turn upregulates 
fatty acid oxidation (Merrill et al. 1997). Increased fatty acid oxidation also increases 
ROS. Therefore, in the absence of glucose PPP activity may be reduced while there 
is an increase in ROS leading to cellular stress. However, little is known about how 
acute or recurrent low glucose may affect the PPP, especially in astrocytes.  
More broadly there is growing recognition of astrocytic involvement and activation in 
other CNS diseases, such as obesity (Horvath et al. 2010, Thaler et al. 2012), 
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Alzheimer’s disease (Mancardi et al. 1983), and Parkinson’s disease (Renkawek et 
al. 1999, Booth et al. 2017). A general marker of astrocyte activation is astrogliosis 
which occurs in many of these disease states (Pekny et al. 2016). Interestingly, 
astrogliosis also occurs during fasting and fed states (Horvath et al. 2010, Thaler et 
al. 2012, Daumas‐Meyer et al. 2018). Astrogliosis manifests as a ramification of 
astrocyte intermediate filaments glial fibrillary acid protein (GFAP) and vimentin, 
which increases morphological complexity. Vimentin fragmentation has also been 
shown to occur in response to inflammatory stimuli (Darlington et al. 2008). 
Despite an increased awareness of the importance of astrocytes in physiological and 
pathophysiological conditions, little is known about the intrinsic responses of 
astrocytes to either acute low glucose or RLG exposure. It was hypothesised there 
would be astrocytic AMPK pathway activation to maintain energy homeostasis. 
AMPK pathway activation should in turn activate catabolic processes, like fatty acid 
metabolism (Ronnett et al. 2009). Indeed, it has previously been shown that 
hypoglycaemia can increase the expression of fatty acid oxidation-related genes 
(Poplawski et al. 2010, Poplawski et al. 2011). Mitochondrial and glycolytic metabolic 
rates were determined, in real-time, using the Seahorse extracellular flux analyser. 
Other metabolic components were measured including, glycogen levels, intracellular 
nucleotide levels, and the expression of metabolic enzymes. The novel findings from 
this work show that human astrocytes intrinsically adapt to RLG stress by increasing 
basal oxygen consumption, glycolytic rates, and fatty acid metabolism, at the 
expense of decreased coupling efficiency. 
Overall aim and objectives 
Fundamentally, RH deprives cells or glucose to generate ATP. Therefore to sustain 
neural function changes in cellular metabolic activity must occur; activation of AMPK, 
metabolic substrate switching, or changes to fuel utilisation. Still, little is known about 
how human astrocytes respond to acute or recurrent low glucose. Therefore, the 
overarching aim of this chapter was to investigate changes to human astrocyte 
metabolic functions after acute and recurrent low glucose treatments including: 
 Is AMPK phosphorylated by low glucose treatment in HPA and U373 cells and 
how is this affected by RLG? 
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 Does RLG induce and alter astrogliosis in HPA cells as measured by altered 
GFAP and Vimentin expression? 
 Does RLG alter mitochondrial function? If so, can this be recovered? 
 Does RLG induce glycogen supercompensation in isolated HPA cells? 
 Does RLG alter glucose uptake, lactate release or glycolytic function in 
human astrocytes?  
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Results 
3.1 HPA AMPK and ACC phosphorylation is increased by low glucose 
AMPK is a physiological fuel gauge that is activated by low glucose levels and the 
increase of AMP within a cell. AMPK activation and phosphorylation at threonine 172 
is necessary for sensing of hypoglycaemia (McCrimmon et al. 2008). However, it is 
unknown whether human astrocytes respond in a similar manner. As such HPAs 
were exposed to 5.5, 2.5 and 0.1 mM glucose for 30 minutes, representative of 
hyperglycaemia, euglycaemia, and hypoglycaemia respectively. Changes in AMPK 
pathway phosphorylation were assessed by Western blotting cell lysates. Treatment 
with 0.1 mM glucose increased phosphorylation of AMPK at threonine 172 (figure 
3.1A,C). Further to this, ACC, a downstream target of phosphorylated AMPK, had 
increased phosphorylation at serine 79 (figure 3.1B). Interestingly, there were no 
significant differences between 5.5 and 2.5 mM glucose treated cells. 
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3.2 HPA and U373 astrocytoma AMPK and ACC phosphorylation is increased 
by low glucose 
It was noticed that serum withdrawal during experiments, regardless of glucose 
concentration, resulted in morphological changes resembling astrogliosis in the HPA 
cells. Therefore to reduce morphological changes and differences induced by serum 
withdrawal and osmolarity, 1% serum and mannitol were included in the treatment 
media. U373 medium did not include 1% serum or any mannitol as they did not react 
to serum withdrawal. 
The aim of this experiment was, firstly, to test whether the increase in AMPK and 
ACC phosphorylation in 0.1 mM glucose was altered by the presence of 1% serum 
and osmotic controls. Secondly, it tests whether AMPK and ACC phosphorylation 
similarly increased with 0.1 mM glucose treatment in U373 cells. After 30 minutes of 
exposure to 2.5 or 0.1 mM glucose containing media, there was a significant 
increase in both pT172 AMPK and pS79 ACC in HPA and U373 cell lysates (figure 
3.2A-F). These data also show the increase in pT172 AMPK in response to low 
glucose is preserved in the presence of serum or mannitol. 
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3.3 HPA AMPK pathway activity after RLG 
It has been previously shown that recurring insulin-induced hypoglycaemia blunts the 
activation of AMPK (Mandal et al. 2017). To test whether this occurred in HPAs, cells 
were exposed to control or RLG for three days and on the last day treated with 2.5 
mM or 0.1 mM glucose for 15 or 30 minutes. Changes in AMPK pathway activation 
in cell lysates was measured by Western blotting. After 15 minutes of 0.1 mM 
glucose treatment both pT172 AMPK, and pS79 ACC did not increase significantly 
(figure 3.3A,B,D). After 30 minutes of 0.1 mM glucose treatment pT172 AMPK and 
pS79 ACC increased significantly (figure 3.3A,C,E). Interestingly, RLG + 2.5 mM 
glucose had a significantly higher pT172 AMPK than control + 2.5 mM (figure 3.3C). 
Similarly, RLG + 0.1 mM glucose, while not significantly different from RLG + 2.5 mM 
glucose, was higher than control + 2.5 mM glucose (figure 3.3C). This shows that 
while the absolute amount of AMPK phosphorylation remains similar after low 
glucose treatment, the increase in pT172 AMPK in response to 0.1 mM glucose is 
lost following RLG. Despite the altered AMPK response, the change in 
phosphorylation of ACC in response to low glucose was maintained (figure 3.3E). 
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3.4 Effects of acute or recurrent low glucose on HPA GFAP 
Astrogliosis occurs in astrocytes in response to overnutrition (Horvath et al. 2010, 
Thaler et al. 2012) and fasting (Daumas‐Meyer et al. 2018). This results in the 
ramification of astrocytic intermediate filaments and an altered cellular morphology. 
Therefore, expression of GFAP in HPA cells following exposure to RLG was 
measured. GFAP content was determined following a 3-hour exposure to 2.5 or 0.1 
mM glucose on the last day. In contrast to expectations, no significant difference in 
GFAP immunostaining was observed between control and low glucose treated cells 
(figure 3.4A,B). 
3.5 RLG increases HPA vimentin content 
The expression of vimentin, another intermediate filament, is also increased by 
astrogliosis (Pekny et al. 2005) and can be fragmented following inflammatory stimuli 
(Darlington et al. 2008). To determine the effect of RLG on cellular vimentin cells 
were exposed to control or RLG with an additional 3-hour exposure to 2.5 or 0.1 mM 
glucose. Vimentin fragmentation and expression increased significantly in cell 
lysates after RLG, determined by Western blotting (figure 3.5C). Additionally, there 
was an increase in lighter vimentin-positive bands detectable indicating increased 
fragmentation (figure 3.5C). Cellular distribution of vimentin, however, was not 
significantly altered by RLG (figure 3.5A,B). 
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3.6 The effects of RLG on HPA and U373 mitochondrial and glycolytic 
phenotype 
To investigate the effects of RLG on human astrocytes a mitochondrial stress test 
was performed. Briefly, HPA and U373 were exposed to 4 days of three hours 
exposures to either control (2.5 mM) or low (0.1 mM) glucose each day before being 
seeded into a 96 well plate compatible with the Seahorse XFe96 extracellular flux 
analyser where their OCR and ECAR was measured following the injection of 
mitochondrial inhibitors. During the assay the glucose concentration in the media 
was 2.5 mM. 
3.6.1 RLG increases baseline mitochondrial metabolism and reduces 
mitochondrial coupling efficiency. 
HPA and U373 baseline OCR was elevated following RLG exposure (figure 3.6.1A-
D), demonstrating sustained alterations to cellular metabolism lasting up to 24 hours 
after the last low glucose exposure. Upon addition of the ATP-synthase inhibitor 
oligomycin, the resulting decrease to ATP production associated-OCR was 
diminished in RLG treated HPA. Thus, the fraction of basal OCR contributing to ATP-
production was reduced in HPA, but not U373 (figure 3.6.1E,F). FCCP, an ionophore 
used to uncouple flow of H+ across the inner mitochondrial membrane from ATP 
production was added to maximally drive ETC oxygen consumption. In both control 
and RLG, OCR increased to ~200% of baseline, however, the RLG treated cells had 
an augmented FCCP-sensitive increase to OCR. In the HPAs, the reduction in spare 
respiratory capacity was mediated by increased basal metabolism (figure 3.6.1F). In 
contrast, U373 cells had an increased spare respiratory capacity (figure 3.6.1H). 
Injection of rotenone and antimycin A, complex I and III inhibitors respectively, were 
used to ablate remaining mitochondrial function. This resulted in significantly 
increased non-mitochondrial OCR in HPA but not U373 cells (figure 3.6.1.1A,B). 
These measurements permitted calculation of proton leak and coupling efficiency. 
The latter significantly decreased in HPA cells (figure 3.6.1.1E), mediated by 
significantly increased proton leak (figure 3.6.1.1C). While proton leak was elevated 
in U373 cells (figure 3.6.1.1D) this did not lead to a change in coupling efficiency 
(figure 3.6.1.1F). 
3.6.2 RLG increases baseline ECAR of HPA but not U373 cells 
Basal ECAR was elevated in HPA cells but not in U373 cells (figure 3.6.2A-D).  
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3.7 The effects of RLG on HPA basal state mitochondrial fuel oxidation 
Astrocytes are metabolically flexible cells, and it was shown previously RLG changes 
mitochondrial and glycolytic functions. To test whether the changes in mitochondrial 
function were due to changes in substrate utilisation a mitochondrial fuel flex test 
was used. Mitochondrial fuel dependency, capacity and flexibility of three key 
substrate metabolic pathways; pyruvate, glutamine, and fatty acids following RLG 
exposure, were examined using the mitochondrial fuel flex test. In each assay the 
glucose concentration was 2.5 mM glucose. 
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3.7.1 RLG increases HPA fatty acid dependency 
Inhibition of fatty acid uptake into the mitochondria using etomoxir to block CPT1a 
caused OCR to decrease in HPA cells. This response was significantly augmented in 
RLG treated HPA cells (figure 3.7.1A). The addition of BPTES and UK5099, to block 
glutamine and pyruvate usage by the mitochondria respectively, was used to 
maximally stimulate fatty acid utilisation. Fatty acid dependency was calculated by: 
𝐹𝑎𝑡𝑡𝑦 𝐴𝑐𝑖𝑑 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑐𝑦 (%) = (
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑂𝐶𝑅 − 𝐸𝑡𝑜𝑚𝑜𝑥𝑖𝑟 𝑅𝑒𝑑𝑢𝑐𝑒𝑑 𝑂𝐶𝑅
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑂𝐶𝑅 − 𝐴𝑙𝑙 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟𝑠 𝑟𝑒𝑑𝑢𝑐𝑒𝑑 𝑂𝐶𝑅
)  𝑥 100 
Fatty acid dependency was significantly higher in RLG compared to control (figure 
3.7.1C).  However, fatty acid capacity was not altered (figure 3.7.1D). FA capacity 
was calculated by: 
𝐹𝑎𝑡𝑡𝑦 𝐴𝑐𝑖𝑑 𝐶𝑎𝑝𝑎𝑐𝑖𝑡𝑦 (%)
= (1 − (
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑂𝐶𝑅 − 𝐵𝑃𝑇𝐸𝑆 𝑎𝑛𝑑 𝑈𝐾5099 𝑟𝑒𝑑𝑢𝑐𝑒𝑑 𝑂𝐶𝑅
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑂𝐶𝑅 − 𝐴𝑙𝑙 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟𝑠 𝑟𝑒𝑑𝑢𝑐𝑒𝑑 𝑂𝐶𝑅
))  𝑥 100 
Fatty acid flexibility, the difference between dependency and capacity, was 
significantly reduced by RLG (figure 3.7.1E)  
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3.7.2 RLG does not change the mitochondrial utilisation of pyruvate in HPA 
Inhibition of pyruvate uptake into the mitochondria via mitochondrial pyruvate carrier 
(MPC) using UK5099 decreased OCR in HPA cells (figure 3.7.2A). The addition of 
etomoxir and BPTES, to block fatty acid and glutamine usage by the mitochondria 
respectively, was used to maximally stimulate fatty acid utilisation. While there was a 
decrease in OCR the remaining OCR was not different between control and RLG 
(figure 3.7.2B). Pyruvate dependency was calculated by: 
𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑐𝑦 (%) = (
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑂𝐶𝑅 − 𝑈𝐾5099  𝑅𝑒𝑑𝑢𝑐𝑒𝑑 𝑂𝐶𝑅
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑂𝐶𝑅 − 𝐴𝑙𝑙 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟𝑠 𝑟𝑒𝑑𝑢𝑐𝑒𝑑 𝑂𝐶𝑅
)  𝑥 100 
Pyruvate dependency (figure 3.7.2C) was not significantly different in RLG treated 
cells. Pyruvate capacity was unchanged by RLG (figure 3.7.2D), as calculated by: 
𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 𝐶𝑎𝑝𝑎𝑐𝑖𝑡𝑦 (%)
= (1 − (
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑂𝐶𝑅 − 𝐵𝑃𝑇𝐸𝑆 𝑎𝑛𝑑 𝑒𝑡𝑜𝑚𝑜𝑥𝑖𝑟 𝑟𝑒𝑑𝑢𝑐𝑒𝑑 𝑂𝐶𝑅
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑂𝐶𝑅 − 𝐴𝑙𝑙 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟𝑠 𝑟𝑒𝑑𝑢𝑐𝑒𝑑 𝑂𝐶𝑅
))  𝑥 100 
Pyruvate flexibility, the differences between dependency and capacity, was not 
significantly altered by RLG (figure 3.7.2E). 
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3.7.3 RLG increases HPA glutamine flexibility 
Inhibition of glutamine usage by the mitochondria via glutaminase was blocked with 
the selective inhibitor BPTES. This caused a decrease in HPA OCR (figure 3.7.3A). 
The addition of UK5099 and etomoxir to inhibit pyruvate and fatty acid oxidation 
respectively was used to maximally stimulate glutamine utilisation (figure 3.7.3B). 
Fatty acid dependency was calculated by: 
𝐺𝑙𝑢𝑡𝑎𝑚𝑖𝑛𝑒 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑐𝑦 (%) = (
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑂𝐶𝑅 − 𝐵𝑃𝑇𝐸𝑆  𝑅𝑒𝑑𝑢𝑐𝑒𝑑 𝑂𝐶𝑅
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑂𝐶𝑅 − 𝐴𝑙𝑙 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟𝑠 𝑟𝑒𝑑𝑢𝑐𝑒𝑑 𝑂𝐶𝑅
)  𝑥 100 
Neither glutamine dependency or capacity were significantly changed by RLG (figure 
3.7.3C,D). Glutamine capacity was calculated by: 
𝐺𝑙𝑢𝑡𝑎𝑚𝑖𝑛𝑒 𝐶𝑎𝑝𝑎𝑐𝑖𝑡𝑦 (%)
= (1 − (
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑂𝐶𝑅 − 𝑈𝐾5099 𝑎𝑛𝑑 𝑒𝑡𝑜𝑚𝑜𝑥𝑖𝑟 𝑟𝑒𝑑𝑢𝑐𝑒𝑑 𝑂𝐶𝑅
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑂𝐶𝑅 − 𝐴𝑙𝑙 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟𝑠 𝑟𝑒𝑑𝑢𝑐𝑒𝑑 𝑂𝐶𝑅
))  𝑥 100 
Due to a trending decrease in glutamine dependency but no change to glutamine 
capacity, this amounted to a significant increase in glutamine flexibility following RLG 
(figure 3.7.3E). 
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3.8 A comparison of basal mitochondrial substrate oxidation between HPA and 
U373 cells 
HPA and U373 cells were noted to have different responses to the same stimuli. To 
discern the source of this variation a direct comparison of mitochondrial fuel 
utilisation was examined. HPA are primary cells and should be more reflective of the 
physiological state, whereas, U373 are cancerous cells. Cancer cells have 
fundamentally altered metabolic profile (Warburg et al. 1936). To evaluate the 
differences between cell types, a Mitochondrial Fuel Flex test was performed under 
basal conditions, containing 2.5 mM glucose. These experiments were completed by 
Julia Vlachaki-Walker and included for completion. 
3.8.1 U373 cells are less dependent on and more flexible with fatty acid 
oxidation than HPA 
As described previously, fatty acid dependency was measured by inhibition of 
CPT1a resulting in a decrease to basal OCR (figure 3.8.1A). Fatty acid dependency 
was significantly lower in U373 cells compared to HPAs (figure 3.8.1C). Addition of 
UK5099 and BPTES were used to block pyruvate and glutamine utilisation allowing 
for fatty acid capacity to be calculated (figure 3.8.1B). Fatty acid capacity was not 
significantly different between cell types (figure 3.8.1 D). As there was no change in 
fatty acid capacity but there was a large decrease in dependency, U373 cells had a 
higher fatty acid flexibility compared to HPA (figure 3.8.1 E). 
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3.8.2 U373 cells are less dependent on pyruvate than HPA 
As previously described pyruvate dependency was measured by blocking the MPC 
with UK5099 which resulted in OCR to decrease (figure 3.8.2A). Pyruvate 
dependency was significantly lower in the U373 cells compared to HPAs (figure 
3.8.2C). Pyruvate capacity was measured by blocking glutamine and fatty acid 
utilisation with BPTES and etomoxir respectively, decreasing OCR (figure 3.8.2B). 
Pyruvate capacity and flexibility were not significantly different between cell types 
(figure 3.8.2D,E). 
3.8.3 U373 cells have a higher capacity and flexibility to oxidise glutamine than 
HPA 
As discussed previously glutamine dependency is determined by the addition of 
BPTES decreasing OCR by inhibiting glutaminase (figure 3.8.3A). Glutamine 
dependency was not significantly different between cell types (figure 3.8.3C). 
Glutamine capacity was determined by the inhibition of mitochondrial fatty acid and 
pyruvate uptake using etomoxir and UK5099 respectively, decreasing OCR (figure 
3.8.3B). Glutamine capacity was significantly higher in U373 cells (figure 3.8.3D). 
Glutamine flexibility, the difference between dependency and capacity, was 
significantly higher in U373 cells than HPA (figure 3.8.3E) 
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3.9 RLG does not alter HPA mitochondrial enzyme expression 
To investigate why mitochondrial metabolism was altered, total levels of 
mitochondrial proteins were assessed after RLG treatment. Succinate 
dehydrogenase (SDHa; figure 3.9A), voltage-dependent anion channel (VDAC; 
figure 3.9B), fatty acid synthase (FAS; figure 3.9C), and carnitine 
palmitoyltransferase-α (CPT1α; figure 3.9D) expression was measured and RLG 
treated cells were not significantly different from control treated cells. This suggests 
that total mitochondrial content is not altered following RLG. 
3.10 Acute and RLG does not alter HPA mitochondrial number or length. 
Given substantial alterations to mitochondrial function and activity being induced by 
RLG, mitochondrial morphology was examined using mitotracker DsRed. 
Interestingly, no significant differences were found between treatments (figure 
3.10A,B), indicating that differences in mitochondrial activity are not caused by 
changes in the mitochondrial filamentous network. 
3.11 Recovery from low glucose increases glycolysis and is enhanced 
following RLG in HPA 
Given that there was an increase in basal ECAR in HPA cells, the effects of glucose 
reperfusion following RLG were examined. On the day of the study, cells were 
acutely incubated in glucose-free medium to examine the effect of glucose 
reperfusion. ECAR and OCR were measured during the addition of 0.5, 2.5 and 5.5 
mM glucose. 
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3.11.1 RLG augments activation of ECAR and reduction of OCR during glucose 
reperfusion in HPA 
Glucose reperfusion increased ECAR which was larger in 2.5 and 5.5 compared to 
0.5 mM glucose (figure 3.11.1A-C). Interestingly, there was a corresponding 
decrease in OCR as cellular metabolism shifts from oxidative phosphorylation 
towards glycolysis, like the Warburg effect where cells have elevated glycolytic 
activity in the presence of ample oxygen (3.11.1D-F) (Warburg et al. 1936). In RLG 
treated cells, the increase in ECAR and decrease in OCR was enhanced at 2.5 mM 
and 5.5 mM glucose (3.11.1A-F). These results are consistent with increased basal 
ECAR following RLG and show an enhanced Warburg-like effect. 
3.11.2 RLG does not affect ECAR or OCR during glucose reperfusion in U373 
cells 
Next, glycolytic re-activation after control or RLG treatment and complete glucose 
withdrawal in U373 cells was examined. Interestingly, ECAR and OCR changed 
equally in all glucose concentrations used in both control or RLG pre-treated cells 
(figure 3.11.2 A-F). Unlike in HPA cells, RLG did not augment ECAR or OCR in 
response to glucose reperfusion. 
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3.12 Prior RLG does not alter 6-NBDG uptake by human primary astrocytes 
HPA 
To test whether RLG-induced changes to ECAR were due to enhanced glucose 
uptake, the non-hydrolysable fluorescent dye, 6-NBDG, which enters the cell by 
glucose transporters, was used. HPA cells were treated to control or RLG and then 
assayed in 2.5 mM glucose. There was no significant difference in 6-NBDG uptake 
between control and RLG treated cells (figure 3.12A). This suggests the changes to 
ECAR are not due to increased glucose uptake. 
3.13 RLG does not alter glycogen storage in HPA or U373 astrocytoma cells 
Astrocytes are the primary source of glycogen in the CNS (Maxwell et al. 1965, 
Cataldo et al. 1986, Oe et al. 2016). This can be utilised to buffer energy supply 
during external energy deprivation. Glycogen content has been speculated to super-
compensate following RH which leads to blunting of CRR (Cryer 2005). Therefore, 
human astrocytes’ glycogen content was measured after prior treatment to control or 
RLG in 2.5 mM glucose. No significant differences were found between control and 
prior RLG in HPA (figure 3.13A) or U373 (figure 3.13B). 
3.14 HPA glycolytic pathway component expression is unchanged by RLG 
As alterations to ECAR were found after RLG, key components of the glycolytic 
pathway were investigated. No significant differences were found in the expression 
of glucose transporter-1 (Glut-1; figure 3.14A), hexokinase 1 (HKI; figure 3.14B), 
hexokinase 2 (HKII; figure 3.14C), hexokinase 3 (HKIII; figure 3.14D), 
phosphofructokinase, platelet (PFK(P); figure 3.14E), or pyruvate kinase M2 (PKM2; 
figure 3.14F). 
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3.15 Maintenance of total ATP and ATP:ADP ratios by HPA and U373 
astrocytoma cells during acute and RLG 
The effect of low glucose on intracellular energy levels was determined by 
measuring total ATP (tATP) as well as the ratio of ATP:ADP. HPA and U373 were 
exposed to RLG with and without a further exposure to 0.1 mM glucose for 15, 30 
and 180 minutes. Even after 180 minutes, there were no significant changes to tATP 
or ATP:ADP within the HPAs (figure 3.15A,C) and U373s (figure 3.15B,D). Similarly, 
the basal ratios between control and RLG were not changed. 
3.16 Acute low glucose exposure alters lactate release in HPA 
Astrocytes are thought to provide lactate to neurons during either situation of high 
ATP demand (e.g. high synaptic activity), or during metabolic stress (e.g. 
hypoglycaemia) (Pellerin et al. 1994, Pellerin et al. 1998, Pellerin 2003). To 
investigate whether lactate released from HPA cells was altered by low glucose the 
cells were cultured in medium containing 2.5 or 0.1 mM glucose for 30 minutes. 
While there was no significant change to lactate levels, however, if the 25-fold 
reduction in glucose concentration is considered there is a large relative increase in 
lactate released (figure 3.16A-B). This suggests that HPAs may respond to low 
glucose by maintaining lactate release. 
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3.17 The effect of prior RLG on lactate release from HPA and U373 
astrocytoma cells during 3 hours of 2.5 or 0.1 mM glucose 
To test whether RLG exposure modulated lactate release from astrocytes HPA and 
U373 cells were exposed to RLG and lactate was measured in the conditioned 
media. Interestingly, 0.1 mM glucose resulted in an absolute decrease in lactate 
concentrations within the medium compared to 2.5 mM. However, RLG did not alter 
the change in lactate concentrations in 0.1 mM glucose, compared to control pre-
treated cells treated to 2.5 mM glucose (figure 3.17A,B). However, if the 25-fold 
reduction in glucose concentration is considered there is a large relative increase in 
lactate released (figure 3.17C,D). It is important to note that the length of treatment 
for this study was 3 hours rather than 30 minutes as in figure 3.16. 
3.18 RLG reduces HPA PPP activity 
As ECAR was increased by RLG but there were no changes to glucose uptake, 
glycogen content, or the expression of glycolytic enzymes, an alternative metabolic 
pathway for glucose was investigated. The PPP is in parallel to glycolysis, separating 
when glucose-6-phosphate (G6P) is converted by rate-limiting enzyme G6P 
dehydrogenase to phosphogluconolactone. The PPP is a major source of cellular 
NADPH that is vital for antioxidant defence mechanisms (Takahashi et al. 2012, 
Stincone et al. 2015). As the PPP requires glucose, it is upregulated in neurons and 
astrocytes in response to high glucose in vitro (Takahashi et al. 2012), it was 
speculated that there would be a decrease in PPP activity in low glucose. To test 
this, 6-aminonicotinamide (6-AN), a G6P dehydrogenase inhibitor, was added to 
cells at 250, and 500 µM for 16 hours. Basal OCR and ECAR were then measured 
for 60 minutes after a 20-minute equilibration period in 2.5 mM glucose. The 
anticipated outcome of inhibiting PPP would be decreased ECAR and increased 
OCR, as glucose could undergo complete oxidation by the mitochondria. Therefore if 
the response is augmented by RLG it would suggest increased PPP activity. 
Interestingly, RLG augmented the 6-AN-dependent increase to OCR at 250 µM in 
comparison to control, but this was not seen with 500 µM (figure 3.18A). Conversely, 
RLG did not affect the decrease in ECAR caused by 6-AN at either 250 or 500 µM 
(figure 3.18B). Taken together these results indicate that PPP activity was increased, 
contradicting our original hypothesis. 
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3.19 Maintaining glucose levels following RLG partially recovers metabolic 
adaptations in HPA 
It has previously been shown that strict avoidance of hypoglycaemia restores 
hypoglycaemia awareness in those with T1DM (Cryer 1994). To test whether the 
metabolic adaptations made by HPA cells could be recovered, HPAs were exposed 
to RLG with an additional 4-day recovery period. In this period cells were maintained 
in 5.5 mM glucose for 19 hours and 2.5 mM glucose for a total of 5 hours. Cells were 
incubated overnight in 5.5 mM glucose to provide sufficient glucose such that the 
glucose did not fall sufficiently below 2.5 mM glucose. To assess changes to 
metabolism, increased basal OCR, basal ECAR, proton leak, and decreased 
coupling efficiency, a mitochondrial stress test was performed on control, RLG or 
RLG with recovery treated cells. Basal OCR was elevated following RLG, whereas 
OCR after the recovery period was comparable to control (figure 3.19A,B). However, 
coupling efficiency was still reduced (figure 3.19C) and proton leak, while trending 
towards recovery, did not reach statistical significance (figure 3.19D). The increase 
to basal ECAR following RLG remained unchanged by a recovery period (figure 
3.19E,F). Taken together these data show that while basal OCR can be restored by 
a recovery period, basal ECAR and coupling efficiency remain altered in HPA cells.  
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Discussion 
Astrocytes are metabolically flexible cells, which, for example, can rapidly upregulate 
glycolysis, partly due to increased expression of PFKFB3 which can stimulate 
glycolysis during stress (Almeida et al. 2004, Snyder et al. 2004). Furthermore, 
transcriptional analysis of astrocytes showed ~34% of astrocytic genes, in 
comparison to neuronal, were metabolism related, aiding in their metabolic flexibility 
(Lovatt et al. 2007). Astrocytes are also intimately associated with the blood-brain 
barrier (BBB) (Virgintino et al. 1997) and are part of the tripartite synapse (Araque et 
al. 1999) making them ideally situated to modulate neuronal function. This study 
gives for the first time a characterisation of the intrinsic metabolic changes of human 
primary astrocytes (HPA) and U373 human astrocytoma cells in response to acute 
and recurrent low glucose (RLG). 
AMPK activity is necessary for GI neurons to sense low glucose (McCrimmon et al. 
2006a). It was therefore examined whether AMPK activation also occurred in human 
astrocytes in response to physiologically relevant glucose levels. Indeed both HPA 
and U373 cells had increased phosphorylation of AMPK at threonine 172, as well as 
increased phosphorylated ACC (a downstream target of AMPK (DAVIES et al. 
1990)), indicating increased AMPK activity (Hawley et al. 1996). Importantly culturing 
HPA cells with 2.5 mM glucose did not increase AMPK phosphorylation compared to 
5.5 mM glucose. This shows that culturing HPA cells in 5.5 and then 2.5 mM as a 
part of the RLG model does not activate AMPK. Therefore, the increase in AMPK 
phosphorylation is also specific to the euglycaemia-like to hypoglycaemia-like 
glucose concentrations. 
To model recurrent hypoglycaemia seen in T1DM HPA and U373 cells were given 
recurrent bouts of low glucose exposure (0.1 mM for 3 hours/day) for 4 days; termed 
recurrent low glucose (RLG). Interestingly, RLG increased basal phosphorylation of 
AMPK in 2.5 mM glucose compared to controls such that it was comparable to a low 
glucose exposure without prior RLG. While AMPK phosphorylation was elevated by 
antecedent RLG a further low glucose exposure did not further elevate AMPK 
phosphorylation; blunting the fold change from baseline in response to low glucose 
as would normally occur (Hardie et al. 2012). This corroborates evidence from a rat 
model of recurrent insulin-induced hypoglycaemia (RIIH) which had decreased 
AMPK phosphorylation compared to acute insulin-induced hypoglycaemia, within the 
143 
mediobasal hypothalamus (Mandal et al. 2017). Interestingly, there was also an 
increase in total AMPK content induced by RIIH, which implies an AMPK-dependent 
energy sensor failure caused by RIIH. In the present study ACC phosphorylation, 
indicating downstream activity of AMPK, was unchanged by RLG; while pAMPK was 
elevated in 2.5 mM glucose following RLG, there is no increase in pACC, and while 
pAMPK was unchanged with a further bout of low glucose, pACC was robustly 
increased. This is interesting as it suggests a disconnection between 
phosphorylation of AMPK and its downstream target ACC. Why elevated pAMPK 
would not result in increased pACC remains unknown. When phosphorylated, ACC 
is inhibited and unable to produce malonyl-CoA as a substrate for fatty acid 
biosynthesis. Therefore if pACC was also elevated by antecedent RLG it would 
inhibit the elevated fatty acid oxidation found in this study. Taken together though 
these results show that HPA and U373 are able to react to pathophysiologically 
relevant (Claret et al. 2007, Beall et al. 2012b) glucose concentrations, but increased 
pAMPK in response to low glucose is blunted by antecedent RLG. 
Astrogliosis is a phenomenon whereby cellular morphology becomes ramified with 
an increase in cytoskeletal components. Astrogliosis occurs in response to a range 
of different stimuli including CNS injury (Burda et al. 2016), CNS diseases (Pekny et 
al. 2016), and energy changes; both fasting and high caloric intake exposure 
increase astrogliosis (Horvath et al. 2010, Thaler et al. 2012, Daumas‐Meyer et al. 
2018). Therefore, it was hypothesised that HPA cells would respond to acute low 
glucose and/or RLG with increased astrogliosis and increased expression of glial 
intermediate filaments GFAP and vimentin. Vimentin expression and fragmentation 
increased in an additive manner to each low glucose exposure, but there was no 
change in vimentin distribution. Importantly the fragmentation of vimentin was not 
due to sample degradation as actin was not degraded. Cleavage of vimentin can be 
due to caspase activity (Darlington et al. 2008). Caspase activity is commonly 
associated with programmed cell death and inflammation (Galluzzi et al. 2016), as 
well as models of hypoglycaemia: oxygen-glucose-deprivation (Nath et al. 2002), 
and acute and recurrent insulin-induced hypoglycaemia (Ouyang et al. 2000, 
Cardoso et al. 2013). Therefore, the fragmentation of vimentin here may be 
indicating an inflammatory response mediated by caspase activity. 
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AMPK pathway activation increases catabolic processes, including fatty acid 
oxidation, to restore energy homeostasis (Ronnett et al. 2009). As AMPK was 
phosphorylated in HPA and U373 cells during low glucose, it was anticipated this 
would increase mitochondrial and glycolytic pathway activity. Interestingly, significant 
increases in basal mitochondrial oxygen consumption in both HPA and U373 were 
found, which is, at least partly, mediated by increased fatty acid oxidation. While fatty 
acids are a high energy substrate, glucose is primarily used by neurons and glia 
(Dienel 2012, Pellerin et al. 2012). This is because fatty acid oxidation is known to 
increase reactive oxygen species (ROS) (St-Pierre et al. 2002). The ROS generated 
by β-oxidation is also particularly detrimental to neurons as they are more sensitive 
to oxidative stress than other neural cells (Bolanos et al. 1997). A mitochondrial 
defence to increased ROS is to uncouple proton flow across the inner mitochondrial 
membrane, mediated by uncoupling proteins or the ATP/ADP antiporter (ANT; 
(Skulachev 1998)). Furthermore, proton leak has been demonstrated to occur when 
isolated mitochondria are treated with fatty acids (Tonkonogi et al. 2000). In the 
present study, RLG also increased proton leak which also likely contributed to a 
decreased coupling efficiency. Previously, β-oxidation genes have been shown to 
increase with acute hypoglycaemia but this is subsequently blunted by RH 
(Poplawski et al. 2011). This contrasts our findings of increased fatty acid oxidation 
following RLG in human astrocyte mono-cultures. However, it is worth noting that 
those measurements were taken from whole rodent mediobasal hypothalamus 
containing multiple cell types. Perhaps the change to astrocytic fatty acid oxidation is 
being masked by responses from other cells, i.e. neurons, which may have a 
different cell-type dependent response to RH. A key regulatory molecule for these 
and related processes is AMPK. Chronic elevation of basal AMPK activity seen in 
this model has been shown in rat myocytes, where AMPK increases mitochondrial 
enzyme expression and cytochrome c oxidase (COX) activity, indicating enhanced 
oxidative capacity (Winder et al. 2000, Ljubicic et al. 2011). This corroborates with 
our data showing increased fatty acid oxidation dependency, but not mitochondrial 
biogenesis, following RLG where AMPK baseline activation may play an important 
role. 
García-Cáceres et al, demonstrated that a loss of insulin receptors on astrocytes led 
to impaired astrocytic glucose uptake (García-Cáceres et al. 2016). This was 
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accompanied by fewer and smaller mitochondrial filaments, suggesting heightened 
mitophagy (García-Cáceres et al. 2016). Furthermore, in our study, increases to 
basal mitochondrial OCR could suggest a change in mitochondrial number and/or 
network morphology, however, no significant differences in protein expression of 
VDAC, SDHa, or CPT1-a or any change to mitochondrial filamentous networks were 
found. Normally, mitochondria are dynamic organelles that undergo fusion and 
fission in a continual manner to partition off unhealthy regions which are then 
targeted for mitophagy (Youle et al. 2012). RLG increased proton leak and decrease 
coupling efficiency indicating some mitochondrial stress. As these changes persist 
up to 4 days since the last low glucose exposure it suggests there is a failure to fully 
resolve mitochondrial stress. This may be due to a failure to appropriately partition 
unhealthy mitochondria by mitochondrial fission. On the other hand, the 
mitochondrial stress induced by low glucose may not be sufficient to elicit changes 
on a network level. Additionally, cells were recovered into serum containing media 
which may provide sufficient insulin and growth factors to recover from each bout of 
low glucose.  
Given that astrocytes are known to alter glycolysis in response to low glucose and 
supply neurons with lactate (Pellerin 2003), it was hypothesised that RLG would alter 
glycolytic flux. RLG exposure increased basal ECAR in HPA cells but not U373 cells. 
Moreover, glucose reperfusion-induced a larger activation of ECAR in HPA cells 
after RLG, and a concomitant decrease in OCR, with 2.5 and 5.5 mM glucose. 
However, there was no difference in response between 2.5 and 5.5 mM glucose. 
This shows that supplying excess glucose does not result in further glucose 
utilisation, and somewhere between 0.5 and 2.5 mM glucose, there was a saturation 
of glycolytic machinery. The U373 cells also increased ECAR and decrease OCR in 
response to glucose reperfusion; however, RLG did not significantly differ from 
controls. Interestingly, the ECAR response to glucose in U373 cells was twice as 
large as in HPA cells. ECAR is a simple measure of the rate of extracellular acid 
produced by cells which mainly comes from lactate release and the formation of 
lactate- and H+ (Blouin et al. 2010, Mookerjee et al. 2015). However, the complete 
breakdown of glucose via oxidative phosphorylation and the TCA cycle produces six 
CO2 molecules. These contribute to ECAR via the reversible hydration and 
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dissociation into bicarbonate and protons (Divakaruni et al. 2014, Sakamaki et al. 
2014): 
H2O + CO2 ↔ H2CO3 ↔ H
+ + HCO3
− 
As RLG did not induce changes to basal lactate release in HPA cells it is probable 
the difference in basal ECAR in HPA cells is likely due to the contribution of CO2 
from, at least in part, elevated mitochondrial respiration. Interestingly, cytosolic 
processes can also produce CO2 while consuming oxygen, for example, the PPP 
when converting 6-phosphogluconate to D-ribulose-5-phosphate (Stincone et al. 
2015). 
Given notable discrepancies in how HPA and U373 respond to acute and recurrent 
low glucose the capacity of the mitochondria to utilise different substrates was 
assessed in basal conditions. Cancerous cells are known to have a markedly 
different metabolic profile to their non-cancerous counterparts (Warburg et al. 1936, 
Dettmer et al. 2013, DeBerardinis et al. 2016). Due to a process known as the 
Warburg effect, cancerous cells are termed aerobically glycolytic; meaning an 
increased reliance on glycolysis to generate ATP even with ample oxygen present 
(Warburg et al. 1936). Nevertheless, while U373 cells are metabolically altered by 
virtue of being cancerous, they were used because the cells proliferated quickly and 
were easy to maintain. This allowed preliminary studies to be carried out before the 
use of slower growing HPA cells. Additionally as the HPA cells are a rare resource 
and U373 cells are more widely used it was important to compare the HPAs to a 
more well understood cell line. The comparison between cell types may also be of 
interest to those that study cancer biology. Interestingly, the HPA cells were more 
dependent on pyruvate oxidation than the U373 while pyruvate oxidation capacity 
and flexibility were similar. This suggests that more of the pyruvate generated by 
HPA goes into the mitochondria for oxidation, in comparison to U373 cells, where 
they are less dependent on pyruvate. Pyruvate either enters the mitochondria or is 
converted to lactate, therefore, pyruvate is likely being converted to lactate in the 
U373 cells as predicted by the Warburg hypothesis (Liberti et al. 2016). When 
studying metabolic changes induced by disease-relevant stimuli it is important to 
consider the differences in metabolic phenotype between primary and cancerous cell 
lines; for example, glucose withdrawal induces cell death in glioblastoma cells but 
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not in normal human astrocytes (Jelluma et al. 2006). Indeed even long-term cell 
culture impacts primary cell metabolism (Dettmer et al. 2013). Nevertheless, primary 
cells more accurately represent physiology and are more appropriate for studies into 
metabolic disorders. 
RLG induced an increase to HPA basal ECAR and enhanced ECAR reactivation 
following acute low glucose withdrawal. Interestingly, brain glucose uptake, 
measured using the labelled glucose analogue [18F]fluorodeoxyglucose, increases 
during hypoglycaemia in people with T1DM (Cranston et al. 2001b), and in those 
with diabetes with intact hypoglycaemia awareness, but, this is lost with IHA 
(Cranston et al. 2001a, Dunn et al. 2007). RH also reduces cerebral blood flow to 
these regions in subjects with T1DM compared to healthy controls (Mangia et al. 
2012). To test whether glucose uptake was altered by RLG in HPA cells the uptake 
of the non-hydrolysable fluorescent glucose analogue 6-NBDG was measured. 
Interestingly, there was no change in 6-NBDG accumulation following antecedent 
RLG suggesting no change in glucose uptake. Therefore, glucose uptake is not the 
cause of increased basal ECAR and increased ECAR reactivation following glucose 
withdrawal. 
Expression of HK2 has been reported to be decreased in STZ induced diabetic rats, 
which was restored upon normalisation of blood glucose levels (Burcelin et al. 1993). 
This suggests high glucose suppresses HK2 expression, but the effects of low 
glucose on glycolytic machinery expression are unknown. In this study, no changes 
to HK1, HK2, HK3, PFK(P), and PKM2 were found showing that increased glycolytic 
rates were not due to increased expression of glycolytic enzymes. However, 
enzymatic expression may not accurately reflect their activity. Therefore, activity 
rates for each enzyme should be determined before ruling out their involvement in 
modulating ECAR. Another mechanism by which glycolytic rates might be increased 
would be through increased translocation of HK2 to the mitochondria. HK2 has been 
previously shown to interact with VDAC (Arzoine et al. 2009), perhaps giving it better 
access to ATP needed to fuel its conversion of glucose to glucose-6-phosphate 
(Bustamante et al. 1977). This could be assessed by comparing the amount of HK2 
found in a mitochondrial fraction following RLG. To see specifically if there is an 
increased interaction with VDAC, co-immunoprecipitation could be performed. 
Nevertheless, these data show HPA and U373 metabolism is altered by RLG. 
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While hypoglycaemia is a significant obstacle to optimal glycaemic control, strict 
avoidance of blood glucose levels of <3 mM can recover hypoglycaemia awareness 
(Fanelli et al. 1993, Cranston et al. 1994, Dagogo-Jack et al. 1994). To test whether 
the changes to HPA metabolism induced by RLG could be resolved in a similar 
fashion a 4-day recovery period was introduced with exposures to euglycaemia-like 
glucose concentration (2.5 mM) each day. Increases to basal OCR were restored to 
normal, but, coupling efficiency remained decreased and proton leak partially 
recovered. The restoration of some aspects of HPA metabolism reflects, in part, the 
recovery seen by avoidance of hypoglycaemia in humans. Nevertheless, there has 
not been a complete restoration to normal function, as some metabolic adaptations 
have persisted. However With enough time, weeks to months, a complete recovery 
may take place. An additional issue with the RLG model is that only four low glucose 
exposures are used which contrasts potentially decades of glucose variation seen in 
T1DM. However, even one exposure to hypoglycaemia in healthy humans decrease 
CRR (Burcelin et al. 1993, Davis et al. 1997), therefore repeated exposures to 
hypoglycaemia or low glucose are not required for blunting of CRR. 
Glycogen is stored primarily in astrocytes (Brown 2004) and is metabolised to 
generate lactate (Dringen et al. 1993). Lactate is then supplied to neurons and used 
as a metabolic substrate (Gruetter 2003, Brown 2004, Cloix et al. 2009). During 
hypoglycaemia or recurrent 2DG induced glucoprivation, brain glycogen in rodents is 
significantly reduced (Choi et al. 2003, Canada et al. 2011) and following restoration 
of euglycaemia glycogen stores increased above pre-hypoglycaemic levels; super-
compensation had occurred. Choi et. al., hypothesised this increased glycogen store 
could be metabolised during future hypoglycaemia delaying the onset of CRR (Choi 
et al. 2003). The increase in glycogen breakdown would lead to an increase in 
lactate production for neurons. However, lactate delivery to the VMN during 
peripheral hypoglycaemia prevents the onset of CRR (Borg et al. 2003). Conversely, 
Herzog et. al., did not observe any glycogen supercompensation in rats after either 
acute or recurrent hypoglycaemia (Herzog et al. 2008). Additionally, no correlation 
has been found in humans between brain glycogen content and hypoglycaemia 
awareness (Öz et al. 2012). Despite RLG altering HPA metabolism, no changes in 
glycogen levels were found, supporting the current literature. However, glycogen 
turnover is necessary for normal brain function (Hertz et al. 2003, Gibbs et al. 2007, 
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Suzuki et al. 2011, Duran et al. 2013) and therefore a model including 
neurotransmitter dynamics and/or co-culturing neurons with astrocytes should be 
employed to completely address this question. 
Lactate is readily used by neurons as a metabolic substrate in euglycaemia. As 
hypoglycaemia ensues, lactate levels are maintained in both new-born dogs 
(Vannucci et al. 1981) and humans without diabetes (Abi-Saab et al. 2002). While 
lactate is maintained, glucose levels within the CNS do decrease, but there is an 
approximate 30-minute lag before CNS levels change (Abi-Saab et al. 2002). Given 
sufficient hypoglycaemia duration lactate levels do fall (Lewis et al. 1974). 
Interestingly the lactate concentration in the brain of people with T1DM and IHA 
decrease during hypoglycaemia compared to people with T1DM and healthy controls 
with normal hypoglycaemia awareness (Wiegers et al. 2016). The depletion of brain 
lactate suggests it is being oxidised and used as a fuel substrate, which prevents the 
onset of CRR and awareness of hypoglycaemia. This supports data by Borg et. al., 
showing an injection of lactate into the VMN prevents the onset of CRR in the 
presence of peripheral hypoglycaemia (Borg et al. 2003). Furthermore, the injection 
of lactate into the periphery can reverse insulin-induced hypoglycaemic stupor-coma 
and decrease the rate of brain glucose utilisation suggesting it is used as a fuel by 
the brain (Thurston et al. 1983). In the present study astrocytes were able to 
maintain lactate release in low glucose for 30 minutes, but, by 3-hours of low glucose 
exposure lactate concentration had significantly decreased. However, the decrease 
in lactate release did not relate to the 25-fold reduction in glucose concentration 
showing there was an increase in lactate release relative to glucose availability. This 
effect was unaltered by prior RLG. The source of lactate in the absence of 
extracellular glucose is likely from the breakdown of glycogen stores (Dringen et al. 
1993). When glycogen is converted to G6P it is unlikely to then be converted to 
glucose due to low G6P phosphatase activity in astrocytes (Stephens et al. 1976, 
Pertsch et al. 1988), therefore, G6P continues through glycolysis to produce lactate. 
Further, to lactate production glycogenolysis and subsequent glycolysis produce 
ATP. In this study up to 3-hours of low glucose, with or without prior RLG, did not 
alter ATP:ADP ratios or total ATP in HPA or U373 cells. In chronic (Vannucci et al. 
1981) and severe acute (McCall et al. 1986) hypoglycaemia, ATP levels are 
sufficiently maintained, with a concurrent reduction in carbohydrates implicating their 
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utilisation as a fuel source. As previously discussed, glycogen content may 
contribute to sustaining intracellular nucleotide levels. However, 4 mM L-glutamine 
was present in the experimental medium used in this study, additionally 1% serum in 
HPA media. It is likely that a combination of intracellular glycogen and the nutrients 
present in the medium all contribute to sustaining intracellular ATP levels in low 
glucose. In addition to this, the mitochondrial and glycolytic adaptations seen may be 
compensatory to maintain cellular energy balance. Taken together these data 
demonstrate the ability of human astrocytes in vitro to increase lactate release 
relative to glucose availability and sustain intracellular nucleotide levels suggesting 
they do adapt to acute low glucose exposure. 
A parallel glucose metabolic pathway is the pentose phosphate pathway (PPP). The 
NADPH produced from the PPP is used to generate reduced glutathione (GSH) 
(Panday et al. 2014), a major cellular antioxidant (Stincone et al. 2015). This 
pathway is upregulated in astrocytes compared to neurons (Allaman et al. 2010, 
Takahashi et al. 2012), and is active as a part of the oxidative stress response 
(Stincone et al. 2015), i.e. high-glucose-induced stress in vitro (Takahashi et al. 
2012) or following hypoglycaemia (McGowan et al. 2006) or glucose deprivation 
(McCrimmon et al. 2004). However, glucose is required for the PPP which detracts 
from ATP generation via glycolysis. Therefore, it was unclear whether the PPP would 
be increased, due to increased ROS, or decreased due to a lack of glucose supply. 
To test PPP activity the rate-limiting enzyme G6P dehydrogenase (G6PDH) was 
inhibited using 6-AN for 16 hours. PPP inhibition should result in an increase in OCR 
and a decrease in ECAR as PPP reduces oxygen consumption and contributes to 
ECAR. Interestingly, the increase to OCR was augmented by prior RLG, suggesting 
increased PPP activity induced by prior RLG. However, 6-AN inhibition of the PPP 
would disrupt a major cellular ROS defence mechanism and predispose a cell to 
oxidative stress which may affect the results. While preliminary, these data indicate 
that PPP activity is enhanced by RLG.  To further investigate PPP activity of G6PDH 
could be assessed with an activity assay (Glock et al. 1953), radioactively labelled 
glucose tracer studies with mass spectroscopy could be used to measure glucose 
flux through the PPP (Kruger et al. 2003). 
An important function of astrocytes is to recycle the excitatory neurotransmitter 
glutamate and subsequent processing through the glutamate-glutamine cycle 
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(Danbolt 2001, Oliet et al. 2001). Glutamate is detoxified by its conversion to 
glutamine by glutamine synthetase in an ATP-dependent reaction (Schousboe et al. 
2013) which is mainly expressed in astrocytes (Norenberg et al. 1979). Glutamine is 
recycled to neurons and converted to glutamate by glutaminase and loaded into 
synaptic vesicles to complete the cycle (Schousboe et al. 2013, Schousboe 2018). 
Astrocytes sequester excess glutamate from the synaptic cleft via excitatory amino 
acid transporter 1 (EAAT1) (Kirischuk et al. 2016). Three Na+ ions are co-transported 
with glutamate, which needs to be balanced by the ATP-dependent Na+/K+ ATPase 
(Cholet et al. 2002, Kirischuk et al. 2016). Thus there is a significant metabolic cost 
for astrocytes to maintain ion homeostasis during the glutamate-glutamine cycle; 
estimated to be approximately 20% of astrocytic ATP production (Silver et al. 1997). 
Tight regulation of glutamate is important as in excess it leads to neurotransmission 
failure and excitotoxicity (Ankarcrona et al. 1995, Yang et al. 1997). Glutamate 
stimulation has been shown to impair astrocytic mitochondrial function; decreasing 
spare respiratory capacity and increasing lactate production (Yan et al. 2017), which, 
when combined with the data in the current study, suggests that mitochondrial 
dysfunction could potentially be exacerbated following recurrent bouts 
hypoglycaemia in the presence of glutamate. Knock down of the astrocytic glutamate 
transporters glutamine aspartate transporter (GLAST) and glutamate transporter-1 
(GLT-1) increases excitotoxicity in rats (Rothstein et al. 1996). Additionally, recent 
observations showed that RH reduces astrocytic glutamate recycling likely through 
reduced glutamate uptake, which led to the failure of glutamatergic 
neurotransmission during subsequent hypoglycaemia (Chowdhury et al. 2017). 
Based on the findings presented here, it is possible that mitochondrial dysfunction 
could reduce glutamate uptake due to the metabolic demands on the Na+/K+-
ATPase, which requires further study. In addition, astrocytes also uptake GABA from 
the synaptic cleft in ex vivo slices of rat cortex (Iversen et al. 1968). However, GABA 
uptake is not associated with a significant metabolic cost (Chatton et al. 2003b), and 
as such may not be affected by any mitochondrial dysfunction. Interestingly, during 
RH a relative increase of GABA within the VMN occurs (Chan et al. 2008) which is 
less metabolically taxing for astrocytes (Chatton et al. 2003a). Therefore, a relative 
excess of GABA to glutamate may result in suppression of neurotransmission 
contributing to CRR, though further investigation is required to test this hypothesis. 
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It is worth noting that there is marked heterogeneity of astrocyte phenotype within 
the brain, including protoplasmic, fibrous, interlaminar, polarised, and varicose 
projection astrocytes (Verkhratsky et al. 2017). The range of astrocyte subtypes 
impact their function, for example, mouse hypothalamic astrocytes express more 
genes for lipid oxidation in comparison to cortical astrocytes that favour lipid 
synthesis, for example SREBP-1 (Boisvert et al. 2018). Additionally, glycogen levels, 
found in mouse astrocytes, within the cortex and hippocampus are higher than 
hypothalamus and other thalamic regions (Oe et al. 2016). This may be reflective of 
differences in regional demand for energy supply, or perhaps the brain regions that 
have higher glycogen are not directly involved in glucose sensing they need to 
maintain their function during low glucose, whereas the hypothalamus needs to be 
more reliant on interstitial glucose concentrations. The subtype and regional 
differences in astrocyte functions could, therefore, result in differential reactions to a 
low glucose stimulus. 
Diabetic encephalopathy is being increasingly recognised as part of the long-term 
sequelae of diabetes (Sima 2010). Furthermore, evidence from epidemiological 
studies implicates diabetes, and hypoglycaemia increasing the risk of cognitive 
dysfunction (McCrimmon et al. 2012). It is unknown by what mechanisms RH 
increases the risk of dementia, but glucose metabolism is altered in several ways in 
Alzheimer’s disease (AD). For example, there is a reduction in glucose transporter 1 
(Glut-1) and 3 (Glut-2) expression in the brains of patients with AD (Simpson et al. 
1994). In an APP-overexpressing mouse model of AD that were Glut-1 deficient had 
a faster onset of neurodegeneration and amyloid-β (Aβ) pathology (Winkler et al. 
2015), implicating glucose uptake in the pathogenesis of AD. Patterns of glucose 
uptake deficiencies have been found in frontotemporal dementia (Grimmer et al. 
2004, Diehl-Schmid et al. 2007), Parkinson’s disease (Kuhl et al. 1984, Peppard et 
al. 1990), and AD (Chase et al. 1984, Duara et al. 1986, McGeer et al. 1986, 
Castellano et al. 2015) which worsens with disease progression. Interestingly the 
decline in glucose uptake is not limited to pathology as healthy elderly subjects had 
widespread decreases in glucose uptake compared to healthy subjects (Garraux et 
al. 1999). In human brains, there is a reduction of glycolytic flux, resulting in an 
accumulation of tissue glucose levels, both of which correlated with severity of AD 
(An et al. 2018). Glucose hypometabolism also increases amyloid precursor protein 
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(APP) mRNA expression in primary rat cortical astroglial cells (Shi et al. 1997). 
Moreover, hypoglycaemia increases ROS (McGowan et al. 2006) which is known to 
be important in the onset of dementia (Huang et al. 2016). By increasing plasma 
glucose levels in patients with AD, memory improvements can be made (Craft et al. 
1999, Craft et al. 2003). In the present study, RLG increases ECAR, indicating 
increased glycolytic flux. This may have been generated by increased CO2 
production by mitochondria, driven by increased fatty acid oxidation, rather than a 
change in glycolysis. It is interesting to speculate that the changes seen in astrocyte 
metabolism in response to RLG may impact dementia-related pathways given 
enough time. 
This study for the first time shows human astrocytes respond to a physiologically 
relevant glucose range by activation of the AMPK pathway. In response to RLG, 
human astrocytes intrinsically adapt their metabolism; increasing mitochondrial 
respiration, mediated in part by fatty acid oxidation, as well as glycolytic rates. This 
does, however, generate a mild to moderate mitochondrial stress seen as an 
increase in proton leak and decreased coupling efficiency. Nevertheless, human 
astrocytes can successfully sustain intracellular nucleotide ratios and maintain 
lactate release in low glucose. Lastly, following RLG a 4-day recovery period 
restored mitochondrial oxygen consumption, but coupling inefficiency and elevated 
basal ECAR remained. While it is difficult to know whether these adaptations directly 
improve or worsen the CRR to hypoglycaemia, they provide an interesting 
examination of the intrinsic responses generated by human astrocytes in response to 
acute or recurrent low glucose in vitro. 
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Chapter 4 
 
 
 
Human astrocytes sustain normal calcium signalling 
in low glucose 
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Introduction 
Calcium signalling is a ubiquitous mechanism in many living cells including 
astrocytes. Early work found calcium transients in astrocytes could be induced by 
mechanical stimulation (Charles et al. 1991). The increases to [Ca2+]i could also 
travel through glial syncytium allowing for the propagation of long range signalling 
from an initial stimulus (Cornell-Bell et al. 1990, Charles et al. 1991, Cornell-Bell et 
al. 1991, Dani et al. 1992). The spread of calcium waves through astroglial 
syncytium has been investigated in vitro and in situ and is due to the intercellular 
diffusion of inositol triphosphate (IP3) via gap-junctions (Verkhratsky et al. 2017). 
Calcium signalling is mediated by a complex interaction between plasma membrane 
and organelle ion channels, pumps and transporters, as well as buffering and 
sensing of cytosolic calcium through calcium binding proteins. 
Gene transcription, metabolism and neurotransmission can all be regulated by 
calcium signalling (Verkhratsky et al. 2012). Accumulation of Ca2+ in the 
mitochondria is necessary for the activation of mitochondrial matrix dehydrogenases, 
including pyruvate dehydrogenase (Denton et al. 1972), isocitrate dehydrogenase 
(Denton et al. 1978), and α-ketoglutarate dehydrogenase (Lawlis et al. 1981). Ca2+ 
has also been shown to activate ATP synthase through the action of Ca2+-binding 
proteins (Yamada et al. 1985, Hubbard et al. 1996, Territo et al. 2000). Therefore, 
astrocyte excitability and metabolism can be modulated by changes in cytosolic 
calcium. Additionally, CaMKK2, an AMPK kinase and activator, is regulated by 
calcium and changes cellular metabolic activity in hypothalamic neurons (Anderson 
et al. 2008). Interestingly, regionally specific control of metabolism, i.e. mitochondria, 
in micro domains can occur in the absence of somatic calcium signalling (Grosche et 
al. 1999). Maintaining ion balance via Na+/K+-ATPase is estimated to use 
approximately 20% of ATP produced by astrocytes (Silver et al. 1997). Similarly, 
plasma membrane Ca2+ ATPase (PMCA) and sarcoplasmic reticulum Ca2+ ATPase 
(SERCA) utilise ATP to maintain calcium homeostasis (Carafoli 1991, Yu et al. 
1993). Therefore, calcium signalling is necessary for regulating metabolism but also 
has a metabolic cost in its maintenance. If uncontrolled, excessive calcium entry into 
the cell can result in oxidative stress and mitochondrial dysfunction (Peng Tsung et 
al. 2010, McElnea et al. 2011). Therefore, well controlled calcium homeostasis is 
essential for astrocytes to survive and react to various stimuli. 
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Ultimately, the exchange of ions between the extracellular space via transporters 
and channels, or from other cells (via gap junctions) couples external stimuli and 
astrocyte excitability leading to changes in gene transcription and metabolism 
(Verkhratsky et al. 2012). Changes in astrocyte calcium can be elicited by 
neurotransmitters, including: glutamate (Cornell-Bell et al. 1990), acetylcholine 
(Araque et al. 2002), serotonin (5HT) (Schipke et al. 2011), noradrenaline (NA) 
(McCarthy et al. 1991), GABA (Kang et al. 1998); as well as purines (Abbracchio et 
al. 2009), pH (Rose et al. 2005), as well as ligands of Gq or Gs-protein coupled 
receptors (Verkhratsky et al. 2017). Astrocytic integration of these inputs is 
necessary for long-term potentiation (LTP) in the hippocampus via the gliotransmitter 
D-serine, for example (Henneberger et al. 2010). ATP-evoked astrocyte Ca2+ 
transients can also promote neurotransmission via glutamate release and 
subsequent activation of glutamate receptors (Perea et al. 2007). Increased [Ca2+]i in 
turn can release gliotransmitters including ATP (Guerra-Gomes et al. 2018). ATP 
release from astrocytes can be via diffusion through connexin hemi-channels (Stout 
et al. 2002), pannexin hemi-channels (Bao et al. 2004), P2X7 receptors (Suadicani et 
al. 2006), and direct exocytotic release (Zhang et al. 2007b). ATP release is also 
required for Ca2+ wave propagation in astrocytes (Guthrie et al. 1999, Cotrina et al. 
2000). Once released, ATP binds to P2X (ionotropic) and/or P2Y (metabotropic) 
receptors to increase [Ca2+]i via direct ion influx or release from intracellular stores 
(Abbracchio et al. 2009). ATP release can also decrease intracellular ATP:AMP 
ratios leading to AMPK activation, found in kidney epithelial and mesangial cells (Chi 
et al. 2014). Extracellular ATP is metabolised by ectonucleotidases to produce 
adenosine (Cunha et al. 1996). Adenosine can then suppress excitatory synapses 
(via A1 receptors) (Dunwiddie et al. 2001), or augment activation of synapses (via 
A2A receptors) (Cunha 2001). 
ATP-evoked [Ca2+]i increases also trigger glutamate release from hippocampal 
synapses (Perea et al. 2007). Glutamate is the predominant excitatory 
neurotransmitter in the brain with receptors on neurons and astrocytes (Meldrum 
2000). Agonism of astrocyte glutamate receptors increases calcium flux (Pearce et 
al. 1986) and can mediate neuronal excitation (Huang et al. 2004). Interestingly, 
glutamate-induced increases in [Ca2+]i can increase glucose uptake 2- to 3-fold 
within 10 seconds of exposure via transport of Glut-1 to the membrane (Loaiza et al. 
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2003), which couples glucose uptake to areas of high synaptic activity. In diseases 
like Alzheimer’s disease, abnormally high extracellular glutamate levels can occur 
leading to excitotoxicity (Hynd et al. 2004). Astrocytes uptake glutamate by Na+-
dependent mechanisms, to decrease excitotoxicity (Anderson et al. 2000, Swanson 
et al. 2004). Astrocytic glutamate uptake requires co-transport of three Na+ ions 
(Levy et al. 1998). To maintain [Na+]i it is actively pumped from the cell by the 
Na+/K+-ATPase (Chatton et al. 2003a). Indeed, the metabolic cost associated with 
maintaining astrocyte Na+/K+-ATPase is estimated to be approximately 20% of ATP 
production (Silver et al. 1997). Interestingly, glutamate uptake stimulates aerobic 
glycolysis in astrocytes to account for the increased metabolic demand (Pellerin et 
al. 1994). SERCA and PMCA consume ATP to maintain calcium homeostasis by the 
reuptake of Ca2+ into the endoplasmic reticulum (ER) (Yu et al. 1993) and export 
from the cell (Carafoli 1991), respectively. NCX enables the influx of Na+ in 
exchange for calcium being exported against a Ca2+ gradient (Blaustein 2010). The 
increase in [Na+]i is exported from the cell by the Na
+/K+-ATPase (Chatton et al. 
2003a). Increased ATP usage will decrease the ratio of ATP:AMP which activates 
the intracellular nucleotide sensor and master energy regulator AMPK (Herzig et al. 
2017). Activation of AMPK inhibits anabolism and increases catabolism to maintain 
[ATP]i (Herzig et al. 2017). 
The mechanisms discussed here all have an energetic cost. In this thesis it was 
shown that total ATP and ATP:ADP ratios were maintained in low glucose but the 
effects on intracellular calcium remain unknown. It has previously been shown that 
glucose-oxygen deprivation increases glutamate accumulation which may be due to 
a failure of glutamate reuptake mechanisms (Goldberg et al. 1993). Furthermore, 
neurodegeneration is dependent on the presence of Ca2+ and its uptake (Goldberg 
et al. 1993). Both high and low extracellular glucose levels increased [Ca2+]i in vitro 
in neurons (Moriyama et al. 2004). However, little is known about the effects of acute 
or recurrent low glucose on astrocyte [Ca2+]i. While astrocytic calcium signalling has 
been implicated in diabetes (Revsin et al. 2005, Lebed et al. 2008, Nagayach et al. 
2014), inflammation (Hamby et al. 2012), Alzheimer's disease (Rossi et al. 2005), 
epilepsy (Carmignoto et al. 2012), and Huntington's disease (Lee et al. 2013), little is 
known about how calcium signalling itself is modulated by neuroglycopenia  
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Monoamines such as noradrenaline (NA) and serotonin (5-hydroxytryptamine; 5HT) 
are neurotransmitters that mediate a range of physiological processes. NA is also a 
catecholamine, like adrenaline. NA is released from locus coeruleus-noradrenergic 
(LC-NA) neurons which are associated with anxiety related behaviours including 
vigilance, attention, and arousal (Elam et al. 1986, Gorman et al. 1993, Dazzi et al. 
2002, Kim et al. 2005, Lapiz et al. 2006). NA binds to α1 receptors which are Gq 
protein coupled and increase [Ca2+]i via IP3, which is associated with 
vasoconstriction, and glucose metabolism (Burcelin et al. 2004, Cotecchia 2010). NA 
also binds to α2 receptors which are Gi protein coupled and inhibits adenylyl cyclase 
activity thus inhibiting cAMP production; associated with inhibiting insulin release, 
stimulating glucagon release, and hepatic gluconeogenesis (Nakaki et al. 1980, 
Fagerholm et al. 2011). β1 and β2 receptors are Gs protein coupled receptors, 
activated by NA, which increase adenylyl cyclase raising [cAMP]i effecting heart 
function, smooth muscle relaxation, and stimulating gluconeogenesis and glycolysis 
(Danulat et al. 1990, Xiao et al. 1995, Fonseca 2010, Gibbs 2015). 
If blood glucose falls below approximately 3.6-3.9 mM counterregulatory hormone 
release occurs, including glucagon and adrenaline (Sprague et al. 2011). NA is also 
released as a part of CRR and has been shown to act in the periphery on the liver 
via β-2 adrenergic receptors to increase glycogenolysis and gluconeogenesis (Exton 
1987). Additionally, α-adrenergic receptor activation has been shown to increase 
hyperglycaemia in vivo (Metz et al. 1978, Nakadate et al. 1980, DiTullio et al. 1984, 
Angel et al. 1990). Glucoprivation within the hypothalamus induces NA, adrenaline, 
and glucagon secretion (Borg et al. 1995, Borg et al. 1997). Ingestion of caffeine has 
also been shown to increase anxiety related pathways which includes the activity of 
LC-NA neurons (Goldberg et al. 1982, Baldwin et al. 1989, Smith et al. 1999). 
Interestingly, coffee (containing caffeine), in a case study, improved hypoglycaemia 
awareness (Kerr et al. 2005). Hypoglycaemia activates LC-NA neurons to release 
NA which mediates hypoglycaemia-associated behavioural changes (Morilak et al. 
1987, Flugge 2000, Yuan et al. 2002). During hypoglycaemia in rats, NA is released 
into the VMN from LC-NA neurons (Beverly et al. 2001), which can be prevented by 
glucose perfusion into the VMN (de Vries et al. 2005). Agonising β2-adrenergic 
receptors in the VMN also enhances CRR response to hypoglycaemia 
(Szepietowska et al. 2011). Furthermore, chronic NA infusion into the VMN induces 
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obesity, glucose intolerance and insulin resistance (Cincotta et al. 2000). NA, 
therefore, has an orexigenic function within the CNS. 
Stress adaptation is a well-known phenomenon in animal models facilitated in part 
by β-adrenergic receptor desensitisation in the cortex (Nomura et al. 1981, Stone et 
al. 1982, Funk et al. 1996). It is possible that, the loss of behavioural changes in IHA 
may be partly due to impaired NA signalling. As hypoglycaemia increases NA 
release (Davis et al. 2000), RH may result in adrenergic receptor desentisation. If β-
adrenergic receptor desensitisation occurs this would prevent the normal activation 
of the amygdala in response to hypoglycaemia and thus contribute to the 
behavioural deficits in IHA. LC-NA neurons project to the lateral orbitofrontal cortex 
(LOFC) to excite GABAergic neurons via β-adrenergic receptors (Cavada et al. 
2000, Ramos et al. 2007). These GABAergic neurons inhibit the glutamatergic 
neurons in the LOFC (Ramos et al. 2007), therefore, reducing glutamatergic 
neurotransmission to the amygdala (Ramos et al. 2007), which normally activates 
GABAergic neurons resulting in reduced activity in the amygdala (Bishop 2007). 
Therefore, NA signalling disinhibits amygdala activity to increase anxiety associated 
behavioural responses. If β-adrenergic receptor desensitisation occurs this might 
prevent the normal activation of the amygdala in response to hypoglycaemia and 
thus contribute to the behavioural deficits in IHA. However, as receptor 
desensitisation is reversible it is plausible that normal adrenergic responses to 
hypoglycaemia can be regained given sufficient avoidance of their activation by strict 
glycaemic control. Indeed, hypoglycaemia awareness can be restored in humans 
with strict avoidance of hypoglycaemia (Fanelli et al. 1993, Cranston et al. 1994, 
Dagogo-Jack et al. 1994, Fritsche et al. 2001). Taken together this suggests β-
adrenergic receptors on the GABAergic neurons in the LOFC may regain NA 
sensitivity allowing for the disinhibition of the amygdala during hypoglycaemia.  
LC-NA neurons also release NA during sensory stimulation, arousal, and locomotion 
that stimulates a global rise in astrocyte [Ca2+]i (Ding et al. 2013). This can be 
blocked by the inhibition of α-1 adrenoreceptors (Ding et al. 2013), indicating 
astrocytes as targets of NA function. Astrocytes also express β-adrenergic receptors 
(Salm et al. 1989, Salm et al. 1992, Shao et al. 1992). Interestingly, β-adrenergic 
agonism within the VMN, and peripherally in rats can enhance CRR (Szepietowska 
et al. 2011, Szepietowska et al. 2013). Furthermore, NA delivery to the VMN 
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increases blood glucose and CRR hormone levels (Chafetz et al. 1986, Steffens et 
al. 1988). NA stimulation of astrocytes results in glucose uptake (Catus et al. 2011) 
and glycogenolysis which produces glucose-6-phosphate which is further 
metabolised by glycolysis to produce ATP and pyruvate. In astrocytes, pyruvate is 
predominantly converted to lactate due to the presence of lactate dehydrogenase 
isomer 5 (LDH5) (Bittar et al. 1996). Interestingly, lactate perfusion into the VMN in 
the presence of systemic hypoglycaemia prevents CRR (Borg et al. 2003). 
Therefore, NA-induced glycogenolysis and subsequent lactate production by 
astrocytes may contribute to defective CRR. Alternatively, the lactate produced by 
the astrocytes in this context, may be required for maintaining energy supply to β-
adrenergic neurons. 
In summary, NA is released within the VMN in response to hypoglycaemia which 
stimulates adrenergic receptors (Chafetz et al. 1986, Steffens et al. 1988, Beverly et 
al. 2001, de Vries et al. 2005). While neuronal responses to NA stimulation have 
been somewhat characterised the role of astrocytic responses to NA have been 
understudied. In particular the following studies aimed to assess the effects of low 
glucose availability on NA signalling in human astrocytes. 
5HT is a neurotransmitter found centrally and acts on sympathoadrenal and 
hypothalamic-pituitary-adrenal pathways (Lowry 2002). Low 5HT signalling is known 
for its role in depression (Mann et al. 1992, Eley et al. 2004). Selective serotonin 
reuptake inhibitors (SSRIs) are effective and commonly used anti-depressant 
medications, including fluoxetine (Amsterdam et al. 1994), sertraline (Glassman et 
al. 2002) and fluvoxamine (Grimsley et al. 1992), among others. However, two case 
studies in patients with T1DM and depression have shown a temporally sensitive 
correlation between SSRI use and IHA and increased hypoglycaemia incidence 
(Sawka et al. 2000, Sawka et al. 2001). In these case studies patients had T1DM 
and suffered from depression. As depression can be a result of diminished 5HT 
signalling (Eley et al. 2004) this could result in an altered baseline from which SSRIs 
may have a different effect on metabolism compared to otherwise healthy individuals 
with diabetes. Nevertheless, the two case studies incidence of hypoglycaemia 
increased with fluoxetine treatment and returned to normal with its discontinuation 
(Sawka et al. 2000, Sawka et al. 2001). These studies provide a correlation between 
the use of SSRIs and increased incidence of hypoglycaemia. Mechanistically, SSRIs 
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may increase 5HT signalling in astrocytes which is known to increase glycogenolysis 
in chick astrocytes, which is necessary for memory consolidation (Gibbs et al. 2014). 
As discussed previously, astrocytic glycogenolysis results in lactate production, and 
while lactate is neuroprotective (Pellerin et al. 2012) it can prevent CRR (Borg et al. 
2003). Nevertheless, these case studies are the only incidences reported of 
hypoglycaemia correlating with SSRI usage. While the incidence of hypoglycaemia 
was temporally correlated with the usage of SSRIs in the patients in the case 
studies, it does not prove causation. 
To clarify whether SSRIs increase the risk of hypoglycaemia and the effects they 
have on CRR, three studies were done in humans and rats. Conversely to the case 
studies, these showed fluoxetine and sertraline improved CRR in healthy people 
(Briscoe et al. 2008b), healthy rats (Sanders et al. 2008), and patients with T1DM 
(Briscoe et al. 2008a). Pre-treatment with sertraline increased glucagon, adrenaline 
and noradrenaline CRR to a single hypoglycaemic exposure indicating increased 
hypothalamic-pituitary-adrenal axis and sympathetic tone in rats (Sanders et al. 
2008). Furthermore, sertraline was able to prevent blunting of the adrenaline and NA 
responses to RH. After 5 years of T1DM and in long standing T2DM glucagon 
secretion is lost or diminished resulting in decreased endogenous glucose 
production (Gerich et al. 1973). Therefore, the enhanced sympathetic activity 
induced by sertraline, including increased glucagon, would help maintain glucagon 
secretion in T1DM. Similarly, in healthy human volunteers given fluoxetine which 
showed improved adrenaline and NA responses to hypoglycaemia (Briscoe et al. 
2008b). Briscoe et. al., also showed enhanced lipolysis, glycogenolysis, and 
ketogenesis which are important catabolic processes fuelling the body (Briscoe et al. 
2008b). However, it is important to note that these studies were carried out on 
otherwise healthy rats and humans respectively, with no diabetes or depression 
which may impact the action of SSRIs. To address this in an additional study Briscoe 
et. al., investigated the impact of fluoxetine on patients with T1DM and their CRR to 
hypoglycaemia (Briscoe et al. 2008a). Even in the presence of T1DM, adrenaline 
and NA responses were improved as well as increased lipolysis; indicating increased 
sympathetic nervous system activity and improved endogenous glucose production 
(Briscoe et al. 2008a). While the effects of fluoxetine were broadly similar between 
healthy volunteers and patients with T1DM, there was no increase in glycogenolysis 
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or ketogenesis in patients with T1DM. Therefore, the effects of SSRIs on 
hypoglycaemia counterregulation are altered by T1DM.  
Mechanistically, it is unclear how SSRIs, 5HT or other serotonergic agonists alter 
CRR. Serotonergic and chatecholaminergic activity is present in the hypothalamus 
and hindbrain nuclei that are important for energy homeostasis and regulation of the 
autonomic response to hypoglycaemia (Blardi et al. 2005). Indeed, fluoxetine 
increases adrenaline and NA which are important for a functional CRR (Bymaster et 
al. 2002). Moreover, third-ventricle injections of fluoxetine in rats causes 
hyperglycaemia in the absence of hyperinsulinaemia (Carvalho et al. 2004).  
Despite the contrasting literature suggesting that SSRIs alter the CRR to 
hypoglycaemia in diabetes, little is known about how astrocytes modulate these CRR 
pathways. In the context of depression, however, a recent study has shown 
fluoxetine exerts its therapeutic effect via astrocytic-dependent ATP release 
increasing brain-derived neurotrophic factor (BDNF) (Kinoshita et al. 2018). ATP and 
its metabolite adenosine have metabolic regulatory functions as discussed 
previously. Astrocytes also have serotonergic receptors (Schipke et al. 2011). Given 
that the mechanisms by which 5HT modulates the CRR are not fully understood this 
study aimed to perform some basic characterisation of the effects of 5HT on isolated 
human astrocytes and neurons in vitro during exposure to euglycaemia-like and 
hypoglycaemic-like glucose levels. 
Astrocytic calcium signalling can modulate whole-body energy metabolism (Chen et 
al. 2016) In rodents it has been shown that activation of neurons in ex vivo slice of 
the NTS rely on functional astrocytes and that astrocytes respond to glucoprivation 
before neurons (Rogers et al. 2018). While astrocytes are recently being investigated 
in more detail, the effects of low glucose on isolated human astrocytes has not been 
studied in detail. Calcium signalling also has a metabolic cost through the function of 
ATP dependent ion pumps, e.g. SERCA (Yu et al. 1993), and Na+/K+-ATPase (Morth 
et al. 2007). As such, it was hypothesised that basal [Ca2+]i would increase as a 
result of calcium dysregulation. The studies presented here expand on works by 
Rogers et. al., (Rogers et al. 2018) McDougal et. al., (McDougal et al. 2011) Marty 
et. al., (Marty et al. 2005) and Chen et. al., (Chen et al. 2016) by characterising the 
calcium responses of isolated human astrocytes to low glucose using the ratiometric 
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calcium sensitive dye fura-2. To characterise the calcium response to purinergic 
stimuli ATP and ADP, and NA, the cell-permeable calcium binding dye fluo-4 was 
used. Lastly, lactate release was measured to test whether monoamine, NA or 5HT, 
modulation of metabolism was affected by low glucose. Briefly, these studies show 
that human astrocytes sustain calcium homeostasis during low glucose-induced 
metabolic stress. 
Overall aim and objectives 
Rodent astrocytes have been shown to respond by changes in [Ca2+]i to low glucose 
stimuli and mediate changes in neuronal activity. Given that calcium signalling 
metabolically taxing, it was hypothesised that the metabolic alterations seen in 
chapter 3 may affect it. Therefore, the principle aim of this chapter was to investigate 
if calcium signalling, either innate or induced, could be altered by acute or recurrent 
low glucose. Specifically the following questions were addressed: 
 Does acute or recurrent low glucose induce changes to [Ca2+]i as seen 
previously? 
 Are astrocyte responses to calcium signalling activators, i.e. purines, NA and 
5HT, altered by acute or recurrent low glucose? 
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Results 
4.1 Low glucose increases basal intracellular Ca2+ in HPA 
Unlike neurons, astrocytes are non-electrically excitable and rely changes in [Ca2+]i 
to propagate signals, regulate their metabolism and release of gliotransmitters 
(Verkhratsky et al. 2012). Astrocytes are known to be activated by glucoprivation 
(McDougal et al. 2011), fasting (Daumas‐Meyer et al. 2018), and obesity (Horvath et 
al. 2010, Thaler et al. 2012), but the intrinsic calcium response to low glucose in 
human astrocytes (0.1mM) has not been characterised. Therefore, HPA cells were 
exposed to three hours of either 2.5 or 0.1 mM glucose and free calcium measured 
during ratiometric imaging. [Ca2+]i was significantly elevated in 0.1 mM glucose 
compared to control (2.5 mM glucose) (figure 4.1A,B). 
4.2 During measurement of intracellular calcium for 90 minutes, intracellular 
calcium increases in HPAs regardless of RLG 
Given [Ca2+]i was increased in HPA by low glucose, a time course of the astrocytic 
response to low glucose was measured using fura-2 and the use of a microscope, 
rather than a plate reader. Figure 4.2A-D shows the raw traces of averaged readings 
from cells from an individual coverslip from control, acute low glucose, antecedent 
RLG, or RLG. A baseline measurement was taken for 5 minutes in 2.5 mM glucose, 
before being perfused with 2.5 or 0.1 mM glucose for 90 minutes. Interestingly, all 
groups after 90 minutes showed between a 5-10% increase in unstimulated [Ca2+]i 
compared to their respective baseline, regardless of glucose concentration. The 
effect of this increase reached significance in cells treated with control conditions 
prior to the day of study (figure 4.2E). The RLG treated cells did increase more than 
the control treated cells but did not reach significance due to large variation between 
coverslips (figure 4.2E). Taken together this data shows that HPA cells do not 
respond to low glucose by increasing [Ca2+]i. 
4.3 ATP increases intracellular Ca2+ in either 2.5 or 0.1 mM glucose in HPA 
To further test whether basal calcium in HPAs was affected by low glucose and to 
establish the sensitivity of HPAs to ATP, they were cultured in 2.5 or 0.1 mM glucose 
for 3 hours and stimulated with 100 µM ATP. There was no significant difference in 
baseline, non-ATP stimulated calcium (figure 4.3A,B). Additionally, there was no 
significant difference in the maximum fold-change of [Ca2+]i (figure 4.3A). However, 
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shortly after the peak response was reached, the ATP-induced response of 2.5 mM 
glucose treated cells was significantly lower than that of 0.1 mM glucose. But, this 
was quickly matched again by the low glucose treated group. 
4.4 The effect of ATP treatment on isolated human neural cells 
While there was conflicting data on whether the [Ca2+]i of HPA cells was increased 
by low glucose it was not the robust response seen by Rogers et. al., (Rogers et al. 
2018). Therefore, perhaps inputs from other cell types are necessary for strong 
astrocytic calcium responses to low glucose. It has been shown that P2 antagonism 
prevents increases in neuronal calcium in response to low glucose (Rogers et al. 
2018), therefore purinergic signalling may be an important factor in mediating 
astrocytic responses to low glucose. Additionally, ATP is necessary for Ca2+ wave 
propagation in astrocytes (Guthrie et al. 1999, Cotrina et al. 2000), and stimulates 
increased [Ca2+]i purinergic signalling (Abbracchio et al. 2009). 
Glucose excited cells, such as GT1-7 glucose-excited neuroblastomas, are 
hyperpolarised by low glucose reducing their firing rates (Beall et al. 2012b). 
Therefore, these cells were used as a positive control to show that cells known to be 
inhibited by low glucose had altered calcium responses to ATP stimulation. The extra 
challenge of an ATP treatment in low glucose may result in an altered calcium 
response due to the metabolic demands of ion channel activity (Carafoli 1991, Yu et 
al. 1993). 
4.4.1 ATP increases intracellular Ca2+ in HPA and U373 astrocytoma cells in 
either 2.5 or 0.1 mM glucose 
HPA and U373 cells were stimulated with ATP after 3 hours of either 2.5 or 0.1 mM 
glucose. In both cell types, 20 (figure 4.4.1A,B), 50 (figure 4.4.1C,D) and 100 µM 
ATP (figure 4.4.1E,F) significantly increased calcium in both 2.5 and 0.1 mM glucose 
compared to vehicle. However, the maximal fold-change in calcium was unaffected 
by glucose concentration used in either cell type (figure 4.4.1G,H). HPA had the 
greatest increase in [Ca2+]i reaching approximately a 2-fold change with 100 µM ATP 
(figure 4.4.1A,G), this compares to a circa 1.2-fold change in U373 cells (figure 
4.4.1F,H). 
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4.4.2 ATP-induced increases in intracellular Ca2+ are attenuated by low glucose 
in GT-1 glucose excited neuroblastoma cells 
GT1-7 cells were treated with 20 (figure 4.4.2A), 50 (figure 4.4.2B), and 100 µM ATP 
(figure 4.4.2C) in either 2.5 or 0.1 mM glucose. ATP treatment significantly increased 
the peak response compared to vehicle treated cells in 2.5 mM glucose at all 
concentrations (figure 4.4.2D). However, only 100 µM ATP induced a significant 
increase in 0.1 mM glucose (figure 4.4.2D). Furthermore, at both 50 and 100 µM 
ATP the peak response was significantly lower in 0.1 compared to 2.5 mM glucose 
treated cells. Together, this shows that ATP-induced calcium responses are 
attenuated by low glucose in GT1-7 glucose-excited neuroblastoma cells. 
4.5 Low concentrations of ATP increase HPA and U373 astrocytoma 
intracellular Ca2+ 
Given that the EC50 for different purinergic receptors is different (Liu et al. 2001, 
Roberts et al. 2006) and 20 µM ATP induced a significant increase in intracellular 
calcium a lower range of ATP concentrations were used to test for a differential 
response. The HPA and U373 cells were treated with 5 (figure 4.5A,B), 10 (figure 
4.5C,D), and 20 µM ATP (figure 4.5E,F). The peak fold-change calcium response 
was significantly elevated in U373 cells at all concentrations compared to vehicle 
(figure 4.5H). However, in the HPA cells significance was only reached with 10 and 
20 µM ATP. Nevertheless, no significant differences were found in either cell type 
between glucose treatments. 
4.6 U373 astrocytoma intracellular Ca2+ response to ADP 
ATP is broken down both intra- and extracellularly to adenosine diphosphate (ADP), 
then adenosine monophosphate (AMP) and adenosine, which can act as separate 
signalling molecules (Eltzschig et al. 2012). Extracellularly ATP can be converted to 
ADP, AMP and/or adenosine by ectonucleotidases: ectonucleotide 
pyrophosphatase/ phosphodiesterase (E-NPP), ecto-nucleoside triphosphate 
diphosphohydrolase (E-NTDPase), and cluster of differentiation 73 (CD73) 
(Velasquez et al. 2014). Therefore, to test whether the rise in [Ca2+]i was mediated 
by ADP, U373 cells were stimulated with 5, 10 and 20 µM ADP. ADP stimulation did 
not significantly alter [Ca2+]i at any concentration used (figure 4.6A-D). 
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4.7 RLG does not modulate the intracellular Ca2+ response to ATP by HPA 
As RLG significantly alters cellular metabolism, the [Ca2+]i response to ATP was 
investigated. HPA cells were treated in control or RLG conditions with or without an 
additional exposure to medium containing 0.1 mM glucose on the final day. Cells 
were subsequently treated with 100 µM ATP. As seen previously, 100 µM ATP 
increased [Ca2+]i but neither prior RLG nor low glucose exposure altered the 
response (figure 4.7A-D). 
4.8 RLG U373 ATP dose responses 
Given that purinergic receptors are differentially activated by different concentrations 
of agonist (Liu et al. 2001, Roberts et al. 2006) a lower range of ATP concentrations 
were used to stimulate U373 astrocytoma cells. As acute low glucose had no effect 
on ATP-induced calcium responses in these cells, they were assayed in 2.5 mM 
glucose after control or prior RLG. 
4.8.1 RLG U373 higher ATP dose response 
The following experiment was carried out by Julia Vlachaki Walker but included for 
completeness. U373 cells were treated with 20 (figure 4.8.1A), 50 (figure 4.8.1B), 
and 100 µM ATP (figure 4.8.1C). The peak ATP-induced response at each 
concentration was calculated and found to be significantly different compared to 
vehicle (figure 4.8.1D). Furthermore, prior exposure to RLG did not affect the calcium 
response of the U373 cells (figure 4.8.1D). 
4.8.2 RLG does not modulate the intracellular Ca2+ response to ATP in U373 
astrocytoma cells 
To establish a more complete concentration curve, and to reveal any subtle 
differences, lower concentrations of ATP were used to stimulate U373 cells after 
control or prior RLG. U373 cells were treated with 5 (figure 4.8.2A), 10 (figure 
4.8.2B), and 20 µM ATP (figure 4.8.2C). The peak fold-change in [Ca2+]i was 
calculated and in control conditions, all ATP concentrations used stimulated a 
significant increase (figure 4.8.2D). However, with antecedent RLG while 10 and 20 
µM ATP significantly increased [Ca2+]i 5 µM did not (figure 4.8.2D). Nevertheless, 
there were no significant differences between control or antecedent RLG at any 
concentration used. 
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4.9 The broad spectrum P2 antagonist, PPADS, but not the P2X7 antagonist, 
A438079, reduce HPA intracellular Ca2+ response to ATP 
The P2X7 receptor has increased expression in diabetic rats’ glomerulus (Vonend et 
al. 2004) and is associated with increased diabetic complications, particularly in the 
kidney (Platania et al. 2017). P2X7 receptors also modulate human astrocyte Ca2+ 
signalling and ATP release (Suadicani et al. 2006). Therefore, to test whether P2X7 
mediates part of the calcium response to ATP treatment and whether this was 
altered by low glucose, HPA cells were treated with 100 µM ATP in combination with 
pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS), a broad-spectrum P2 
receptor inhibitor, and 100 µM A438079 (A4) to block P2X7 receptor activity. PPADS 
significantly attenuated the ATP-induced increase in [Ca2+]i, only in acute low 
glucose conditions (figure 4.9A,B). A4 did not significantly alter the ATP-induced 
[Ca2+]i. Figure 4.9D shows the peak fold change in [Ca
2+]i of HPA cells treated with 
100 µM and purinergic inhibitors. 
4.10 Noradrenaline increases HPA and U373 astrocytoma intracellular Ca2+ 
NA is released from locus coeruleus noradrenergic (LC-NA) neurons during 
hypoglycaemia (Morilak et al. 1987, Flugge 2000, Yuan et al. 2002). NA can 
stimulate glycogenolysis (Hutchinson et al. 2007, Gibbs et al. 2008a, Gibbs et al. 
2008b, Gibbs 2015), leading to increased lactate release from astrocytes (Bittar et al. 
1996). Importantly lactate perfusion into the VMN prevents full CRR to 
hypoglycaemia and increased lactate production may occur following RLG (Borg et 
al. 2003), which may occur by lactate induced GABA release (Chan et al. 2013). To 
determine whether HPA or U373 cells are sensitive to NA, they were treated with 10 
(figure 4.10A,B), 50 (figure 4.10C,D) and 100 µM NA (figure 4.10E,F) in 2.5 or 0.1 
mM glucose containing media. HPAs had approximately a 1.75-fold increase to 
[Ca2+]i compared to 1.2-fold in U373 cells (figure 4.10G,H). There was no difference 
between 2.5 and 0.1 mM glucose treated cells at any concentration in either cell type 
(figure 4.10A-H). Preliminary experiments in SH-SY5Y neuroblastoma cells showed 
no sensitivity to NA (data not shown). 
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4.11 Noradrenaline increases lactate release from HPA, U373 astrocytoma and 
SH-SY5Y 
NA can stimulate glycogenolysis and increase lactate production (Bittar et al. 1996, 
Hutchinson et al. 2007, Gibbs et al. 2008a, Gibbs et al. 2008b, Gibbs 2015), which 
can negatively affect CRR to hypoglycaemia (Borg et al. 2003). Therefore, to test the 
effect of NA on both astrocytes and a neuronal cell line, lactate was measured in 
conditioned media from HPA, U373 and SH-SY5Y neuroblastoma cells exposed to 
2.5 or 0.1 mM glucose conditions. While NA did not evoke a significant increase in 
[Ca2+]i in SH-SY5Y cells NA may affect glycolytic pathways altering lactate release. 
NA significantly increased extracellular lactate concentrations by approximately 3-
fold, 1.5-fold, and 2-fold for HPA, U373 and SH-SY5Y cells, respectively (figure 
4.11A-C).  The absolute amount of lactate present in the conditioned media was 
highest in the HPA (figure 4.11A). NA-stimulated lactate release from U373 cells was 
significantly lower in 0.1 mM glucose compared to control conditions (figure 4.11B). 
Furthermore, vehicle-treated cells cultured in 0.1 mM glucose also had significantly 
lower lactate levels in the extracellular medium (figure 4.11B). 
4.12 Noradrenaline does not alter extracellular ATP in U373 astrocytoma and 
SH-SY5Y cells 
ATP is co-released by sympathetic nerves (Burnstock 1990) and can modulate 
noradrenaline release in rat brain cortex (von Kügelgen et al. 1994). Furthermore, 
glutamate and adenosine stimulated release of ATP from astrocytes is dependent on 
glycogenolysis (Xu et al. 2013). However, whether or not this occurs with NA 
stimulation, known to induce glycogenolysis in astrocytes (Gibbs 2015), is unknown. 
To test whether this was the case, U373 and SH-SY5Y cells were treated with NA, 
and ATP content in conditioned media measured. Neither NA nor low glucose 
altered the eATP levels in conditioned media in either cell type (figure 4.12A,B). 
There was no detectable eATP in conditioned media from HPA cells under any 
conditions. 
4.13 Serotonin increases extracellular lactate from U373 astrocytoma cells, but 
not HPA or SH-SY5Y cells 
5HT has been implicated in modifying hypoglycaemia awareness (Sawka et al. 2000, 
Sawka et al. 2001, Briscoe et al. 2008a, Briscoe et al. 2008b, Sanders et al. 2008). 
Moreover, 5HT also mediates some of its effects on memory and learning in a 
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glycogenolysis-dependent manner (Gibbs 2015), which should also increase lactate 
release in astrocytes (Newman et al. 2011). To test whether lactate release was 
altered by 5HT, HPA, U373 and SH-SY5Y cells were stimulated with vehicle or 50 
µM 5HT and lactate content of conditioned media quantified. There were no 
significant differences between 5HT and vehicle; regardless of glucose concentration 
in either HPA (figure 4.13A) or SH-SY5Y cells (figure 4.13B). However, 5HT did 
significantly increase lactate in the conditioned media of U373 cells (figure 4.13B) 
but this was unaffected by glucose concentration. 
4.14 Serotonin does not alter extracellular ATP of U373 astrocytoma cells or 
SH-SY5Y cells. 
To test whether 5HT altered release of ATP from SH-SY5Y (figure 4.14A) or U373 
(figure 4.14B) cells, they were exposed to 30 minutes of 2.5 or 0.1 mM glucose with 
vehicle or 50 µM 5HT. The amount of ATP in the conditioned media was assayed 
and shown to be unaffected by 5HT in either cell type and unaltered by changes in 
glucose concentration. 
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Discussion 
Recurrent hypoglycaemia and diabetes are known to impair counterregulation (Heller 
et al. 1991, Segel et al. 2002). A complete understanding of glucose-sensing in the 
brain remains unknown and the aetiology of CRR blunting is poorly understood. 
Additionally, while the role of neurons as glucose-sensors has been known since 
1953 (Mayer 1953), astrocytes have relatively recently come into the spotlight 
(Young et al. 2000, Ainscow et al. 2004, Guillod-Maximin et al. 2004, Lam et al. 
2005b). Still, the effects of RLG on astrocytic calcium signalling remain poorly 
understood. Astrocytic signalling and activation is mediated by changes in [Ca2+]i 
(Charles et al. 1991, Verkhratsky et al. 2012). Inter-astrocyte calcium signalling is 
also required for long range calcium wave propagation (Cornell-Bell et al. 1990, 
Cornell-Bell et al. 1991). Calcium signalling can modulate mitochondrial function by 
the activation of pyruvate, isocitrate, and α-ketoglutarate dehydrogenases and 
electron transport activity (Denton et al. 1972, Denton et al. 1978, Lawlis et al. 1981, 
Yamada et al. 1985, Hubbard et al. 1996, Territo et al. 2000). And in mouse neurons 
calcium signalling also increases AMPK activity via CaMKK2 (Anderson et al. 2008). 
While calcium can modulate mitochondria and therefore cellular metabolism (Denton 
et al. 1972, Denton et al. 1978, Lawlis et al. 1981, Yamada et al. 1985, Hubbard et 
al. 1996, Territo et al. 2000), calcium homeostasis requires a metabolic input; for 
example, the reuptake of calcium into the endoplasmic reticulum and its export 
through the plasma membrane by SERCA and PMCA respectively both require ATP 
(Carafoli 1991, Yu et al. 1993). Moreover, elevated resting [Ca2+]i has been reported 
in neurons with concomitant mitochondrial dysfunction in mice with STZ-induced 
diabetes and db/db mice (Kostyuk et al. 1999). Furthermore, a low glucose (0.5 mM) 
or glucoprivic (5 mM 2-DG in 5 mM glucose) challenge increases [Ca2+]i in a subset 
of NTS astrocytes (McDougal et al. 2011). Additionally, using DREADD (designer 
receptors exclusively activated by designer drugs) technology, Chen et. al., 
demonstrated that increasing intracellular calcium in the GFAP expressing cells of 
the mouse arcuate nucleus increased food intake (Chen et al. 2016); demonstrating 
a role of astrocytes in regulating whole body energy homeostasis. 
In the present study, 3 hours of low glucose exposure had conflicting outcomes 
depending on the methodology used to investigate the response. Using a plate 
reader there was a small increase in basal, unstimulated [Ca2+]i, however, using a 
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microscope to measure [Ca2+]i imaging rig no significant difference was found. This 
may be due to a more prolonged imaging period with the microscope which could 
induce damage from the lasers used. Additionally, the cells studied with the plate 
reader had a higher confluency than those on glass coverslips used under the 
microscope. This may affect autocrine and paracrine signalling. For example, P2 
signalling appears to be necessary for astrocyte-neuron signalling in reacting to 
glucoprivation or low glucose (McDougal et al. 2011). Given that RLG alters 
astrocyte metabolic phenotype (e.g. increased fatty acid oxidation and decreased 
coupling efficiency) and calcium homeostasis has a metabolic cost, it is plausible 
that calcium signalling may be affected by RLG. Over a 90-minute imaging period, 
HPA cell [Ca2+]i significantly increased by about 10-20%, but this occurred in both 
2.5 and 0.1 mM glucose and in control or RLG treated cells. Therefore, it is unlikely 
that prior RLG exposure or acute exposure to 0.1 mM glucose is having a large 
effect on HPA [Ca2+]i. The increase in [Ca
2+]i may be mediated by stress induced 
during the imaging period. For example, repeated light doses are known to be toxic 
to cells in vitro (Wang 1976, Tinevez et al. 2012). However, there may be an 
additional source of stress that is mediating this rise in calcium that remains 
unknown. Taken together, these studies contrast the findings by McDougal et. al. 
showing increased intracellular calcium in astrocytes in response to low glucose 
(McDougal et al. 2011). However, those studies used ex vivo slices from mice, 
whereas, the present studies were performed using human astrocytes without 
neuronal input. Furthermore, recent data suggests a large degree of heterogeneity in 
astrocytes within the brain (Verkhratsky et al. 2017). McDougal et. al. used brain 
slices containing the NTS, a region involved in regulating whole-body energy 
homeostasis (Grill et al. 1998, Marty et al. 2007), whereas, the HPA cells used in this 
study were from a generic sub-ventricular white matter region and have been 
cultured for up to 20 passages in vitro. Therefore, the HPA cells may no longer 
accurately represent their physiological setting, and/or input from other cell types is 
necessary for astrocytic glucose-sensing. Nevertheless, as shown previously, human 
astrocytes are able to defend intracellular ATP/ADP nucleotide ratios well after RLG 
and 3 hours of low glucose exposure. While these astrocytes suitably match ATP 
supply to demand they are not under the added pressure of recycling 
neurotransmitters, supporting neuronal function or being stimulated with additional 
astrocytic agonists. 
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Despite glucose not conclusively altering [Ca2+]i in HPA cells, it was hypothesised 
that an additional challenge from ATP, a purinergic agonist, may have been altered 
by low glucose. ATP is also an important gliotransmitter (Guerra-Gomes et al. 2018) 
that can stimulate glutamate release from neurons (Perea et al. 2007), the principle 
neurotransmitter in the brain. ATP is also released from neurons in vitro in response 
to low glucose challenge (Zhang et al. 2007a). Interestingly, recent evidence shows 
astrocytic activation of chatecholaminergic neurons in mouse hindbrain is dependent 
on purinergic activity (Rogers et al. 2018). Nevertheless, ATP-induced increase in 
[Ca2+]i in HPA and U373 cells were unaffected by low glucose. This shows that in 
addition to sustaining ATP production in low glucose, ATP-induced calcium signalling 
is maintained. The glucose excited GT1-7 cells were used as a positive control to 
show that ATP-induced increases in [Ca2+]i can be attenuated by low glucose 
exposure, in a known glucose-sensing cell line (Beall et al. 2012b). This occurs as 
glucose excited cells via the K+ATP channel depolarise in high glucose and are 
hyperpolarised during low glucose (Beall et al. 2012a). Interestingly, ATP stimulated 
a 5-fold larger increase in [Ca2+]i in HPA cells compared to U373 and GT1-7 cells. 
Purinergic receptor desensitisation can occur with repeated exposure to agonists 
(Kasakov et al. 1982). Therefore, the higher sensitivity found in HPA cells, may be 
due to the absence of detectable levels of ATP in HPA conditioned media resulting in 
no receptor desensitisation. Additionally, P2 receptors may be more highly expressed 
in HPA cells than the U373 or GT1-7 cells. 
ATP is metabolised extracellularly into ADP, AMP and adenosine by extracellular 
ectonucleotidases (E-NPP, E-NTDPase, and CD73) (Cunha et al. 1996, Velasquez 
et al. 2014). Adenosine can suppress (via A1 receptors) (Dunwiddie et al. 2001) or 
augment (via A2A receptors) (Cunha 2001) synapse excitation, therefore, modulating 
neurotransmission. Therefore, to determine whether the increase to [Ca2+]i was due 
to ATP breakdown and to characterise the intracellular calcium response to other 
purinergic receptor modulators, U373 cells were stimulated with ADP, which had no 
significant effect. Therefore, the ATP-induced calcium transients were likely due to 
ATP itself and not its breakdown products. However, to rule out whether adenosine 
was acting on adenoreceptors receptors and increasing [Ca2+]i adenosine should be 
used to treat the cells in a similar manner. Nevertheless, to confirm that ATP was 
binding to purinergic receptors and having a direct effect on [Ca2+]i, the broad 
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spectrum P2 inhibitor, PPADs, was used to block purinergic receptors. Interestingly, 
this only significantly reduced [Ca2+]i in 0.1 mM glucose compared to vehicle. 
However, there was also no significant difference between 2.5 or 0.1 mM glucose 
treated cells also given PPADs. This suggests that while some of the ATP-induced 
increase in [Ca2+]i is due to receptors blocked by PPADs, the majority is being 
mediated by those that are not, i.e. P2X4, P2Y1, P2Y11, P2Y13, or P2Y14. P2X7 is a 
receptor found in astrocytes and when sufficiently activated can result in release of 
excitatory amino acids (Duan et al. 2003), and ATP (Suadicani et al. 2006). A 
selective P2X7 antagonist, A4, did not significantly alter ATP-induced [Ca
2+]i 
responses, therefore P2X7 is not involved in the calcium response in HPA cells at the 
concentrations used in the current study. P2X7, is a heterotrimeric receptor that 
requires higher ATP concentrations to fully activate it (Syed et al. 2012). Therefore, 
to fully rule out P2X7 activity in HPA and U373 cells, a high concentration of ATP 
should be used. 
During hypoglycaemia in rats, NA is released from LC-NA neurons into the VMN (de 
Vries et al. 2005). Additionally, this response was prevented by glucose perfusion 
into the VMN during systemic hypoglycaemia (de Vries et al. 2005). This provides 
compelling evidence that NA is a part of the CRR to hypoglycaemia. NA is known to 
have effects on metabolism, for example, α-adrenergic receptor activation has been 
shown to increase hyperglycaemia in vivo (Metz et al. 1978, Nakadate et al. 1980, 
DiTullio et al. 1984, Angel et al. 1990), and, β2-adrenergic receptor agonism in the 
VMN improves CRR (Szepietowska et al. 2011). Repeated 2-DG-induced 
glucoprivation also blunts the NA response to further glucoprivation and 
glucoregulatory responses, including decreased activation of chatecholaminergic 
cells (Sanders et al. 2000). 
NA binds to adrenergic receptors to increase [Ca2+]i, or to either increase or 
decrease [cAMP]i depending on the receptor. NA has been shown to increase 
glucose uptake and increase glycogenolysis specifically in astrocytes (Salm et al. 
1989, Salm et al. 1992, Shao et al. 1992) (Catus et al. 2011). Activation of β-
adrenergic receptors increases cAMP which activates protein kinase A which then 
activates glycogenolysis via activating glycogen phosphorylase (Mayes et al. 2003). 
By this process, glycolytic activity will increase within astrocytes and result in 
increased lactate production due to astrocytes expressing LDH5 (Bittar et al. 1996). 
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This lactate release could be detrimental to CRR (Borg et al. 2003). In the present 
study HPA, U373 and SH-SY5Y neuroblastoma cells had increased lactate levels in 
their conditioned media. SH-SY5Y cells were used as a comparator for differences in 
responses of human astrocytes and neurons to neurotransmitters. Interestingly, the 
lactate release from U373 cells was diminished in low glucose, but not HPA or SH-
SY5Y cells. Interestingly, lactate uptake and utilisation triggers GABA release within 
the VMN which is normally suppressed during hypoglycaemia but enhanced 
following RH (Chan et al. 2013). In euglycaemia GABA suppresses the release of 
glucagon and adrenaline, whereas in hypoglcyaemia GABAergic tone is suppressed 
(Zhu et al. 2010). The decrease in lactate release from U373 cells during hypo would 
hypothetically correspond in less GABA release; however, no decrease is seen in 
HPA cells. In previous studies presented in this thesis (figure 3.17) RLG did not 
affect lactate release from either U373 or HPA cells. Still, if NA increases lactate 
release from human neural cells this could suppress glucagon and adrenaline 
release.  
It is interesting that the SH-SY5Y cells had an increase in lactate production, albeit 
lower than the astrocytes, as mature neurons contain very little glycogen (Brown 
2004). Therefore, it is unlikely that NA would be triggering significant glycogenolysis. 
NA could be stimulating glycolysis which would increase lactate production. 
NA significantly increased [Ca2+]i in both HPA and U373 cells, whereas, SH-SY5Y 
cells did not. Therefore, HPA and U373 cells likely contain α-adrenergic receptors 
that increase [Ca2+]i, whereas SH-SY5Y cells do not. Previously α-adrenergic 
receptors have been confirmed in rat and human astrocytes immunochemically in 
situ (Aoki et al. 1998, Milner et al. 1998, Glass et al. 2001). As NA did not increase 
[Ca2+]i in SH-SY5Y cells, the increased lactate release is likely mediated by β-
adrenergic receptors that use the secondary signalling molecule cAMP. Likewise, the 
HPA and U373 cells may also contain β-adrenergic receptors.  
Neurons are able to use lactate as a metabolic substrate during energy deprivation 
or to fuel high levels of activity (Pellerin 2003). This may be important when LC-NA 
neurons become particularly active in response to stressors, like hypoglycaemia. On 
the other hand, lactate can be detrimental to CRR as exogenous lactate supply to 
the VMN prevents CRR to hypoglycaemia (Borg et al. 2003). Either way, the lactate 
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release caused by NA in HPA, U373 and SH-SY5Y cells was unaffected by the 
amount of glucose present. This data therefore shows that the action of NA on 
isolated astrocytes and neuronal cells is preserved during acute low glucose. Lastly, 
NA did not significantly alter any ATP release from U373 or SH-SY5Y cells, 
suggesting that NA mediates its effects in an ATP-independent manner. Taken 
together these data show that HPA, U373 and SH-SY5Y cells are sensitive to NA 
signalling by increasing [Ca2+]i, in HPA and U373 cells, or increasing lactate release 
in all cell types. Given that RH blunts NA signalling (Davis et al. 1997), it would be 
interesting to determine whether the NA response is altered by RLG. 
5HT is a monoamine that modulates mood (Martinowich et al. 2008), memory 
formation (Gibbs 2015), and hypoglycaemia counterregulation (Briscoe et al. 2008a, 
Briscoe et al. 2008b, Sanders et al. 2008). SSRIs are used to treat depression by 
preventing reuptake of 5HT leading to increased seretonergic activity in hindbrain 
nuclei which are associated with mood control (Stahl 1998, Andrews et al. 2015). 
Additionally, while some evidence suggests SSRI usage worsens hypoglycaemia 
awareness and incidence (Sawka et al. 2000, Sawka et al. 2001), SSRIs have also 
been shown to improve the CRR (Briscoe et al. 2008a, Briscoe et al. 2008b, Sanders 
et al. 2008). Mechanistically, 5HT improved glucoregulatory hormone responses, 
autonomic drive, and increased lipolysis and hepatic glucose production that help 
defend against hypoglycaemia (Briscoe et al. 2008a, Briscoe et al. 2008b, Sanders 
et al. 2008). 
5HT acts via serotonergic receptors 5HT1-7 which mainly act through modulating 
[cAMP]i (Nichols et al. 2008). Increased [cAMP]i can activated glycogenolysis via 
PKA activation of glycogen phosphorylase (Gibbs 2015) and therefore modulate 
lactate release from astrocytes (Bittar et al. 1996). While U373 cells increased 
lactate release when treated with 5HT, HPA and SH-SY5Y cells did not. This 
indicates that U373 cells likely express 5HT4, 6 and 7 receptors that are Gs-protein 
coupled and increase [cAMP]i. Likewise, these receptors are unlikely to be present in 
HPA or SH-SY5Y cells. 5HT2 and 5HT3 receptors can increase [Ca
2+]i via calcium 
release from intracellular stores or influx of Ca2+ ions (Nichols et al. 2008). Future 
studies should investigate whether 5HT is increasing intracellular calcium in HPA, 
U373 or SH-SY5Y cells as this could alter their activation state. 
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Depending on the site of SSRI-induced lactate release it may have differential effects 
on CRR. For example, 5HT mediated lactate release could contribute to neuronal 
supply according to the astrocyte-neuron lactate shuttle hypothesis (Pellerin et al. 
2012). This could then facilitate the activity of neurons that do not directly sense 
glucose, i.e. LC-NA neurons in the locus coeruleus. In this context SSRIs could 
contribute to CRR. Conversely, if SSRIs increase serotonergic activity resulting in 
lactate release in the VMN this would be detrimental to CRR (Borg et al. 1997). 
The data presented in this chapter show that HPA do not increase [Ca2+]i in 
response to acute or recurrent low glucose. Additionally, ATP and NA-induced [Ca2+]i 
are unaffected by low glucose, while glucose excited GT1-7 cells are. While calcium 
homeostasis requires ATP (Carafoli 1991, Yu et al. 1993), astrocytes sustain calcium 
homeostasis during glucose restriction. These data are in conjunction with findings 
from chapter 3 where both HPA and U373 cells defend intracellular nucleotide ratios 
during acute and recurrent low glucose. These studies characterise for the first time 
the responses of isolated human astrocytes to low glucose with additional 
stimulation. However, a more replete model including the interaction of other cell 
types would likely alter the results. For example, rat and mouse hindbrain astrocytes 
can react to low glucose by increasing [Ca2+]i when not in isolation (McDougal et al. 
2011, Rogers et al. 2018). This suggests that other cellular inputs might trigger the 
astrocytic calcium response to low glucose that then mediates changes in neuronal 
activity.  
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Glucose variation increases inflammation in human 
astrocytes 
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Introduction 
All forms of diabetes are associated with pathological hyperglycaemia, which 
induces inflammation (Lin et al. 2005). The current medical practice is to restore 
euglycaemia with glucose-lowering agents, such as, sulfonylureas, metformin, and in 
those without endogenous insulin production, exogenous insulin is provided. The 
implementation of these glucose lowering medications must be measured as 
iatrogenic hypoglycaemia can be a common occurrence, particularly in those with 
T1DM undergoing intensive insulin therapy (Edridge et al. 2015). The occurrence of 
hypoglycaemia is the limiting factor in sustaining optimal glucose control (Cryer 
2008). Indeed, as optimal glucose control is not achieved currently diabetes still 
causes a progressive deterioration of the central and peripheral nervous system (Di 
Mario et al. 1995, Jacobson et al. 2007, Little et al. 2007) as well as the vasculature 
(Duh et al. 1999). 
Hypoglycaemia in healthy people, and those with diabetes, increases 
proinflammatory, prothrombotic and proatherogenic cytokines, including 
plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF), 
vascular adhesion molecules, and interleukin-6 (IL-6) (Gogitidze Joy et al. 2010, 
Wright et al. 2010). The inflammatory response to hypoglycaemia is exacerbated by 
recovery immediately to hyperglycaemic conditions where oxidative stress and 
inflammation are further worsened (Ceriello et al. 2012). Interestingly, while RH 
blunts the CRR to further hypoglycaemia, it appears to exacerbate cytokine release 
(Joy et al. 2015) and prevent the normal rise in leukocytes, which are strongly 
correlated with the adrenaline response to hypoglycaemia (Ratter et al. 2017).  
Inflammation is involved in many CNS diseases (Chavarria et al. 2004). Within the 
CNS microglia are the predominant immune cells, and are activated by RH in 
diabetic rats (Won et al. 2012). However, astrocytes are also sensitive to 
inflammatory stimuli (John et al. 2001, Murakami et al. 2003, Walter et al. 2004, 
Ballerini et al. 2005, Kucher et al. 2005, Narcisse et al. 2005) and can release a 
range of pro-inflammatory factors including tumour necrosis factor-α (TNF-α) (Beattie 
et al. 2002, Pribiag et al. 2013, Habbas et al. 2015), IL-1β (Choi et al. 2014) and IL-6 
(Erta et al. 2015). Moreover, some studies show that astrocytes regulate the 
inflammatory response of microglia (Aloisi et al. 1997, Vincent et al. 1997, Pyo et al. 
2003, Min et al. 2006, Kim et al. 2010). Diabetes is characterised by hyperglycaemia, 
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as such much work has focussed on the effects of high glucose exposure has on a 
range of cell types. Astrocytes exposed to high glucose increase cytokine 
expression, including: TNF-α, IL-6, IL-1B, IL-4, and VEGF (Wang et al. 2012). 
Interestingly, co-treatment with ROS scavengers and inhibition of NFκB prevented 
cytokine expression, indicating hyperglycaemic mediated CNS inflammation may be 
mediated by NFκB and oxidative stress. In glucose/oxygen deprivation, an ischaemia 
model, IL-1β, IL-6, and TNF-α expression increased as well as NFκB activation in 
astrocytes (Zhao et al. 2013). 
Inflammatory signalling can modulate the activity of local neurons, for example 
central administration of IL-6 increases energy expenditure in mice and protects 
against diet induced obesity (Wallenius et al. 2002). Additionally, IL-6 activates the 
hypothalamic-pituitary-adrenal axis (van der Meer et al. 1996) and increases 
glucagon secretion in man (Tsigos et al. 1997). Within the CNS, astrocytes are the 
principle source of IL-6 (Van Wagoner et al. 1999) and therefore may directly 
modulate whole-body energy status through inflammatory signalling. Additionally, 
astrocyte specific inactivation of NFκB protected against high fat diet induced obesity 
in mice (Buckman et al. 2015, Douglass et al. 2017). Fasting also induces astrocyte 
expansion and activation (Daumas-Meyer et al. 2018), but the effects on 
inflammatory signalling remain unknown. The present study aimed to characterise 
the cytokines released by isolated human astrocytes in response to acute and 
recurrent low glucose treatment. Interesting targets were then validated and 
quantified. In brief these studies show that macrophage migration inhibitory factor 
specifically is upregulated by low glucose exposure. Secondly, U373 cells have 
upregulated PAI-1 release following RLG. Lastly, preliminary evidence suggests that 
general cytokine release is increased with low glucose and RLG in HPA cells. 
Overall aim and objectives 
Hypoglycaemia induces the increase of inflammatory markers in humans and these 
may be associated with acute and chronic consequences of T1DM. Furthermore, 
extremes in nutritional state induce changes in astrocyte inflammatory state. 
However, the study of human astrocytes during acute and recurrent low glucose has 
not thoroughly investigated changes to cytokine release. This chapter’s primary aim 
was to uncover cytokines released by HPA cells during acute and recurrent low 
glucose. This was achieved by addressing the following research questions: 
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 What cytokines are released by HPA cells during acute and recurrent low 
glucose? 
 How may these cytokines contribute to impaired hypoglycaemia 
counterregulation? 
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Results 
5.1 Identification of cytokines differentially released by HPA exposed to 
glucose variation 
Hypoglycaemia triggers cytokine release in both healthy people and those with 
diabetes (Gogitidze Joy et al. 2010, Wright et al. 2010), although typically those with 
diabetes have higher baseline cytokine levels than controls. However, the specific 
release of cytokines within the CNS in response to low glucose is less understood. 
Hyperglycaemia and high glucose triggers the release of cytokines from glial cells 
(Lin et al. 2005, Wang et al. 2012). And glucose/oxygen deprivation also releases 
cytokines from astrocytes. This study aimed to characterise the cytokines that are 
differentially released from HPA cells exposed to control, acute low glucose, 
antecedent low glucose or RLG. Using a human cytokine array panel more cytokines 
were detectable in the conditioned media from acute low glucose, antecedent low 
glucose and RLG treated HPA cells than control (figure 5.1A). The map of where 
each cytokine is detected is in figure 5.1B. IL-13, MIF and PAI-1 were strongly 
detected in the control samples and appeared to be differentially regulated by 
glucose treatments. To semi-quantitatively analyse the change densitometric 
analysis was performed. IL-13 appeared to be increased compared to control in all 
groups (figure 5.2A). MIF appeared to be elevated in all groups compared to control 
but especially so in low glucose (figure 5.2B). PAI-1 appeared to be elevated by low 
glucose (figure 5.2C). The additional densitometry of all detectable cytokines can be 
found in appendix B. 
5.2 Interleukin-13 in the conditioned media of HPA and U373 astrocytoma cells 
is unaltered by RLG 
IL-13 is a cytokine with similar activity to IL-4 (Minty et al. 1993). IL-13 is an anti-
inflammatory cytokine that is necessary for the suppression of post-prandial hepatic 
glucose production (Stanya et al. 2013). IL-13 KO in mice induces insulin resistance, 
weight gain and metabolic syndrome, implicating IL-13 as an important metabolic 
regulator (Stanya et al. 2013). However, despite an apparent increase in IL-13 
release by RLG in the cytokine array panel, there was no significant difference found 
in HPA or U373 cells using targeted ELISA (figure 5.2A,B). 
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5.3 Plasminogen activator inhibitor-1 in the conditioned media of HPA and 
U373 astrocytoma cells is unaltered by RLG 
PAI-1 is a serine protease inhibitor which prevents plasmin from degrading 
extracellular matrix proteins involved in the clotting response (Ghosh et al. 2011). In 
T2DM PAI-1 is elevated and implicated in insulin resistance (Potter van Loon et al. 
1993, Juhan-Vague et al. 2003), and therefore also correlates with development of 
T2DM (Festa et al. 2002). Furthermore, PAI-1 is also detected in the cerebrospinal 
fluid of patients with AD (Sutton et al. 1994). Plasmin, inhibited by PAI-1, normally 
degrades Aβ, therefore PAI-1 may contribute to Aβ accumulation in AD (Kutz et al. 
2012). However, despite there being an apparent increase in PAI-1 release from 
HPA in the cytokine array panel, there were no significant differences detected in 
HPA cells (figure 5.3A). Interestingly, U373 cells did significantly increase PAI-1 
release when treated with RLG compared to control and acute low glucose treated 
cells (figure 5.3B). Antecedent RLG also increased from control but did not reach 
significance. It appears that PAI-1 may remain elevated even following a recovery 
period. Furthermore, the release of PAI-1 appears to be a dose dependent response, 
where each bout of low glucose increases PAI-1 expression. 
5.4 Macrophage-migration inhibitory factor in the conditioned media of HPA or 
U373 astrocytoma cells is unaltered by RLG 
MIF is an inflammatory cytokine that suppresses glucocorticoid function (Calandra et 
al. 1995), and triggers the release of other pro-inflammatory cytokines (Riedemann 
et al. 2003). MIF can also increase glucose uptake in skeletal muscle (Benigni et al. 
2000) and cardiac (Liang et al. 2015) cells. Interestingly, it is upregulated in T1DM 
(Ismail et al. 2016), T2DM (Yabunaka et al. 2000, Herder et al. 2008, Stosic-Grujicic 
et al. 2008) and AD (Popp et al. 2009, Bacher et al. 2010). However, despite there 
being an apparent increase in MIF release from HPA in the cytokine array panel, 
there were no significant differences detected in HPA or U373 cells following control 
or recurrent low glucose treatment (figure 5.4A,B). 
5.5 Macrophage-migration inhibitory factor release from U373 human 
astrocytoma cells is increased by 24 hours of low glucose treatment 
Given that modest increases in MIF were seen over the 3-hour treatment period, a 
24 hour incubation period was used to provide sufficient time for MIF to accumulate 
in the conditioned media allowing for more pronounced differences between groups. 
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During this time, U373 cells were treated with 5, 2.5, 1 and 0.1 mM glucose. By 24 
hours, the conditioned media of cells treated with 0.1 mM glucose had significantly 
higher MIF concentrations than the other groups (figure 5.5A). No other glucose 
concentrations significantly differed. This work was completed by Julia Vlachaki 
Walker and included here for completeness.  
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Discussion 
Acutely inflammation is necessary for the resolution of injuries and beneficial. 
However, chronic low-grade inflammation is linked to the onset of pathologies, such 
as obesity and insulin resistance (Heilbronn et al. 2008). Indeed, metabolism and 
inflammation are intrinsically linked (O'Neill et al. 2016). 
Both hyperglycaemia, in rat adipocytes and mouse astrocytes (Lin et al. 2005, Wang 
et al. 2012), and hypoglycaemia, in human plasma (Gogitidze Joy et al. 2010, Wright 
et al. 2010, O'Neill et al. 2016), trigger the release of PAI-1, VEGF, vascular 
adhesion molecules, and IL-6 (Gogitidze Joy et al. 2010, Wright et al. 2010). 
Additionally, cytokines can act within the brain to modulate whole body energy 
homeostasis via the hypothalamic-pituitary-adrenal axis (van der Meer et al. 1996). 
Microglia are the principle immune cells of the brain (Won et al. 2012), however 
astrocytes are also sensitive to inflammatory stimuli, such as ATP or cytokines like 
TNF-α or IL-1β and release cytokines in response (John et al. 2001, Beattie et al. 
2002, Murakami et al. 2003, Walter et al. 2004, Ballerini et al. 2005, Kucher et al. 
2005, Narcisse et al. 2005, Pribiag et al. 2013, Choi et al. 2014, Erta et al. 2015, 
Habbas et al. 2015) The inflammatory responses of astrocytes can modulate whole-
body energy homeostasis, as an astrocyte specific NFκB KO reduced diet induced 
obesity in mice (Buckman et al. 2015, Douglass et al. 2017). While some evidence 
using a glucose/oxygen deprivation model in rats shows astrocytic cytokine release 
and NFκB activation (Zhao et al. 2013), the effects of repeated glucose variation 
(5.5, 2.5 and 0.1 mM glucose) has not been well studied on isolated human 
astrocytes. This data presented here characterises the release of cytokines from 
human astrocytes in vitro when treated with low glucose. 
The cytokine array panel was used as a screening tool to identify cytokines that were 
differentially released from astrocytes by RLG. Only one set of biological replicates 
was used for this screen meaning no statistical significance could be determined. 
However, several cytokines appeared to be altered by RLG. Generally, there were 
more cytokines detectable in the experimental groups, including acute low glucose, 
antecedent RLG and RLG, in comparison to control. Interestingly, the highest 
detection of cytokines was in the antecedent RLG group. These data corroborate 
findings that recovery from low glucose to high glucose can exacerbate inflammatory 
response (Ceriello et al. 2012), and RH appears to exacerbate cytokine release (Joy 
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et al. 2015). This could mean that people with T1DM would have elevated basal 
cytokine levels, resulting in chronic inflammatory signalling. Indeed, people with 
T1DM had higher baselines cytokine levels compared to healthy controls (Wright et 
al. 2010). Additionally, unlike, the CRR to hypoglycaemia being blunted by 
hypoglycaemia, the inflammatory response remains equal to if not greater than 
controls (Joy et al. 2015). Therefore, inflammatory signalling may contribute to 
blunting the CRR by modulating metabolism. For example, MIF has been shown to 
increase glucose uptake and AMPK activation, and disrupt mitochondrial function 
(Benigni et al. 2000, Miller et al. 2008, Preau et al. 2013). 
To validate some of the top hits from the cytokine screen, IL-13, PAI-1 and MIF were 
quantified following the same treatment using ELISAs. Interestingly, no significant 
differences were found in IL-13 and MIF in HPA or U373 cells, or PAI-1 in HPA cells 
from a 3-hour treatment period. Despite the cytokine array panel allowing for the 
simultaneous semi-quantitative assessment of 37 cytokines, array panel is optimised 
for all the cytokines. Therefore, the array panel will not be optimised for the detection 
each cytokine individually. Moreover, this may result in a non-linear relationship 
between amount of signal and cytokine present, making quantification unreliable. 
Therefore, ELISAs were used to fully quantify and validate prospective targets. 
PAI-1, however, was significantly elevated in the U373 cells by RLG, compared to 
acute low glucose and control treated cells, unlike the HPAs where no significant 
differences were found. Inflammatory signalling is an integral part of cancer 
progression (Coussens et al. 2002), and cytokine signalling can be different between 
primary and immortalised cell lines, in human respiratory cells, for example (Ferreira 
Lopes et al. 2017). Nevertheless, as PAI-1 inhibits plasmin and prevents the 
degradation of clots it increases risk of atherothrombosis (Vaughan 2005). 
Furthermore, plasmin also degrades Aβ, the key component of amyloid plaques in 
Alzheimer’s disease, therefore, elevated PAI-1 may increase the predispose a 
person to increased risk of dementia (Kutz et al. 2012). Indeed, PAI-1 levels are 
elevated in the cerebrospinal fluid of people with Alzheimer’s disease (Sutton et al. 
1994). 
While MIF did not reach statistical significance in short-term low glucose exposure, 
there was a consistent trend seen between the cytokine array panel and the ELISAs 
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including two different cell lines, HPA and U373 cells. Over a 24-hour period, MIF 
was significantly released from U373 cells compared to controls. MIF release has 
previously been shown to be induced by prolonged hypoglycaemia in a human 
glioblastoma cell line (LN18) (Bacher et al. 2003). Interestingly, MIF is constitutively 
produced and packaged into intracellular stores (Lue et al. 2002) which are also 
strongly influenced by circadian rhythms (Petrovsky et al. 2003). The generation of 
samples for these studies was carried out at different times in the day which may 
have influenced the sensitivity of the astrocytes to release MIF. Therefore, future 
experiments could be optimised to account for circadian rhythms. 
MIF can activate AMPK (Miller et al. 2008) and promote glucose uptake in skeletal 
muscle (Benigni et al. 2000), cardiac (Liang et al. 2015), therefore, astrocytic MIF 
release may also affect glucose uptake within the CNS. This hypothesis could be 
tested by injecting rats with MIF and measuring changes in cerebral glucose 
concentration using microdialysis complemented with glucose transporter gene 
expression analysis. Interestingly, MIF is elevated in T1DM (Ismail et al. 2016), 
T2DM (Yabunaka et al. 2000, Herder et al. 2008, Stosic-Grujicic et al. 2008) and AD 
(Popp et al. 2009, Bacher et al. 2010) implicating it in the relationship between CNS 
metabolic stress and neurodegeneration. Neurofibrillary tangles are associated with 
multiple neurodegenerative disorders, known as tauopathies, including AD, Pick 
disease, and frontotemporal dementia (Iqbal et al. 2010). Interestingly, a MIF KO 
model protected against the hyperphosphorylation of tau protein and thus reducing 
its aggregation (Li et al. 2015). If the inverse is true, and MIF release can trigger tau 
phosphorylation, this provides a novel link between hypoglycaemia and the neuron-
toxic accumulation of NFTs. Tau is a cytoskeletal component found in neurons, 
however, MIF is proposed to modulate macrophage migration by remodelling the 
cytoskeleton (McCarthy et al. 1979, Pick et al. 1979). Disruption of mitochondrial-
cytoskeletal interaction impairs mitochondrial function in human heart (Saks et al. 
2012) which MIF can mediate (Preau et al. 2013). MIF also activates AMPK and 
promotes glucose uptake. Taken together MIF is a hub for metabolic and immune 
interaction which may be altered RLG in human astrocytes.  
While preliminary these findings represent an interesting therapeutic target that 
warrants further investigation. Further, quantitative, analysis of cytokines released 
from astrocytes in response to acute and recurrent low glucose could be investigated 
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using cytokine multiplex techniques. This method enables the simultaneous 
detection of multiple cytokines in a quantitative manner (Burkert et al. 2012) unlike 
the cytokine array panel used in the work presented above. Additionally, as 
previously established in chapter 3, RLG alters human astrocyte metabolic function. 
A question remaining is whether the metabolic dysfunction is affected by or affects 
the changes in inflammatory signalling discussed in this chapter. To test this, the 
same RLG model could be used whilst inhibiting or exacerbating inflammatory 
signalling and measuring the effect on metabolism using mitochondrial stress tests 
as outlined in chapter 3.  
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Glucose variation alters human primary astrocyte 
mRNA expression 
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Introduction 
With the advent of next generation sequencing technologies, the changes to gene 
expression can be characterised and tested for novel targets in an unbiased manner. 
In the studies presented here RNA-sequencing was used to identify differentially 
expressed genes in human primary astrocytes (HPA) exposed to control, acute low 
glucose, antecedent recurrent low glucose, or RLG. 
Previously, microarray and reverse transcriptase PCR (RT-PCR) techniques have 
been used to investigate how fasting and low glucose treatment affects the 
expression of metabolic genes in rat hypothalamic and cortical tissues (Poplawski et 
al. 2010). Interestingly, 48-hour fasting increased altered metabolic gene expression 
profiles that would indicate increased fatty acid oxidation and decreased 
mitochondrial glucose metabolism (Poplawski et al. 2010), which partly corroborates 
data from chapter 3 of this thesis. Differences in results may be due to the use of rat 
brain tissue extracts containing multiple cell types rather than isolated HPA cells, 
indicating different cell-type-dependent responses to low glucose and nutritional 
restriction. Additionally, the changes in glycolytic gene expression were primarily 
seen in the hypothalamic tissue extracts and not in the cortex (Poplawski et al. 
2010), and the HPA cells used in this thesis were not hypothalamic. Nevertheless, 
this thesis expands on previous studies by using RNA-seq instead of microarrays 
and RT-PCR. While microarrays have a good dynamic range and are relatively high 
throughput, compared to RT-PCR, RNA-seq has a higher dynamic range. 
Furthermore, RNA-seq also improves on microarrays as it does not require a priori 
knowledge of sequences of interest (Hoheisel 2006). Additionally, the unbiased 
approach of RNA-seq allows for the detection of the full combinatorial splicing 
pattern of a transcript and repeat elements (Kratz et al. 2014). In comparison to 
quantitative-PCR (q-PCR) and RT-PCR, RNA-seq is much higher throughput; q-PCR 
and RT-PCR can measure tens of targets in parallel compared to tens of thousands 
in RNA-seq. Lastly, RNA-seq gives an increasingly accurate assessment of the 
entire transcriptome which can provide a powerful tool to elucidate changes in gene 
expression between different groups of interest (Kukurba et al. 2015).  
To the author’s knowledge this is the first characterisation of the transcriptome of 
human primary astrocytes exposed to RLG used to replicate the chronic glucose 
variation seen in T1DM. A more in-depth description of the means by which RNA-
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seq is carried out can be found in chapter 2 of this thesis. Briefly, once RNA has 
been extracted from cells the RNA underwent poly-A selection to enrich mRNAs. 
The transcripts were fragmented and converted to complimentary DNA (cDNA). 
Sequencing primers were added and sequencing performed using Illumina HiSeq 
2500 sequencer. Raw read data underwent FastQC quality control. Reads were 
mapped to the human reference genome GRCh38 using the read-aligning software 
STAR (Dobin et al. 2013, Dobin et al. 2015). Gene abundance was calculated with 
featureCounts software (Liao et al. 2014). Differential gene expression was 
calculated by a series of contrasts between groups of interest using DESeq2 (Love 
et al. 2014). Lastly, gene set enrichment was calculated using the web-based Enrichr 
software (Chen et al. 2013, Kuleshov et al. 2016). 
Overall aim and objectives 
Very few studies have attempted to measure changes in gene expression of 
astrocytes during acute and recurrent glucose. The studies that have been 
completed used rodent models and mircoarrays to investigate genes of interest. 
Acute and recurrent low glucose-induced gene expression changes have not been 
investigated in human astrocytes. Therefore, the aim of this chapter was to identify 
novel genes of interest that were significantly altered by glucose variation. To 
investigate this, the following research questions were explored: 
 Does acute or recurrent low glucose induce changes in differential gene 
expression? 
 If so, what gene ontologies are they associated with? 
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Results 
6.1 Quality control following RNAseq 
The Phred quality score briefly is a measure of how accurate the determination of 
each base is during the RNA sequencing (Ewing et al. 1998a, Ewing et al. 1998b). 
The Phred score is logarithmically linked to error probabilities meaning a quality 
score of 10 has a 90% base call accuracy, a score of 20 has a 99% base call 
accuracy, and so on (Ewing et al. 1998a). The Phred score was calculated by the 
Exeter Sequencing Service and shows good quality read accuracy with Phred scores 
>30 giving a base call accuracy of >99.9% (Fig 6.1A). 
6.2 STAR read mapping 
The output data from RNA-sequencing was mapped to the human reference genome 
GRCh38 using STAR software (Dobin et al. 2013). All the reads generated by RNA-
sequencing from each sample are attempted to be aligned to the reference genome 
in a two-part process; firstly, seed searching, and secondly, clustering, stitching and 
scoring. The number of uniquely mapped reads is a percentage of the total number 
of reads generated from each sample that were successfully mapped to the 
reference genome (Dobin et al. 2015). All of the samples had a score of >80% which 
is regarded as good (Dobin et al. 2015) (table 6.1). 
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Table 6.1. Read mapping using STAR had a high percentage of uniquely 
mapped reads 
Sample Biological replicate number Uniquely Mapped Reads (%) 
Control 1 92.26 
Control 2 92.06 
Control 3 91.67 
Control 4 92.24 
Control 5 91.48 
Low glucose 1 92.06 
Low glucose 2 92.09 
Low glucose 3 92.70 
Low glucose 4 92.34 
Low glucose 5 92.63 
Antecedent RLG 1 92.01 
Antecedent RLG 2 92.23 
Antecedent RLG 3 91.75 
Antecedent RLG 4 92.23 
Antecedent RLG 5 91.54 
RLG 1 91.96 
RLG 2 91.49 
RLG 3 92.21 
RLG 4 91.55 
RLG 5 86.00 
Table 6.1 shows the uniquely mapped reads as a percentage for each sample that 
underwent RNA sequencing and read mapping using STAR. This is a metric which is 
defined as the proportion of input reads that are uniquely mapped. A score of >80% 
is considered good. 
6.3 Differential gene expression results 
Differential gene expression analysis was performed using DESeq2 through a series 
of contrasts between groups of interest. The contrast is a determination of whether 
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the log2 fold change of two groups, or levels, is significantly different from zero. False 
discovery rates (FDR) were corrected for using Benjamini-Hochberg corrections. The 
resulting data was then represented as a volcano plot which depicts the significance 
(log10 adjusted-P value) versus effect size (fold-change; log2) on the y- and x-axes 
respectively. Any genes that were significantly different following FDR correction 
(α<0.05) and had an effect size >0.5 log2 were highlighted in red. 
6.3.1 Low glucose exposure on the last day of treatment differentially regulates 
gene expression unlike prior exposure to RLG 
A contrast of groups treated to 2.5 or 0.1 mM low glucose on the last day (control 
and antecedent RLG versus low glucose and RLG) had the largest number (74) of 
differentially expressed genes (figure 6.2.1A). A complete list of differentially 
expressed genes can be seen in appendix D, supplementary table 1. A contrast of 
cells exposed to control or RLG prior to the day of collection (control and low glucose 
versus antecedent low glucose and RLG) showed no significantly differentially 
expressed genes. 
6.3.2 Low glucose, but not antecedent RLG or RLG, differentially regulates 
gene expression 
Acute low glucose significantly altered the expression of 60 genes compared to 
control samples with the highest significance and largest effect size genes depicted 
in figure 6.2.2A. A complete list of differentially expressed genes can be seen in 
appendix D, supplementary table 2. Conversely, antecedent RLG and RLG did not 
significantly alter gene expression compared to control (figure 6.2.2BC). 
6.3.3 Antecedent RLG significantly altered gene expression compared to low 
glucose and RLG but low glucose and RLG did not differ 
Antecedent RLG significantly altered the expression of 16 genes compared to low 
glucose (figure 6.2.3A; see the appendix D, supplementary table 3 for a complete 
list). Furthermore, RLG significantly altered the expression of one gene TMEM116, 
compared to antecedent RLG. However, RLG did not significantly differentially 
regulate gene expression compared to acute low glucose. 
6.4 Enrichr gene ontology data 
Genes that were determined to be differentially expressed by DESeq2 were exported 
and uploaded as an unweighted crisp data set for gene ontology enrichment 
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assessment by fisher-exact tests and pathway analysis using the web-based 
program Enrichr (Chen et al. 2013, Kuleshov et al. 2016). The gene sets were 
compared against models of biological systems generated by the gene ontology 
(GO) consortium (The Gene Ontology et al. 2000, The Gene Ontology Consortium 
2017). Additionally, the gene sets were compared against KEGG pathways which 
are pathway maps representing the current understanding of the interactions 
between proteins (Kanehisa et al. 2000, Kanehisa et al. 2016, Kanehisa et al. 2017). 
Significance was determined if there was a significant overlap, or enrichment, of 
DEGs identified in the GO or KEGG gene sets, using fisher-exact tests. Multiple 
correction testing adjustment was included using the Benjamini-Hochberg method. 
Only the groups with more than one differentially expressed gene were included in 
this analysis. Therefore, the comparisons analysed here were 2.5 versus 0.1 mM 
glucose, control versus low glucose, and low glucose versus RLG. The tables below 
(6.2.1. 6.2.2, 6.2.3, 6.3.1, 6.3.2, 6.4.1, 6.4.2 and 6.5) contain the pathways that were 
determined to be significantly enriched (α<0.05) after p-value adjustment. The genes 
that made a pathway significantly enriched, and the pathways are also included. Of 
interest, a number of endoplasmic reticulum (ER), mitochondrial and inflammatory 
pathways were identified as being significantly enriched by the different treatments. 
6.4.1 Biological process enrichment analysis 
Biological process gene ontologies are defined the contribution of a gene or gene 
product to a specific objective, for example mitochondrial electron transport, NADH 
to ubiquinone (GO:0006120) (The Gene Ontology et al. 2000). This is usually 
comprised of multiple molecular functions which combine to perform higher level, for 
example cell proliferation or apoptosis, or lower level and more specific functions. 
The differentially expressed gene sets were compared against biological process 
gene sets to search for enrichment (tables 6.2.1, 6.2.2, and 6.2.3). 
6.4.1.1 Biological process enrichment: 2.5 versus 0.1 mM glucose treated cells 
The 73 genes that were determined to be differentially regulated by 0.1 mM glucose 
treatment compared to 2.5 mM glucose were analysed by using Enrichr GO 
biological process 2018 program. The ten pathways are listed in table 6.2.1. Of these 
the top three pathways were associated with different aspects of mitochondrial 
function and shared the same three genes, XBP1, HERPUD1 and HSPA1A. 
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Interestingly, XBP1 has been previously identified in ER stress-mediated β-cell 
apoptosis (Laybutt et al. 2007). XBP1 is a key effector of the unfolded protein 
responses in mammals (Yoshida et al. 2001). Additionally, mitochondrial electron 
transport, between NADH and ubiquinone, was also significantly enriched which is 
associated with mitochondrial complex 1 (Janssen et al. 2006). 
6.4.1.2 Biological process enrichment: control versus low glucose 
The 60 genes that were differentially regulated by low glucose in comparison to 
control were analysed by using Enrichr GO biological process 2018 program. The 
top ten pathways are listed in table 6.2.2. For a complete list see appendix D, 
supplementary table 4. In this instance, the top results were nearly all associated 
with ER-stress, and negative regulation of the apoptotic signalling pathways. Three 
common genes were often upregulated as in the 2.5 versus 0.1 mM glucose 
comparison, XBP1, HERPUD1 and HSPA1A. 
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Table 6.2.1. Biological process pathway analysis of differentially expressed 
genes in 2.5 versus 0.1 mM glucose treated cells 
Term 
Adjusted 
P-value 
Genes 
negative regulation of endoplasmic reticulum 
stress-induced intrinsic apoptotic signaling pathway 
(GO:1902236) 
0.017 
XBP1;HERPUD1;
HSPA1A 
regulation of endoplasmic reticulum stress-induced 
intrinsic apoptotic signaling pathway (GO:1902235) 
0.022 
XBP1;HERPUD1;
HSPA1A 
negative regulation of response to endoplasmic 
reticulum stress (GO:1903573) 
0.022 
XBP1;HERPUD1;
HSPA1A 
mitochondrial electron transport, NADH to 
ubiquinone (GO:0006120) 
0.050 
MT-ND4L;MT-
ND4;MT-ND2 
negative regulation of transcription from RNA 
polymerase II promoter in response to stress 
(GO:0097201) 
0.050 BAG3;HSPA1A 
regulation of DNA endoreduplication (GO:0032875) 0.050 FBXW7;E2F7 
regulation of amyloid-beta clearance (GO:1900221) 0.050 SRF;LDLR 
positive regulation of cytokine-mediated signaling 
pathway (GO:0001961) 
0.050 
MAVS;TSLP;HSP
A1A 
positive regulation of actin filament bundle 
assembly (GO:0032233) 
0.050 
FHOD1;ABL1;SY
NPO 
regulation of mitotic cell cycle phase transition 
(GO:1901990) 
0.050 
CDC20;TUBA1A;
HECW2;TUBB4B;
TUBA4A 
 
Table 6.2.2. Biological process pathway analysis of differentially expressed 
genes in control versus low glucose treated cells 
Term Adjusted 
P-value 
Genes 
negative regulation of intrinsic apoptotic signaling 0.00002 DNAJA1;XBP1;M
223 
pathway (GO:2001243) DM2;HSPB1;HER
PUD1;HSPA1A 
response to unfolded protein (GO:0006986) 0.00007 DNAJA1;HSPA5;
HSPB1;HERPUD
1;HSPA1A 
negative regulation of programmed cell death 
(GO:0043069) 
0.001 DNAJA1;XBP1;H
SPA5;TSLP;HSP
B1;FMN2;CD44;E
PHB4;HSPA1A 
negative regulation of endoplasmic reticulum stress-
induced intrinsic apoptotic signaling pathway 
(GO:1902236) 
0.002 XBP1;HERPUD1;
HSPA1A 
negative regulation of apoptotic process 
(GO:0043066) 
0.002 DNAJA1;XBP1;H
SPA5;TSLP;HSP
B1;FMN2;CD44;E
PHB4;HSPA1A 
IRE1-mediated unfolded protein response 
(GO:0036498) 
0.003 XBP1;HSPA5;CX
XC1;EXTL3 
regulation of endoplasmic reticulum stress-induced 
intrinsic apoptotic signaling pathway (GO:1902235) 
0.003 XBP1;HERPUD1;
HSPA1A 
negative regulation of response to endoplasmic 
reticulum stress (GO:1903573) 
0.004 XBP1;HERPUD1;
HSPA1A 
positive regulation of ubiquitin-protein transferase 
activity (GO:0051443) 
0.010 ARRDC4;CDC20;
FBXW7 
regulation of apoptotic process (GO:0042981) 0.010 DNAJA1;XBP1;H
SPA5;TSLP;HSP
B1;FMN2;INHBA;
CD44;EPHB4;HS
PA1A 
6.4.1.3 Biological process enrichment: antecedent RLG versus low glucose 
The 16 genes that were differentially regulated by antecedent RLG compared to low 
glucose were analysed by using Enrichr GO biological process 2018 program. This 
comparison shows the recovery from prior low glucose treatments. Indeed, glucose 
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reperfusion following hypoglycaemia is a contributor to neuronal death (Suh et al. 
2007). The top ten pathways are listed in table 6.2.3. For a complete list see 
appendix D, supplementary table 5. Interestingly, some of the upregulated processes 
involved the upregulation of the inflammatory cytokine IL-6, and more generic 
immune responses. Similarly to the previous comparisons, ER-stress related 
processes were also upregulated. 
Table 6.2.3. Biological process pathway analysis of differentially expressed 
genes in low glucose versus antecedent recurrent low glucose (RLG) treated 
cells 
Term Adjusted 
P-value 
Genes 
positive regulation of interleukin-6 production 
(GO:0032755) 
1.7x10-3 XBP1;TSLP;ERE
G 
positive regulation of multicellular organismal 
process (GO:0051240) 
2.6x10-3 XBP1;LDLR;ERE
G;BCL9L 
negative regulation of cell activation (GO:0050866) 3.4x10-3 THBD;LDLR 
positive regulation of immune response 
(GO:0050778) 
0.0380 XBP1;EREG 
cholesterol homeostasis (GO:0042632) 0.0380 XBP1;LDLR 
IRE1-mediated unfolded protein response 
(GO:0036498) 
0.0380 XBP1;EXTL3 
keratinocyte differentiation (GO:0030216) 0.0380 TXNIP;EREG 
sterol homeostasis (GO:0055092) 0.0380 XBP1;LDLR 
regulation of DNA replication (GO:0006275) 0.0380 ESCO2;EREG 
epidermal cell differentiation (GO:0009913) 0.0411 TXNIP;EREG 
 
6.4.2 Molecular function enrichment analysis 
A molecular function is defined as the biochemical activity of gene products, for 
example enzyme, NADH dehydrogenase (ubiquinone) activity (GO:0008137) (The 
Gene Ontology et al. 2000). The molecular function shows the functional capability 
rather than whether it is being completed. Furthermore, molecular functions are not 
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tied to a specific cellular localisation. The differentially expressed gene sets were 
compared against molecular function gene sets to search for enrichment. 
6.4.2.1 Molecular function enrichment: 2.5 versus 0.1 mM glucose treated cells 
The 73 genes that were differentially regulated by 0.1 mM glucose compared to 2.5 
mM glucose treated cells were analysed by using Enrichr GO molecular function 
2018 program. The top ten pathways are listed in table 6.3.1. For a complete list see 
appendix D, supplementary table 6. Of interest, electron transport chain functions 
were significantly altered by 0.1 mM glucose, centering on the differential expression 
of MT-ND4L, MT-ND4 and MT-ND2. Also, the gene RELA was involved in three of 
the top ten molecular functions. The gene product of RELA also is commonly known 
as p65 and is a part the NF-κB, an immune master-regulator transcription factor 
(Brasier 2006).   
Table 6.3.1. Molecular function pathway analysis of differentially expressed 
genes in 2.5 versus 0.1 mM glucose treated cells 
Term 
Adjusted 
P-value 
Genes 
phosphate ion binding (GO:0042301) 0.011 MTHFD2;RELA 
purine ribonucleoside triphosphate binding 
(GO:0035639) 
0.011 
TUBA1A;ABL1;TU
BE1;PEX1;TUBB4
B;RND3;TUBA4A;
HSPA1A 
guanyl ribonucleotide binding (GO:0032561) 0.011 
TUBA1A;TUBE1;T
UBB4B;RND3;TUB
A4A 
NADH dehydrogenase (ubiquinone) activity 
(GO:0008137) 
0.011 
MT-ND4L;MT-
ND4;MT-ND2 
NADH dehydrogenase (quinone) activity 
(GO:0050136) 
0.011 
MT-ND4L;MT-
ND4;MT-ND2 
GTP binding (GO:0005525) 0.011 
TUBA1A;TUBE1;T
UBB4B;RND3;TUB
A4A 
purine ribonucleoside binding (GO:0032550) 0.011 TUBA1A;TUBE1;T
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UBB4B;RND3;TUB
A4A 
cadherin binding (GO:0045296) 0.017 
EHD1;EIF5;BAG3;
PLIN3;DBN1;HSPA
1A 
transcriptional activator activity, RNA polymerase II 
distal enhancer sequence-specific binding 
(GO:0001205) 
0.033 SRF;RELA 
transcription factor activity, RNA polymerase II 
core promoter sequence-specific (GO:0000983) 
0.036 SRF;RELA 
 
6.4.2.2 Molecular function enrichment: control versus low glucose 
The 60 genes that were differentially regulated by low glucose compared to control 
were analysed by using Enrichr GO molecular function 2018 program. The 4 
enriched pathways are listed in table 6.3.2. The four pathways involved protein 
binding functions and DEGs that produce heat-shock family proteins. 
Table 6.3.2. Molecular function pathway analysis of differentially expressed 
genes in control versus low glucose treated cells 
Term 
Adjusted 
P-value 
Genes 
C3HC4-type RING finger domain binding 
(GO:0055131) 
0.008 DNAJA1;HSPA1A 
cadherin binding (GO:0045296) 0.005 
EIF5;HSPA5;CDC4
2EP1;PLIN3;CORO
1B;DBN1;HSPA1A 
ubiquitin-like protein ligase binding (GO:0044389) 0.008 
DNAJA1;HSPA5;F
BXW7;MDM2;TXNI
P;HSPA1A 
ubiquitin protein ligase binding (GO:0031625) 0.008 
DNAJA1;HSPA5;F
BXW7;MDM2;TXNI
P;HSPA1A 
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6.4.2.3 Molecular function enrichment: antecedent RLG versus low glucose 
The 16 genes that were differentially regulated by antecedent RLG versus low 
glucose treatment were analysed by using Enrichr GO molecular function 2018 
program. No molecular function gene ontologies were significantly enriched. 
6.4.3 Cellular component enrichment analysis 
The cellular component refers to where the action of a gene product takes place, for 
example, mitochondrial respiratory chain complex I (GO:0005747) (The Gene 
Ontology et al. 2000). The differentially expressed gene sets were compared against 
cellular component sets to search for enrichment. 
6.4.3.1 Cellular component enrichment: 2.5 versus 0.1 mM glucose treated 
cells 
The 73 genes that were differentially regulated by 0.1 mM glucose compared to 2.5 
mM glucose treated cells were analysed by using Enrichr GO cellular component 
2018 program. The 3 pathways are listed in table 6.4.1. The top hit, GO:0005747, 
corresponds to the previous identification of mitochondrial associated biological 
processes in table 6.2.1 and 6.3.1 and shares the same DEGs. 
Table 6.4.1. Cellular component pathway analysis of differentially expressed 
genes in 2.5 versus 0.1 mM glucose treated cells 
Term 
Adjusted 
P-value 
Genes 
mitochondrial respiratory chain complex I 
(GO:0005747) 
0.029 
MT-ND4L;MT-
ND4;MT-ND2 
cytoskeleton (GO:0005856) 0.029 
TUBA1A;MAP7D1;A
BL1;TARS;SYNPO;
TUBB4B;DBN1;TUB
A4A 
actomyosin (GO:0042641) 0.029 
FHOD1;SYNPO;DB
N1 
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6.4.3.2 Cellular component enrichment: control versus low glucose treated 
cells 
The 60 genes that were differentially regulated by low glucose compared to control 
treated cells were analysed by using Enrichr GO cellular component 2018 program. 
The three significantly enriched components are listed in table 6.4.2. These three 
components involved a number of heat-shock family genes as well as cytoskeletal 
components which resulted in cellular structural elements being altered. 
Table 6.4.2. Cellular component pathway analysis of differentially expressed 
genes in control versus low glucose treated cells 
Term 
Adjusted 
P-value 
Genes 
focal adhesion (GO:0005925) 9x10-5 
HSPA5;RPS19;CDC
42EP1;HSPB1;LPP;
RND3;CD44;CORO
1B;HSPA1A 
actomyosin (GO:0042641) 0.019 
FHOD1;CORO1B;D
BN1 
cytoskeleton (GO:0005856) 0.027 
DNAJA1;TUBA1A;C
DC42EP1;HSPB1;F
MN2;TUBB4B;DBN1 
 
6.4.3.3 Cellular component enrichment: antecedent RLG versus low glucose 
The 16 genes that were differentially regulated by antecedent RLG compared to low 
glucose treated cells were analysed by using Enrichr GO cellular component 2018 
program. No cellular components were significantly enriched. 
6.4.4 KEGG pathway 
KEGG pathways are computerised cellular processes and molecular functions 
(Kanehisa et al. 2000). The differentially expressed gene lists were compared 
against the database of KEGG pathways to search for pathway enrichment. 
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6.4.4.1 KEGG pathway enrichment: 2.5 versus 0.1 mM glucose treated cells 
The 73 genes that were differentially regulated by 0.1 mM glucose compared to 2.5 
mM glucose were analysed by using Enrichr KEGG 2016 program. Only Pathogenic 
Escherichia coli infection_Homo sapiens_hsa05130 was significantly enriched. 
However, the DEGs involved in this pathway are cytoskeletal related and this may be 
a false positive, especially as these samples were cultured in aseptic conditions. 
Table 6.5. KEGG pathway analysis of differentially expressed genes in 2.5 
versus 0.1 mM glucose treated cells 
Term 
Adjusted 
P-value 
Genes 
Pathogenic Escherichia coli infection_Homo 
sapiens_hsa05130 
0.004 
TUBA1A;ABL1;TUB
B4B;TUBA4A 
 
6.4.4.2 KEGG pathway enrichment: 2.5 versus 0.1 mM glucose treated cells 
The 60 genes that were differentially regulated by low glucose compared to control 
treated cells were analysed by using Enrichr KEGG 2016 program. No KEGG 
pathways were significantly enriched. 
6.4.4.3 KEGG pathway enrichment: antecedent RLG versus low glucose 
treated cells 
The 16 genes that were differentially regulated by antecedent RLG compared to low 
glucose treated cells were analysed by using Enrichr KEGG 2016 program. No 
KEGG pathways were significantly enriched. 
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Discussion 
In chapter 3 of this thesis RLG treatment significantly altered mitochondrial function 
in both HPA and U373 cells. Interestingly, low glucose differentially regulated the 
expression of several mitochondrial encoded genes that are enriched in gene sets 
associated with mitochondrial respiration (tables 6.2.1, 6.2.2, 6.3.1, and 6.4.1). In 
particular, four genes, MT-ND4L, MT-ND4, MT-ND2, and MT-ATP6 had increased 
gene expression (0.33, 0.25, 0.16 and 0.19 respectively) and are all part of 
mitochondrial respiratory complex I (Andrews et al. 2013) which is reflected with the 
enrichment of mitochondrial respiratory chain complex 1 (GO:0005747). Complex I 
translocates protons into the intramitochondrial membrane space by transferring 
electrons from NADH to coenzyme Q10 (Janssen et al. 2006). Despite enrichment of 
genes in complex I, this does not provide any information on how the proton 
pumping function of complex I is altered. To assess changes in complex I function its 
activity can be assessed in isolated mitochondria by following the conversion of 
NADH to NAD+ and the simultaneous alteration a colourimetric electron acceptor dye 
such as nitrotetrazolium blue chloride (NBT) which can be measured by changes in 
optical density as described previously (Li et al. 2010). If complex I is inhibited this 
decreases ATP synthesis and can increase ROS production leading to apoptosis 
(Loeffen et al. 1998, Li et al. 2003). 
Earlier in this thesis the expression levels of glycolytic enzyme hexokinase 2 (HK2) 
were measured to test whether it was contributing to RLG-induced altered glycolytic 
activity. There was no change to protein content in the HPA cells. However, following 
RNA-seq and DGE analysis HK2 was a differentially expressed gene with an 
increased log2 fold-change of 0.36. Interestingly, this did not result in detectable 
changes in protein expression. However, mRNA expression does not always 
strongly correlate with steady state protein levels (Tian et al. 2004). This can be due 
to changes in post-transcriptional regulatory processes, protein half-life, and error in 
quantifying both mRNA and protein levels (Greenbaum et al. 2003). 
The endoplasmic reticulum (ER) consists of a network of membranes that 
coordinates the tertiary folding and maturations of proteins (Braakman et al. 2011). 
Some GO terms (tables 6.2.1 and 6.2.2) that involve regulation of endoplasmic 
reticulum stress response are enriched. These centre on the detection of X-box 
binding protein 1 (XBP1), homocysteine inducible ER protein with ubiquitin like 
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domain 1 (HERPUD1), and heat shock protein family A member 1A (HSPA1A) as 
genes that are differentially expressed by low glucose exposure. The ER stress 
response is induced by glucose deprivation (Benavides et al. 2005, Ikesugi et al. 
2006, de la Cadena et al. 2014), and altered redox state (Harding et al. 2003) and 
calcium dysregulation (Høyer-Hansen et al. 2007). This reduces protein folding and 
thus increases unfolded proteins which in turn further activates ER stress and 
triggers the unfolded protein response (Ron et al. 2007). Interestingly, this was 
reflected by low glucose upregulating GO terms involved in the unfolded protein 
response (GO:0006986, GO:1900101, and GO:0036500). Dysfunctional ER stress 
responses have been implicated in diabetes and obesity (Park et al. 2013, Jiang et 
al. 2015, Wu et al. 2015). A gene central to this is XBP1, a transcription factor that 
upregulates the unfolded protein response (Iwakoshi et al. 2003). In HPA cells low 
glucose significantly regulated XBP1 expression with an increased log2 fold change 
of 0.28. Increased XBP1 expression is associated with the induction of immune 
plasma cells becoming “professional secretory cells” (Shaffer et al. 2004). Aside from 
upregulating ER function and protein folding, XBP1 binds to the promotor of genes 
associated with glycolysis, gluconeogenesis and lipid metabolism (Acosta-Alvear et 
al. 2007). Interestingly, XBP1 haploinsufficiency creates severe insulin resistance 
and diabetes (Ozcan et al. 2004). Conversely, XBP1 overexpression can improve 
glucose tolerance in ob/ob diabetic mice (Zhou et al. 2011). This may be due to its 
ability to increase glycolysis via changes in HK2 expression (Liu et al. 2016). 
Therefore, the increase in XBP1 expression found by RNA-seq may be underlying 
some of the enhanced glycolytic activity seen in the HPA cells induced by RLG 
treatment discussed in chapter 3. Furthermore, the enrichment of GO terms 
associated with ER stress implicates modifications to ER stress induced by low 
glucose treatment in HPA cells. This supports a previous study demonstrating 
glucose and oxygen deprivation increases ER stress in astrocytes (Benavides et al. 
2005).  
In chapter 5, preliminary evidence suggests low glucose and RLG increase 
inflammatory cytokine release by HPA cells. Interestingly, RNA-seq and subsequent 
gene ontology analysis shows enrichment of GO terms associated with cytokine 
signalling and immune cell regulation (GO:0001961, GO:2000662, GO:0032755, 
GO:0043031, and GO:1903978). It is known that hypoglycaemia increases the 
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release of inflammatory cytokines, including interleukin-6 (IL-6) (Gogitidze Joy et al. 
2010, Wright et al. 2010, O'Neill et al. 2016). Interestingly, the transcription factor 
XBP1, discussed earlier as a regulator of ER stress, can induce IL-6 expression in B 
cells (Iwakoshi et al. 2003). The enriched GO terms also include pathways involved 
in the regulation of macrophage and microglial cell activation. Taken together these 
data support the role for hypoglycaemia causing inflammation. 
Some of the most significantly enriched cellular component GO terms were 
cytoskeletal related (GO:0015630, GO:0015629, GO:0001725, GO:0099513, 
GO:0005874 and GO:0005856). Astrogliosis is a marker of astrocyte activation that 
is characterised by a ramification of cell morphology (Pekny et al. 2005). This can be 
induced by nutritional changes (Horvath et al. 2010, Thaler et al. 2012, Daumas‐
Meyer et al. 2018), as well as in response to CNS pathologies and trauma (Pekny et 
al. 2005). While no significant changes to GFAP were found, the RNA-seq analysis 
suggests that microtubule proteins are differentially expressed by low glucose 
(TUBA1A, TUBE1, TUBA4A and TUBB4B). This indicates that changes in 
cytoskeletal networks are modified in HPA cells during low glucose treatment. While 
low glucose did not generally appear to change gross cellular morphology, it may be 
prudent to examine this more closely. 
Taken together there are many interesting differentially expressed genes and 
enriched gene ontologies altered by low glucose treatment. But it remains unknown 
how these pathways are altered, and what functional outcome that would have. 
While low glucose appears to be the largest driving factor in regulating gene 
expression, RLG did not appear to impact gene expression greatly. This could 
indicate that normal gene expression changes induced by low glucose are blunted 
by RLG. 
Despite the success in identifying multiple DEGs and enriched gene ontologies, 
there are still opportunities for more refined analysis. The DESeq2 analysis for 
differentially expressed genes was carried out using a series of contrasts. This could 
increase the FDR by doing multiple comparisons. However, this is a relatively small 
increase in FDR, eight contrasts, compared to the comparisons between 
approximately 20,000 genes in each sample. The false discovery rate was corrected 
for using Benjamini-Hochberg corrections within contrast comparisons, but this was 
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unable to be used for the multiple contrasts performed. FDR corrections can also 
eliminate true positives, reducing their power (Benjamini et al. 1995). Following 
abundance estimation, genes with low reads are often excluded as random changes 
in a sample can have a large impact on variance (Love et al. 2014). While DESeq2 
software accounts for this in part, often genes with read counts below a manually set 
threshold are excluded from differential gene expression analysis. In this study 
genes with <5 reads across all samples were excluded from further analysis. 
However, a higher threshold could have been used which would have eliminated 
many lowly expressed genes that are unlikely to have a physiological impact and 
improved the power for detection of differentially expressed genes lost through FDR 
corrections. Additionally, the need for FDR corrections could be avoided through a 
multi-factor analysis design, with subsequent post-hoc analysis. Nevertheless, this 
first pass analysis gives a good indication that HPA gene expression is differentially 
regulated by low glucose exposure.  
The differentially expressed gene sets derived from DESeq2 analysis were put into 
the web-based program Enrichr as a crisp data set with no membership weighting 
included. Crisp data sets are simple as membership to a classifying factor, or gene 
ontology in this case, is binary, i.e. yes or no, 0 or 1 (Kuleshov et al. 2016). A fuzzy 
data set is one in which membership can be partial, i.e. a value between 0 and 1. 
However, fuzzy data sets only marginally improve enrichment analysis (Kuleshov et 
al. 2016), therefore the crisp data sets used here are still valid. Nonetheless, gene 
enrichment analysis could be improved using GOseq which takes into account gene 
length (Young et al. 2010). Genes with a longer sequence are often overrepresented 
by abundance estimation which means they are more likely to be detected as being 
differentially expressed and therefore the contribution to GO enrichment is 
overestimated (Young et al. 2010). Before this data analysis is prepared for peer-
reviewed publication read length should be considered during GO analysis and, 
therefore, GOseq should be used as an alternative to Enrichr. A flaw of gene 
enrichment analysis is that it assumes each gene contributes an equal weight to the 
functional gene set it is compared to (Subramanian et al. 2005). Therefore, weighted 
gene co-expression network analysis (WGCNA) could be utilised to look for 
relationships between highly correlated gene clusters or modules that takes into 
account the weighting of gene interactions (Langfelder et al. 2008). This provides 
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more information into network connectivity rather than simple membership 
enrichment (Alexeyenko et al. 2012). The identification of hub genes would allow for 
potentially novel targets to be found and their functional significance could be 
confirmed experimentally. 
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Conclusions 
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7.1 Research questions and novelty of the study 
The purpose of this research was to characterise the effect of how hypoglycaemia-
like, low glucose treatments affected human astrocytes in isolation. In this concluding 
chapter the author presents a recapitulation of the principle findings, and places 
them in the context of current understanding. Secondly, the limitations of the studies 
and suggested future research will be discussed. Lastly, a conclusion of the work is 
presented. 
Briefly, the novel contribution of this work is that human astrocyte mitochondrial and 
glycolytic metabolism is fundamentally altered by acute and recurrent low glucose 
(RLG) which can be partially restored by recovery from RLG. Despite significant 
metabolic alterations to RLG astrocytic calcium signalling remained unaffected. But, 
release of cytokines, particularly macrophage-migration inhibitory factor (MIF) was 
increased by low glucose treatment. Lastly, for the first time low glucose-induced 
differentially expressed genes were identified in human primary astrocytes, which is 
also a resource for further data mining. 
7.2 Key outcomes of the study 
7.2.1 Chapter 3 
Astrocytic sensitivity to changes in low glucose was measured by phosphorylation 
and activation of AMPK. AMPK is necessary for neuronal glucose sensing whole-
body energy metabolism (Claret et al. 2007) and can upregulate astrocytic catabolic 
metabolism (Voss et al. 2015). HPA AMPK was activated by low glucose but, this 
was blunted by RLG, which is a novel finding in astrocytes. Moreover, RLG 
increased mitochondrial activity, which was at least in part through increased fatty 
acid dependency; while there was a concurrent decrease in coupling efficiency, likely 
mediated by increased proton leak. RLG also increased HPA glycolytic activity and 
augmented glucose reperfusion activation of glycolysis. Through these metabolic 
adaptations astrocytes can sustain both intracellular nucleotide content and ratios, 
as well as lactate release. Lastly, the metabolic adaptions by HPA cells induced by 
RLG could be restored by maintenance in euglycaemia-like glucose concentrations. 
This chapter also showed important differences in the metabolic phenotype between 
HPA and U373 astrocytoma cells. U373 cells were less dependent on fatty acid or 
pyruvate oxidation and had increased glutamine metabolic flexibility. 
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7.2.2 Chapter 4 
Previous studies have shown activation of astrocytes to low glucose exposure, the 
ability to sense hypoglycaemia and roles in CRR (Marty et al. 2005, McDougal et al. 
2013a, McDougal et al. 2013b, Chen et al. 2016, Rogers et al. 2016, Rogers et al. 
2018). As calcium signalling incurs a significant metabolic cost, it was hypothesised 
that calcium signalling would be elevated by acute and dysregulated by RLG 
treatment. Conversely, it was found that astrocytes sustain basal intracellular 
calcium levels and maintain a normal [Ca2+]i response to ATP and noradrenaline 
treatment in low glucose. Additionally, noradrenaline-induced lactate release was 
unaffected in HPA but significantly attenuated in U373 cells by low glucose. 
7.2.3 Chapter 5 
Modulation of astrocytic inflammatory signalling protects against diet induced obesity 
in mice (Buckman et al. 2015, Douglass et al. 2017). As astrocytes have an 
inflammatory function in the CNS, a cytokine screen was performed to identify 
cytokines in HPA conditioned media following RLG. Several targets of interest were 
identified and further validated using targeted ELISAs. MIF maintained a consistent 
but non-significant trend to be increased by RLG. To allow for further accumulation a 
24 hour low glucose exposure was used which significantly increased MIF release 
from U373 cells. This is a novel finding and interesting as MIF is detrimental to 
diabetes and dementia. 
7.2.4 Chapter 6 
RNA-sequencing was used as an unbiased screen for RLG-induced differential gene 
expression in HPA cells. Whilst a preliminary analysis, further gene ontology 
investigation demonstrated several mitochondrial-associated genes which may 
underlie the changes to mitochondrial function seen in chapter 3. Additionally, 
endoplasmic reticulum-associated gene ontologies were significantly altered by RLG 
which is has not been shown to be associated with low glucose in astrocytes before. 
Interestingly, this may also underpin mitochondrial changes seen in chapter 3. ER 
stress increases mitochondrial respiration to improve cell survival (Knupp et al. 
2018). Therefore, if the gene ontologies identified in ER stress do translate to actual 
protein misfolding then this may also contribute to the mitochondrial stress in chapter 
3. This could be tested by inhibiting or activating ER stress and assessing whether 
mitochondrial disruption could be rescued or exacerbated during RLG. Lastly, 
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several inflammatory markers were also differentially expressed by glucose variation 
which corroborates data from chapter 5. Mitochondria that excessively produce 
ROS, which can be induced by fatty acid oxidation (St-Pierre et al. 2002), activate 
the NLRP3 inflammasome complex which leads to IL-1β production and increased 
cytokine signalling (Zhou et al. 2010). Perhaps ER stress-induced mitochondrial 
alterations may modulate the inflammatory response to low glucose. 
7.3 Relationships to previous research 
Since the turn of the millennium, the specific role of astrocytes sensing low glucose 
has been discovered (Marty et al. 2005, McDougal et al. 2013a, McDougal et al. 
2013b, Chen et al. 2016, Rogers et al. 2016, Rogers et al. 2018). In chapter 3 it was 
shown that astrocytes react to low glucose by increasing AMPK phosphorylation and 
activity, a mechanism known in glucose-sensing neurons (Claret et al. 2007). 
McDougal et al, demonstrated that in vitro glucose deprivation of NTS astrocytes 
stimulates astrocytic Ca2+ signalling (McDougal et al. 2013a). Additionally, 
modulation of Ca2+ signalling in astrocytes can bi-directionally control food intake 
(Chen et al. 2016). While these authors have shown a change in [Ca2+]i to be 
involved in calcium signalling, this was not seen in the HPA or U373 cells (see 
chapter 4). As the primary signalling modality of astrocytes is based on Ca2+ this was 
unexpected and contradicts the literature. Nevertheless, fluorocitrate-induced 
inhibition of glial metabolism is detrimental to the neuronal response to low glucose 
(McDougal et al. 2013b, Rogers et al. 2016, Rogers et al. 2018). For the first time, 
the studies presented in this thesis characterise the metabolic alterations of human 
astrocytes to acute and RLG. Astrocytes become more dependent on fatty acid 
metabolism to increase mitochondrial respiration. The increased mitochondrial 
metabolism and fuel switching may facilitate the protection of astrocytic intracellular 
nucleotide levels and delay the onset of low glucose sensing. There was also an 
increase in basal AMPK phosphorylation after RLG compared to control which could 
increase catabolic processes to maintain intracellular nucleotide levels, but also alter 
metabolic phenotype; AMPK activation disinhibits fatty acid oxidation (Minokoshi et 
al. 2002, Yamauchi et al. 2002), for example, and may be increasing the 
dependency on fatty acids seen in the HPA cells. 
Hypoglycaemia increases inflammatory cytokine levels in humans (Gogitidze Joy et 
al. 2010, Wright et al. 2010). Cytokines, such as IL-6, can directly modulate neuronal 
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metabolism, altering the hypothalamic pituitary adrenal axis for example (Naitoh et 
al. 1988, Späth-Schwalbe et al. 1994). Additionally, disruption of astrocyte NFκB 
signalling protects against diet induced obesity (Buckman et al. 2015, Douglass et al. 
2017). The studies presented in chapter 5 demonstrate astrocytic cytokine release in 
acute low glucose which was exacerbated by RLG, supporting data showing RH 
increases cytokine production in humans (Joy et al. 2015). Interestingly, in chapter 6, 
RNA-sequencing found differentially expressed genes involved with inflammatory 
signalling which also implicates astrocytes as inflammatory mediators of the 
response to hypoglycaemia. RNA-sequencing also corroborated findings from 
chapter 3 and demonstrated significant changes in mitochondrial associated gene 
ontologies.  
7.4 Limitations the study 
While specific limitations within each preceding chapter have been covered in the 
discussion, there are more general limitations of this experimental paradigm. These 
studies were a characterisation of astrocytes in isolation, in vitro which should be 
confirmed in more complete experimental models, i.e. in vivo. It is known the gene 
expression of astrocytes in vitro differs from in vivo (Passaquin et al. 1994). 
Astrocytes are a heterogeneous cell type (Wang et al. 2008) with significant 
differences in neurotransmitter sensitivity when astrocytes from different brain 
regions are cultured in vitro (Schousboe et al. 1979). Therefore, it would be 
important to study astrocytes from different brain regions, in situ, to account for 
astrocyte heterogeneity. Furthermore, these astrocytes were isolated from a sub-
ventricular grey matter region of a 17-year old male. Therefore, it is unknown which 
region they are from and what impact this has on their morphology. Additionally, in 
situ astrocytes have many thousands of processes (Bushong et al. 2002) which 
cannot be replicated without the complex interaction with both other cell types and a 
three-dimensional (3D) extracellular matrix. Indeed, 3D cultures can greatly alter 
cellular behaviour (Weaver et al. 1997). As such, both the HPA and U373 cells had a 
relatively simple morphology. The input of signalling molecules from other cell types 
and the interstitial microenvironment is replaced in culture with supplementation with 
foetal bovine serum which differs from normal physiology (Foo et al. 2011). 
Furthermore, in vitro usage of animal and human derived products can differentially 
affect cell phenotype and expression profile (van der Valk et al. 2010). U373 cells 
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are an astrocytoma cell line, cancerous, and therefore have fundamentally different 
behaviour and metabolism (Warburg et al. 1936). Therefore, metabolic challenges of 
these cells would also not precisely replicate the physiological setting; but, this is 
why human primary astrocytes were used where possible. 
Nevertheless, while no cell culture model can fully replicate their normal environment 
this experimental paradigm has some advantages. Firstly, the characterisation of 
isolated astrocytes enables a resolution of cellular behaviour that is not easily 
achieved in vivo. For example, measuring mitochondrial and glycolytic metabolism 
from just astrocytes in vivo would not be possible with the current technology 
available. Again, the separation of different brain cell types allows for distinct 
transcriptome and proteome profiling with subsequent comparisons between cell 
types (Cahoy et al. 2008). While these studies have their advantages further 
validation in vivo is required and future experiments should address this. For 
example, through the use of viral vector injections requiring the GFAP promotor 
could be used to modulate gene expression in astroglial cells specifically (Brenner et 
al. 1994). Mechanistic questions could be answered by inhibiting or enhancing 
expression of genes involved in a target process. One could test whether astrocytic 
fatty acid usage modulates the counterregulatory response. For example, if CPT1-a 
expression is reduced, does this improve the counterregulatory response? 
7.5 Future directions 
Ultimately, the aim of this thesis is to elucidate mechanisms by which astrocytes 
respond to acute and recurrent low glucose. This forms the fundamental research 
that can be expanded upon to improve hypoglycaemia detection in people with 
impaired hypoglycaemia awareness, and to better understand astrocytic roles in 
whole-body energy homeostasis. 
Astrocytic support of neuronal cells relies on provision of metabolic support (Pellerin 
et al. 2012). Beyond direct energy substrate production astrocytes directly contribute 
to the metabolically costly glutamate-glutamine cycle (Silver et al. 1997), as 
mentioned in the discussion of chapter 3. Therefore, mitochondrial dysfunction may 
attenuate the required Na+ homeostasis for glutamate signalling which would impair 
glutamate recycling. If this hypothesis is correct, there are two implications. Firstly, 
excess glutamate accumulation in the synaptic cleft, by insufficient astrocytic 
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glutamate uptake, could lead to excitotoxicity (Rothstein et al. 1996). However, after 
RH in rats glutamate levels are decreased in the VMH, which was due to neuronal-
astrocyte glutamate-glutamine recycling dysfunction (Chowdhury et al. 2017). 
Decreased glutamate released, from neurons, could be due to a failure of astrocytes 
to recycle the glutamate to glutamine and provide it to neurons. Strategies that 
restore glutamate-glutamine cycle functionality may therefore improve the normal 
hypoglycaemia-induced glutamate release in the VMH. One such method would be 
to enhance system N amino acid transporter 3 (SNAT3) activity as it is the primary 
glutamine exporter in astrocytes (Boulland et al. 2002, McKenna 2007). 
Hypothetically, increased SNAT3 expression would increase glutamine release from 
astrocytes and supply neurons with more glutamine to increase glutamate synthesis. 
Interestingly, knocking out SNAT3 results in hypoglycaemia in mice (Chan et al. 
2016). Moreover, a mouse Nuclear factor-erythroid 2-related factor 2 (Nrf2) KO 
model decreases SNAT3 expression (Lister et al. 2018) and worsens RH-associated 
brain damage in mice too (McNeilly et al. 2016). Therefore, if the inverse is true, an 
NRF2 activator, such as dimethyl fumarate (commercially available as Tecfidera, and 
safe for human consumption) (Linker et al. 2011), could increase SNAT3 expression 
in astrocytes and improve glutamate-glutamine recycling. 
The mechanism by which this mitochondrial dysfunction occurs is not fully elucidated 
yet. One driver in the metabolic phenotype change may be due to inflammatory 
signalling. Changes in mitochondrial function, for example increased ROS 
production, can increase inflammatory signalling (Zhou et al. 2010). Additionally, if 
ER stress is increased by low glucose as indicated by RNA-seq in chapter 6, 
unfolded proteins may occur triggering the unfolded protein response (UPR) and 
increasing ER stress. In itself, this can lead to increased mitochondrial respiration 
(Knupp et al. 2018). Interestingly, MIF, a cytokine released in response to low 
glucose from U373 cells, as shown in chapter 5, causes mitochondrial dysfunction in 
cardiac cells by disrupting cytoskeletal components (Preau et al. 2013). Therefore, 
low glucose-induced MIF release may contribute to the mitochondrial changes seen 
in chapter 3. To test the hypothesis that the inhibition of MIF action would prevent or 
reduce mitochondrial dysfunction, cells could be treated with RLG, or rats with RH 
with or without an inhibitor of MIF, for example ISO-1 (Al-Abed et al. 2011). If ISO-1 
reduces RLG induced mitochondrial dysfunction the subsequent effects on the CRR 
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could be measured by measuring glucose infusion rates or counterregulatory 
hormone release during an acute hyperinsulinaemic-hypoglycaemic clamp. 
It is known that strict glycaemic control and avoidance of hypoglycaemia can lead to 
a restoration of hypoglycaemia awareness (Fritsche et al. 2001). Similarly, the 
mitochondrial adaptations induced by RLG could be partially restored in vitro by 
stopping low glucose treatments and maintenance in 2.5 mM glucose or stock 
media. However, whether or not these changes are completely reverted given 
sufficient time should be investigated with a longer time period, as the effects of a 
single hypoglycaemic episode can last for up to a week in humans (Chow et al. 
2014b). An issue with longer duration treatments in vitro is that cell division occurs 
which may affect the outcome of treatment. This could be addressed by using 
dibutyryl cAMP which matures the astrocyte phenotype and reduces division rates 
(Wang et al. 2008, Paco et al. 2016). 
The adaptation of the astrocytes to increase fatty acid dependency could cause 
increased ROS production (St-Pierre et al. 2002). This coincides with elevated 
proton leak, a mitochondrial defence against ROS (Skulachev 1998, Tonkonogi et al. 
2000). Therefore, oxidative stress may be increasing within the cell or specifically in 
the mitochondrial compartment, which could damage mitochondrial function 
(Kowaltowski et al. 1999). This could be investigated using intracellular ROS 
fluorescent probes or using electron paramagnetic resonance techniques. 
Additionally, the increased fatty acid dependency may allow for astrocytic nucleotide 
levels to be maintained even in low glucose. Therefore, increased fatty acid 
dependency may prevent the appropriate astrocytic response to low glucose and 
inhibit normal CRR. This could be investigated by modulating fatty acid activity in 
vivo by overexpressing CPT1-a in glial cells using a Gfap promotor, or constitutively 
activating AMPK to disinhibit fatty acid uptake. Subsequently, the effect of this 
change in fatty acid metabolism on CRR could be tested using an acute 
hyperinsulinaemic-hypoglycaemic clamp and measuring the counterregulatory 
hormone production. The hypothesis being that increased glial fatty acid dependency 
inhibits CRR. 
Lastly, the RNA-sequencing data provides a resource for further data mining. Whilst 
in the short-term multi-factor analysis and improved fuzzy GO analysis should be 
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completed, validation and functional characterisation of differentially expressed 
genes should be investigated. Furthermore, how acute and RLG affects the 
epigenetic methylation of DNA will be performed. In combination with the RNA-seq 
data this will be the first comprehensive assessment of the low glucose-induced 
changes to HPA epigenome and transcriptome. 
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Table 7.1 Key targets for future research. The table below presents a list of key targets and mechanisms revealed during this 
thesis that would be  a priority for future research. 
Target Evidence Future research questions 
Glutamate-
glutamine cycle 
RLG-induced mitochondrial dysfunction in HPA cells may be 
exacerbated when challenged with additional glutamate 
signalling which may lead to impaired glutamate-glutamine 
recycling. 
Does modulating neuron-astrocyte 
glutamate-glutamine recycling improve the 
counterregulatory response to 
hypoglycaemia? 
SNAT3 A SNAT3 KO mouse model results in hypoglycaemia and 
Nrf2 KO decreases SNAT3 expression, therefore increasing 
Nrf2 activity may enhance SNAT3 expression and increase 
glutamine export from astrocytes to improve glutamate-
glutamine recycling. 
Does dimethyl fumarate, an Nrf2 activator, 
increase SNAT3 expression in astrocytes 
and improve glutamate-glutamine recycling 
by increasing astrocytic glutamine export? 
MIF MIF causes mitochondrial dysfunction in cardiac muscle cells 
and is released from U373 and HPA cells. MIF release is 
increased by low glucose and may contribute to astrocytic 
RLG-induced mitochondrial dysfunction. 
Does blocking MIF signalling protect 
mitochondria from RLG-induced 
mitochondrial dysfunction? 
Mitochondrial ROS Fatty acid oxidation increases ROS in mitochondria. Both 
fatty acid oxidation and proton leak were increased by RLG in 
HPA cells indicating ROS may be increased by RLG. 
Does preventing ROS in astrocytes inhibit 
RLG-induced mitochondrial dysfunction? 
CPT1-a Fatty acid oxidation increases in HPA after RLG. This may be 
enabling astrocytes to maintain intracellular nucleotide levels 
Does increased fatty acid oxidation impair 
the counterregulatory response in vivo? 
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and ratios during low glucose. 
AMPK AMPK inactivation has previously been implicated in blunting 
CRR. In HPA cells RLG induced an elevated phosphorylation 
of AMPK in 2.5 mM glucose compared to control treated cells. 
Chronic AMPK activation may be increasing fatty acid 
oxidation by disinhibiting CPT1-a. 
Does chronic AMPK activation increased 
fatty acid oxidation and thus worsens the 
CRR in vivo? 
Unfolded protein 
response pathway 
RNA-seq has shown HPA cells have differentially regulated 
gene expression in pathways associated with the 
endoplasmic reticulum stress response and unfolded protein 
response pathway. This may increase ROS within the cell 
and increase cellular stress. 
How does ER-stress affect the astrocytic 
response to low glucose and does it impact 
hypoglycaemia CRR? 
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7.5 Final conclusion 
In conclusion, this thesis is a characterisation of the intrinsic responses of human 
astrocytes in response to acute and recurrent low glucose. This includes the novel 
findings that astrocytes react to low glucose and metabolism is both altered by RLG 
and recovered following RLG avoidance. While it is unlikely these changes exactly 
replicate those induced by RH in astrocytes in situ, these adaptations could be a 
protective response, or contribute to hypoglycaemia-induced CRR blunting.  
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Characterisation of HPA cells morphology and 
GFAP expression in cell culture 
  
248 
Introduction 
Due to cell culture-induced selective pressures and genetic drift cells may have no 
longer closely represent their original phenotype (Hughes et al. 2007). Furthermore, 
immortalised or cancerous cells have altered metabolic phenotypes (Warburg et al. 
1936). Indeed, U373 cells had several differences from HPA cells, discussed in 
chapter 3. Long-term cell culture and successive sub-culturing leads to genetic drift 
and divergent phenotypes (Chang-Liu et al. 1997, Sambuy et al. 2005). Furthermore, 
contamination of cell cultures with undesired cell types is common (Markovic et al. 
1998). 
Long term cell culture of HPA cells changes cellular morphology 
As a broad measure of phenotypic drift cellular morphology was assessed by 
staining for GFAP, a key marker of astrocyte phenotype (Bignami et al. 1972). A 
comparison was made between passage 11 and 18 cells (supplementary figure 1A 
and B). Note, these passage numbers encompassed the differences between which 
most experiments were carried out in this thesis. Firstly, all cells observed stained 
positive for GFAP indicating an astrocyte pure culture. Corrected total cell 
fluorescence (CTCF), a measure of staining intensity, was unchanged between 
young and old cells (supplementary figure 1C). Using built in components of the 
image analysis software FIJI (Fiji is just image J; v1.52a) shape descriptors were 
calculated and compared. Perimeter to area ratio was significantly decreased in 
passage 18 cells (supplementary figure 1D) compared to passage 11, indicating a 
decrease in morphological complexity. Roundness was not different between groups 
(supplementary figure 1E). Solidity and circularity trended (p<0.1) to be higher in 
older cells (supplementary figure 1F and H). Aspect ratio trended (p<0.1) to be lower 
in passage 18 compared to passage 11 cells. This data shows passage 18 cells 
have some morphological differences to passage 11 cells.  
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Discussion 
Phenotypic drift of cells occurs during long term cell culture (Hughes et al. 2007). 
Therefore, using cells within a narrow range of passage numbers will improve 
variability between experiments and improve reproducibility (Hughes et al. 2007). It 
is also important to ensure cell type is as expected due to large amounts of cell line 
contamination occurring in the scientific community (Markovic et al. 1998, Buehring 
et al. 2004). Therefore, HPA cells used in experimentation were used between 
passages 10-20 to minimise these problems. However, some cellular morphological 
differences were detected between passage 11 and 18 cells, indicating some 
phenotypic drift had occurred. The HPA cells did stain positive for GFAP suggesting 
they are astrocytes and as there were no cells which did not stain negative for GFAP 
it also indicates there is no contamination with another cell line. 
To determine whether any phenotypic drift that had occurred impacted the functions 
assessed in this study, comparisons could have been made between passage 10 
and 20 cells, the maximum difference in passage number, to test for significant 
differences. Additionally, to further validate cell type and possible cross 
contamination, DNA profiling could be used or markers for likely cell contaminators 
like microglia (CD11b; (Ford et al. 1995)) or neurons (NeuN; (Gusel’nikova et al. 
2015)), for example.  
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Additional detection of cytokines from human 
primary astrocyte conditioned media 
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Introduction 
Inflammation is a physiological response to noxious stimuli, however it can contribute 
to pathogenesis in many diseases (Heilbronn et al. 2008). Hypoglycaemia has 
previously been shown to stimulate the release of cytokines in man (Gogitidze Joy et 
al. 2010, Wright et al. 2010). However, the release of cytokines from isolated human 
astrocytes has not been investigated well. Therefore, a cytokine array panel was 
used to screen for cytokines that may be differentially released from astrocytes 
following RLG. 
Result 
Detection of cytokines in conditioned media from human primary astrocytes 
(HPA) exposed to recurrent low glucose (RLG) 
Cytokine release from HPA cells appears to be altered RLG. The following cytokines 
were detected in the cytokine array panel: C5/C5a, CD40L, G-CSF, GM-CSF, 
CXCL1, I-309, sICAM-1, IFN-γ (figure 7.2.1A,B,C,D,E,F,G,H), IL-1a, IL-1β, IL-1ra, IL-
2, IL-4, IL-5, IL-6, IL-8 (figure 7.2.2A,B,C,D,E,F,G,H), IL-10, IL-12-p70, IL-16, IL-17, 
IL-17E, IL-23, IL-27, IL-32a (figure 7.2.3A,B,C,D,E,F,G,H), IP10, I-TAC, sTREM-1, 
MCP-1, MIP-1A, RANTES, MIP-1B, TNF-α, and SDF-1 (figure 
7.2.4A,B,C,D,E,F,G,H,I). The expression of cytokines in the control cells was 
relatively low, with many cytokines below detection level. Comparatively, the 
expression of cytokines appeared most prevalent cells treated with antecedent RLG. 
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Discussion 
While there are many cytokines detected by the cytokine array panel it is a semi-
quantitative measure of each target. Therefore, validation with quantitative ELISAs is 
required to establish whether a cytokine is differentially regulated by low glucose 
exposure. Nevertheless, if inflammatory signalling is significantly altered by acute 
low glucose this could prove to be an exciting avenue of research to pursue. 
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Standard curves for enzyme-linked immunosorbent 
assays 
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Analysis of enzyme-linked immunosorbent assays 
To analyse ELISA data raw optical density data was extracted and put into a web-
based ELISA analysis software tool found on www.elisaanalysis.com. A 4-parameter 
logistic regression algorithm was used as recommended by manufacturers to 
generate a standard curve from samples of known concentration. The regression 
formula was as follows: 
𝑦 = 𝑑 +
𝑎 − 𝑑
1 + (
𝑥
𝑐)
𝑏
 
Where y = response value e.g. optical density, x = dose value e.g. concentration, a 
and d are the asymptotic ends, b controls the transition between the two asymptotes, 
and c is the transition point midway between the two asymptotes where the direction 
of the curve changes (Dunn et al. 2013). 
For an example of standard curves for an IL-13 ELISA, a PAI1 ELISA, and a MIF 
ELISA see supplementary figure 3.1A, B and C respectively. The sensitivity ranges 
for each ELISA are as follows: IL-13 94-6000 pg/ml, PAI1 ELISA 102-25000 pg/ml, 
and MIF ELISA 8.23-6000 pg/ml. 
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Supplementary table 1. Differentially expressed genes induced by 0.1 mM 
glucose compared to 2.5 mM glucose treated cells 
Gene ENSEMBL ID 
Base 
Mean 
log2 Fold-
Change 
lfcSE padj 
MANF ENSG00000145050 599.575 0.365 0.063 7.84E-05 
TSLP ENSG00000145777 435.295 0.588 0.104 7.84E-05 
IVNS1AB
P 
ENSG00000116679 1033.816 0.362 0.066 1.66E-04 
UBTF ENSG00000108312 646.619 -0.276 0.051 2.10E-04 
BAG3 ENSG00000151929 457.971 -0.333 0.062 2.20E-04 
TUBA1A ENSG00000167552 2943.742 -0.274 0.053 4.08E-04 
HSPA1A ENSG00000204389 125.121 -0.699 0.137 5.97E-04 
SRF ENSG00000112658 235.965 -0.387 0.077 6.51E-04 
TXNIP ENSG00000265972 752.547 -1.724 0.349 9.90E-04 
MINDY3 ENSG00000148481 477.137 0.262 0.054 1.20E-03 
EXTL3 ENSG00000012232 328.437 -0.372 0.077 1.69E-03 
MT-
ND4L 
ENSG00000212907 10950.516 0.326 0.070 3.65E-03 
FBXW7 ENSG00000109670 573.778 0.337 0.074 4.55E-03 
CLHC1 ENSG00000162994 59.805 0.650 0.144 4.63E-03 
TARS ENSG00000113407 1944.367 0.172 0.038 4.63E-03 
IRF1 ENSG00000125347 273.315 -0.340 0.075 4.63E-03 
TUBB4B ENSG00000188229 1068.985 -0.413 0.092 4.68E-03 
EIF5 ENSG00000100664 3079.852 0.219 0.049 4.80E-03 
SYNPO ENSG00000171992 59.493 -0.683 0.155 6.14E-03 
IBTK ENSG00000005700 1218.915 0.198 0.046 8.23E-03 
BCL9L ENSG00000186174 190.312 -0.518 0.120 8.60E-03 
PEX1 ENSG00000127980 378.811 0.318 0.075 1.03E-02 
PLIN3 ENSG00000105355 550.956 -0.300 0.071 1.04E-02 
SGIP1 ENSG00000118473 873.826 0.330 0.078 1.10E-02 
NAMPT ENSG00000105835 477.162 0.337 0.080 1.10E-02 
LDLR ENSG00000130164 1074.790 -0.326 0.077 1.10E-02 
MT-ND4 ENSG00000198886 
132078.26
2 
0.249 0.059 1.11E-02 
ARL4C ENSG00000188042 146.609 0.489 0.118 1.48E-02 
MVK ENSG00000110921 107.106 -0.470 0.114 1.48E-02 
FHOD1 ENSG00000135723 378.504 -0.388 0.094 1.48E-02 
XBP1 ENSG00000100219 983.400 0.237 0.058 1.67E-02 
WDR36 ENSG00000134987 597.763 0.235 0.058 1.95E-02 
CDC20 ENSG00000117399 314.827 -0.475 0.118 1.98E-02 
EHD1 ENSG00000110047 253.753 -0.377 0.094 1.98E-02 
SLC38A
1 
ENSG00000111371 443.976 0.223 0.056 2.29E-02 
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CD55 ENSG00000196352 436.637 0.266 0.067 2.32E-02 
ZC3H6 ENSG00000188177 183.543 0.422 0.107 2.32E-02 
CCDC25 ENSG00000147419 471.434 0.206 0.052 2.32E-02 
NAB2 ENSG00000166886 160.546 -0.407 0.103 2.32E-02 
LINC010
50 
ENSG00000271216 30.309 0.915 0.234 2.57E-02 
HERPUD
1 
ENSG00000051108 1060.067 0.274 0.070 2.57E-02 
CLSPN ENSG00000092853 177.633 -0.375 0.097 2.83E-02 
MTHFD2 ENSG00000065911 1050.437 0.255 0.066 2.83E-02 
MT-ATP6 ENSG00000198899 59640.661 0.187 0.048 2.83E-02 
PNMA1 ENSG00000176903 540.991 -0.217 0.056 3.09E-02 
ZNF330 ENSG00000109445 323.717 0.274 0.072 3.28E-02 
TUBE1 ENSG00000074935 144.558 0.377 0.099 3.30E-02 
E2F7 ENSG00000165891 1122.375 0.268 0.070 3.30E-02 
WSB1 ENSG00000109046 2277.164 0.290 0.077 4.02E-02 
DCTN4 ENSG00000132912 1011.598 0.160 0.043 4.08E-02 
CEP170
B 
ENSG00000099814 82.942 -0.464 0.124 4.08E-02 
AJUBA ENSG00000129474 704.902 -0.218 0.058 4.08E-02 
CENPB ENSG00000125817 279.448 -0.423 0.113 4.08E-02 
MT-ND2 ENSG00000198763 29540.481 0.162 0.043 4.08E-02 
MGAT1 ENSG00000131446 772.774 -0.280 0.075 4.16E-02 
MAP7D1 ENSG00000116871 484.820 -0.282 0.076 4.17E-02 
RND3 ENSG00000115963 2648.063 0.305 0.083 4.17E-02 
NABP1 ENSG00000173559 344.282 0.310 0.084 4.17E-02 
HECW2 ENSG00000138411 743.925 0.303 0.082 4.17E-02 
TUBA4A ENSG00000127824 314.455 -0.356 0.096 4.17E-02 
PACRGL ENSG00000163138 143.410 0.390 0.105 4.17E-02 
DBN1 ENSG00000113758 366.902 -0.359 0.097 4.17E-02 
ERMP1 ENSG00000099219 182.851 0.315 0.085 4.17E-02 
ECM2 ENSG00000106823 422.926 0.300 0.081 4.17E-02 
ABL1 ENSG00000097007 526.352 -0.287 0.078 4.17E-02 
TMEM11
6 
ENSG00000198270 107.819 0.460 0.124 4.17E-02 
MAVS ENSG00000088888 1823.207 -0.192 0.053 4.75E-02 
RELA ENSG00000173039 350.050 -0.278 0.077 4.86E-02 
CROCC
P3 
ENSG00000080947 20.235 0.807 0.223 4.92E-02 
WFS1 ENSG00000109501 165.696 -0.385 0.107 4.92E-02 
MATR3 ENSG00000015479 72.708 0.504 0.140 4.92E-02 
ZNF117 ENSG00000152926 197.044 0.336 0.093 4.92E-02 
ZNF160 ENSG00000170949 463.337 0.241 0.067 4.92E-02 
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This table shows the genes that were calculated to be significantly (p<0.05) 
differentially regulated by the software DESeq2 during a contrast of 2.5 and 0.1 mM 
glucose treated HPA cells. 
Supplementary table 2. Differentially expressed genes induced by low glucose 
compared to control treated cells 
Gene ENSEMBL ID 
Base 
Mean 
log2 Fold-
Change 
lfcSE padj 
TXNIP ENSG00000265972 746.811 -2.161 0.233 1.59E-16 
E2F7 ENSG00000165891 1165.980 0.451 0.081 1.02E-04 
IVNS1AB
P 
ENSG00000116679 1094.735 0.483 0.090 1.72E-04 
HECW2 ENSG00000138411 791.570 0.562 0.103 1.72E-04 
HSPA1A ENSG00000204389 129.631 -0.933 0.176 2.40E-04 
ATP6 ENSG00000198899 61681.992 0.284 0.055 4.59E-04 
THBD ENSG00000178726 843.004 0.363 0.073 1.01E-03 
ND4L ENSG00000212907 11177.298 0.475 0.097 1.33E-03 
RND3 ENSG00000115963 2866.415 0.436 0.093 2.00E-03 
MANF ENSG00000145050 631.756 0.405 0.086 2.00E-03 
TSLP ENSG00000145777 461.264 0.680 0.144 2.00E-03 
HSPA5 ENSG00000044574 13380.727 0.343 0.072 2.00E-03 
ARRDC4 ENSG00000140450 101.869 -0.807 0.171 2.00E-03 
TUBB4B ENSG00000188229 1065.602 -0.478 0.105 3.63E-03 
TUBA1A ENSG00000167552 3053.849 -0.310 0.069 4.00E-03 
HERPUD
1 
ENSG00000051108 1117.074 0.332 0.075 5.80E-03 
ND4 ENSG00000198886 
133291.58
0 
0.370 0.084 5.80E-03 
ADAMTS
6 
ENSG00000049192 192.668 0.679 0.154 5.92E-03 
BCL9L ENSG00000186174 182.548 -0.675 0.156 7.58E-03 
PLIN3 ENSG00000105355 572.449 -0.429 0.100 8.33E-03 
KIAA110
9 
ENSG00000138688 1367.839 0.311 0.074 1.12E-02 
TBC1D8 ENSG00000204634 824.931 0.345 0.085 1.88E-02 
LPP ENSG00000145012 2045.102 0.252 0.062 1.88E-02 
HK2 ENSG00000159399 568.131 0.364 0.091 2.06E-02 
ZC3H6 ENSG00000188177 192.734 0.535 0.133 2.06E-02 
IBTK ENSG00000005700 1239.309 0.277 0.069 2.06E-02 
UBTF ENSG00000108312 670.508 -0.310 0.077 2.06E-02 
SYNGR2 ENSG00000108639 163.828 -0.687 0.171 2.06E-02 
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LINC007
02 
ENSG00000233117 190.571 0.581 0.145 2.12E-02 
INHBA ENSG00000122641 1177.565 0.380 0.096 2.44E-02 
FMN2 ENSG00000155816 754.142 0.327 0.083 2.70E-02 
RNF181 ENSG00000168894 697.084 -0.317 0.081 2.74E-02 
FBXW7 ENSG00000109670 576.644 0.402 0.103 2.74E-02 
DNAJA1 ENSG00000086061 2855.938 -0.294 0.076 2.74E-02 
FHOD1 ENSG00000135723 376.249 -0.445 0.115 2.74E-02 
ND2 ENSG00000198763 30185.58 0.246 0.063 2.74E-02 
CDC20 ENSG00000117399 303.855 -0.535 0.139 2.76E-02 
CD109 ENSG00000156535 1376.444 0.291 0.075 2.76E-02 
CENPB ENSG00000125817 286.676 -0.529 0.137 2.76E-02 
DCAF16 ENSG00000163257 270.755 0.413 0.108 3.16E-02 
CD44 ENSG00000026508 7605.176 0.215 0.056 3.17E-02 
ZNF776 ENSG00000152443 244.777 -0.445 0.117 3.17E-02 
NAALAD
L2 
ENSG00000177694 246.646 0.514 0.136 3.57E-02 
CORO1B ENSG00000172725 194.292 -0.656 0.174 3.60E-02 
RPS28 ENSG00000233927 141.310 -0.679 0.180 3.60E-02 
VGLL3 ENSG00000206538 1238.122 0.340 0.091 3.64E-02 
HSPB1 ENSG00000106211 506.869 -0.609 0.163 3.64E-02 
EIF5 ENSG00000100664 3142.685 0.254 0.068 3.64E-02 
TTC3 ENSG00000182670 4467.921 0.228 0.061 3.64E-02 
MDM2 ENSG00000135679 1650.008 0.227 0.061 3.66E-02 
XBP1 ENSG00000100219 1057.580 0.282 0.076 3.81E-02 
EPHB4 ENSG00000196411 173.693 -0.500 0.135 3.86E-02 
RPS19 ENSG00000105372 1289.627 -0.454 0.123 3.86E-02 
CLHC1 ENSG00000162994 61.687 0.798 0.216 3.88E-02 
CTSD ENSG00000117984 207.745 -0.777 0.210 3.90E-02 
DBN1 ENSG00000113758 368.581 -0.460 0.126 4.39E-02 
EXTL3 ENSG00000012232 327.473 -0.431 0.119 4.71E-02 
LDLR ENSG00000130164 1038.284 -0.371 0.102 4.80E-02 
CDC42E
P1 
ENSG00000128283 276.332 -0.613 0.169 4.83E-02 
CXXC1 ENSG00000154832 96.564 -0.596 0.165 4.95E-02 
This table shows the genes that were calculated to be significantly (p<0.05) 
differentially regulated by the software DESeq2 during a contrast of control and low 
glucose treated HPA cells. 
Supplementary table 3. Differentially expressed genes induced by antecedent 
RLG compared to low glucose treated cells 
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Gene ENSEMBL ID baseMean log2FoldChange lfcSE padj 
THBD ENSG00000178726 840.365 -0.496 0.071 5.82E-08 
RND3 ENSG00000115963 2962.663 -0.446 0.089 4.48E-03 
MANF ENSG00000145050 647.956 -0.439 0.092 5.83E-03 
TSLP ENSG00000145777 480.599 -0.666 0.139 5.83E-03 
XBP1 ENSG00000100219 1066.535 -0.371 0.078 5.83E-03 
IVNS1ABP ENSG00000116679 1150.191 -0.438 0.096 1.32E-02 
DEPP1 ENSG00000165507 424.987 0.547 0.121 1.32E-02 
SYNPO ENSG00000171992 63.930 0.986 0.230 2.89E-02 
ESCO2 ENSG00000171320 169.325 0.542 0.127 2.89E-02 
BCL9L ENSG00000186174 194.479 0.740 0.173 2.89E-02 
LDLR ENSG00000130164 1132.249 0.497 0.115 2.89E-02 
CDC20 ENSG00000117399 330.960 0.657 0.157 3.08E-02 
EREG ENSG00000124882 3885.744 -0.430 0.103 3.08E-02 
EXTL3 ENSG00000012232 343.269 0.458 0.109 3.08E-02 
SMOX ENSG00000088826 14.605 1.834 0.437 3.08E-02 
TXNIP ENSG00000265972 736.275 2.072 0.502 3.70E-02 
This table shows the genes that were calculated to be significantly (p<0.05) 
differentially regulated by the software DESeq2 during a contrast of low glucose and 
antecedent RLG treated HPA cells. 
Supplementary table 4. Significantly affected biological process gene 
ontologies caused by acute low glucose treatment compared to control 
Term 
Adjusted 
P-value Genes 
negative regulation of intrinsic apoptotic 
signaling pathway (GO:2001243) 0.00002 
DNAJA1;XBP1;MDM2;
HSPB1;HERPUD1;HS
PA1A 
response to unfolded protein (GO:0006986) 0.00007 
DNAJA1;HSPA5;HSPB
1;HERPUD1;HSPA1A 
negative regulation of programmed cell death 
(GO:0043069) 0.001 
DNAJA1;XBP1;HSPA5;
TSLP;HSPB1;FMN2;C
D44;EPHB4;HSPA1A 
negative regulation of endoplasmic reticulum 
stress-induced intrinsic apoptotic signaling 
pathway (GO:1902236) 0.002 
XBP1;HERPUD1;HSP
A1A 
negative regulation of apoptotic process 
(GO:0043066) 0.002 
DNAJA1;XBP1;HSPA5;
TSLP;HSPB1;FMN2;C
D44;EPHB4;HSPA1A 
IRE1-mediated unfolded protein response 
(GO:0036498) 0.003 
XBP1;HSPA5;CXXC1;
EXTL3 
regulation of endoplasmic reticulum stress- 0.003 XBP1;HERPUD1;HSP
267 
induced intrinsic apoptotic signaling pathway 
(GO:1902235) 
A1A 
negative regulation of response to 
endoplasmic reticulum stress (GO:1903573) 0.004 
XBP1;HERPUD1;HSP
A1A 
positive regulation of ubiquitin-protein 
transferase activity (GO:0051443) 0.010 
ARRDC4;CDC20;FBX
W7 
regulation of apoptotic process (GO:0042981) 0.010 
DNAJA1;XBP1;HSPA5;
TSLP;HSPB1;FMN2;IN
HBA;CD44;EPHB4;HS
PA1A 
regulation of DNA endoreduplication 
(GO:0032875) 0.015 FBXW7;E2F7 
proteasome-mediated ubiquitin-dependent 
protein catabolic process (GO:0043161) 0.015 
CDC20;HSPA5;FBXW7
;HECW2;MDM2;RNF18
1 
regulation of endoplasmic reticulum unfolded 
protein response (GO:1900101) 0.019 XBP1;HSPA5 
ATF6-mediated unfolded protein response 
(GO:0036500) 0.019 XBP1;HSPA5 
positive regulation of multicellular organismal 
process (GO:0051240) 0.019 
XBP1;RPS19;INHBA;L
DLR;BCL9L 
negative regulation of cell activation 
(GO:0050866) 0.020 THBD;LDLR 
protein localization to mitochondrion 
(GO:0070585) 0.020 DNAJA1;HK2 
negative regulation of cell division 
(GO:0051782) 0.020 TXNIP;E2F7 
regulation of lamellipodium morphogenesis 
(GO:2000392) 0.020 CD44;CORO1B 
negative regulation of cellular response to 
transforming growth factor beta stimulus 
(GO:1903845) 0.020 
CD109;BCL9L;HSPA1
A 
ubiquitin-dependent protein catabolic process 
(GO:0006511) 0.020 
CDC20;XBP1;HECW2;
TTC3;MDM2;RNF181 
negative regulation of DNA damage response, 
signal transduction by p53 class mediator 
(GO:0043518) 0.021 MDM2;CD44 
PERK-mediated unfolded protein response 
(GO:0036499) 0.021 HSPA5;HERPUD1 
negative regulation of transforming growth 
factor beta receptor signaling pathway 
(GO:0030512) 0.021 
CD109;BCL9L;HSPA1
A 
regulation of triglyceride biosynthetic process 
(GO:0010866) 0.023 FBXW7;LDLR 
negative regulation of intrinsic apoptotic 
signaling pathway by p53 class mediator 
(GO:1902254) 0.026 MDM2;CD44 
negative regulation of signal transduction by 
p53 class mediator (GO:1901797) 0.027 MDM2;CD44 
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regulation of B cell differentiation 
(GO:0045577) 0.027 XBP1;INHBA 
positive regulation of proteasomal ubiquitin-
dependent protein catabolic process 
(GO:0032436) 0.032 
MDM2;HERPUD1;HSP
A1A 
maintenance of protein localization in 
organelle (GO:0072595) 0.035 HSPA5;HK2 
positive regulation of proteasomal protein 
catabolic process (GO:1901800) 0.035 
FBXW7;MDM2;HSPA1
A 
ribosomal small subunit assembly 
(GO:0000028) 0.037 RPS28;RPS19 
negative regulation of transmembrane receptor 
protein serine/threonine kinase signaling 
pathway (GO:0090101) 0.037 
CD109;BCL9L;HSPA1
A 
regulation of transforming growth factor beta 
receptor signaling pathway (GO:0017015) 0.039 
CD109;BCL9L;HSPA1
A 
negative regulation of cell cycle process 
(GO:0010948) 0.040 FBXW7;MDM2;E2F7 
cellular response to unfolded protein 
(GO:0034620) 0.043 HSPA5;HSPA1A 
positive regulation of erythrocyte differentiation 
(GO:0045648) 0.043 INHBA;HSPA1A 
regulation of mitotic cell cycle phase transition 
(GO:1901990) 0.044 
CDC20;TUBA1A;HEC
W2;TUBB4B 
positive regulation of immune effector process 
(GO:0002699) 0.046 XBP1;RPS19 
chaperone mediated protein folding requiring 
cofactor (GO:0051085) 0.046 HSPA5;HSPA1A 
regulation of DNA damage response, signal 
transduction by p53 class mediator 
(GO:0043516) 0.047 MDM2;CD44 
negative regulation of wound healing 
(GO:0061045) 0.047 THBD;CD109 
regulation of protein catabolic process 
(GO:0042176) 0.047 HECW2;MDM2;FMN2 
This table shows the biological process gene ontologies that were calculated to be 
significantly (p<0.05) differentially regulated by the software EnrichR from a list of 
gene differentially regulated by 0.1 mM glucose compared to 2.5 mM glucose HPA 
cells. 
Supplementary table 5. Significantly affected biological process gene 
ontologies caused by antecedent RLG treatment compared to acute low 
glucose 
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Term 
Adjusted 
P-value Genes 
positive regulation of interleukin-6 production 
(GO:0032755) 
0.0017 XBP1;TSLP;EREG 
positive regulation of multicellular organismal 
process (GO:0051240) 
0.0026 
XBP1;LDLR;EREG;BC
L9L 
negative regulation of cell activation 
(GO:0050866) 
0.0034 THBD;LDLR 
positive regulation of immune response 
(GO:0050778) 
0.0380 XBP1;EREG 
cholesterol homeostasis (GO:0042632) 0.0380 XBP1;LDLR 
IRE1-mediated unfolded protein response 
(GO:0036498) 
0.0380 XBP1;EXTL3 
keratinocyte differentiation (GO:0030216) 0.0380 TXNIP;EREG 
sterol homeostasis (GO:0055092) 0.0380 XBP1;LDLR 
regulation of DNA replication (GO:0006275) 0.0380 ESCO2;EREG 
epidermal cell differentiation (GO:0009913) 0.0411 TXNIP;EREG 
positive regulation of defense response 
(GO:0031349) 
0.0416 TSLP;EREG 
positive regulation of cytokine secretion 
(GO:0050715) 
0.0416 XBP1;TSLP 
regulation of interleukin-5 secretion 
(GO:2000662) 
0.0418 TSLP 
regulation of smooth muscle cell differentiation 
(GO:0051150) 
0.0418 EREG 
negative regulation of macrophage activation 
(GO:0043031) 
0.0418 LDLR 
regulation of microglial cell activation 
(GO:1903978) 
0.0418 LDLR 
sterol import (GO:0035376) 0.0418 LDLR 
positive regulation of B cell differentiation 
(GO:0045579) 
0.0418 XBP1 
cholesterol import (GO:0070508) 0.0418 LDLR 
polyamine biosynthetic process (GO:0006596) 0.0418 SMOX 
negative regulation of smooth muscle cell 
differentiation (GO:0051151) 
0.0418 EREG 
regulation of lysosomal protein catabolic 
process (GO:1905165) 
0.0418 LDLR 
regulation of interleukin-13 production 
(GO:0032656) 
0.0418 TSLP 
positive regulation of amyloid-beta clearance 
(GO:1900223) 
0.0418 LDLR 
regulation of endoplasmic reticulum unfolded 
protein response (GO:1900101) 
0.0418 XBP1 
intestinal lipid absorption (GO:0098856) 0.0418 LDLR 
positive regulation of triglyceride biosynthetic 
process (GO:0010867) 
0.0418 LDLR 
cellular biogenic amine catabolic process 0.0418 SMOX 
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(GO:0042402) 
positive regulation of production of molecular 
mediator of immune response (GO:0002702) 
0.0418 XBP1 
cellular triglyceride homeostasis 
(GO:0035356) 
0.0418 XBP1 
regulation of MHC class II biosynthetic process 
(GO:0045346) 
0.0418 XBP1 
regulation of immunoglobulin production 
(GO:0002637) 
0.0418 XBP1 
response to interleukin-4 (GO:0070670) 0.0418 XBP1 
negative regulation of nitrogen compound 
metabolic process (GO:0051172) 
0.0418 LDLR 
regulation of nitrogen compound metabolic 
process (GO:0051171) 
0.0418 LDLR 
positive regulation of synapse maturation 
(GO:0090129) 
0.0418 CDC20 
regulation of immunoglobulin secretion 
(GO:0051023) 
0.0418 XBP1 
chylomicron remnant clearance (GO:0034382) 0.0418 LDLR 
regulation of synapse maturation 
(GO:0090128) 
0.0418 CDC20 
negative regulation of fibrinolysis 
(GO:0051918) 
0.0418 THBD 
adipose tissue development (GO:0060612) 0.0418 XBP1 
intestinal cholesterol absorption (GO:0030299) 0.0418 LDLR 
regulation of mast cell activation 
(GO:0033003) 
0.0418 TSLP 
positive regulation of immunoglobulin secretion 
(GO:0051024) 
0.0418 XBP1 
ATF6-mediated unfolded protein response 
(GO:0036500) 
0.0418 XBP1 
fatty acid homeostasis (GO:0055089) 0.0418 XBP1 
regulation of amyloid-beta clearance 
(GO:1900221) 
0.0418 LDLR 
transcription, DNA-templated (GO:0006351) 0.0418 
IVNS1ABP;XBP1;ERE
G 
intracellular cholesterol transport 
(GO:0032367) 
0.0418 LDLR 
positive regulation of epidermal growth factor-
activated receptor activity (GO:0045741) 
0.0418 EREG 
regulation of interleukin-6 biosynthetic process 
(GO:0045408) 
0.0418 EREG 
positive regulation of interleukin-5 production 
(GO:0032754) 
0.0418 TSLP 
regulation of cell motility (GO:2000145) 0.0418 RND3;EREG 
positive regulation of cellular biosynthetic 
process (GO:0031328) 
0.0418 LDLR;EREG 
cellular response to interleukin-4 0.0418 XBP1 
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(GO:0071353) 
neuron differentiation (GO:0030182) 0.0418 XBP1;MANF 
regulation of amyloid fibril formation 
(GO:1905906) 
0.0418 LDLR 
positive regulation of cell proliferation 
(GO:0008284) 
0.0418 XBP1;TSLP;EREG 
positive regulation of interleukin-13 production 
(GO:0032736) 
0.0418 TSLP 
skin development (GO:0043588) 0.0418 TXNIP;EREG 
positive regulation of response to external 
stimulus (GO:0032103) 
0.0418 THBD;TSLP 
positive regulation of macromolecule 
biosynthetic process (GO:0010557) 
0.0418 XBP1;EREG 
positive regulation of cellular component 
organization (GO:0051130) 
0.0418 CDC20;LDLR 
positive regulation of cellular process 
(GO:0048522) 
0.0418 XBP1;TSLP;EREG 
neuron development (GO:0048666) 0.0418 XBP1;MANF 
negative regulation of cell division 
(GO:0051782) 
0.0442 TXNIP 
negative regulation of myotube differentiation 
(GO:0010832) 
0.0442 XBP1 
positive regulation of endoplasmic reticulum 
unfolded protein response (GO:1900103) 
0.0453 XBP1 
regulation of cytokine biosynthetic process 
(GO:0042035) 
0.0453 EREG 
polyamine metabolic process (GO:0006595) 0.0453 SMOX 
positive regulation of cell differentiation 
(GO:0045597) 
0.0453 XBP1;BCL9L 
negative regulation of muscle cell 
differentiation (GO:0051148) 
0.0456 EREG 
negative regulation of hemostasis 
(GO:1900047) 
0.0456 THBD 
cellular response to low-density lipoprotein 
particle stimulus (GO:0071404) 
0.0456 LDLR 
positive regulation of triglyceride metabolic 
process (GO:0090208) 
0.0456 LDLR 
positive regulation of leukocyte activation 
(GO:0002696) 
0.0456 TSLP 
regulation of triglyceride biosynthetic process 
(GO:0010866) 
0.0456 LDLR 
negative regulation of endoplasmic reticulum 
stress-induced intrinsic apoptotic signaling 
pathway (GO:1902236) 
0.0456 XBP1 
regulation of B cell differentiation 
(GO:0045577) 
0.0456 XBP1 
regulation of fibrinolysis (GO:0051917) 0.0456 THBD 
negative regulation of coagulation 
(GO:0050819) 
0.0456 THBD 
272 
positive regulation of response to endoplasmic 
reticulum stress (GO:1905898) 
0.0456 XBP1 
positive regulation of response to cytokine 
stimulus (GO:0060760) 
0.0456 TSLP 
negative regulation of platelet activation 
(GO:0010544) 
0.0456 THBD 
positive regulation of lymphocyte differentiation 
(GO:0045621) 
0.0456 XBP1 
positive regulation of secretion (GO:0051047) 0.0456 XBP1 
heparan sulfate proteoglycan biosynthetic 
process (GO:0015012) 
0.0456 EXTL3 
establishment or maintenance of actin 
cytoskeleton polarity (GO:0030950) 
0.0456 RND3 
cellular biogenic amine biosynthetic process 
(GO:0042401) 
0.0456 SMOX 
negative regulation of striated muscle cell 
differentiation (GO:0051154) 
0.0456 XBP1 
positive regulation of cytokine production 
(GO:0001819) 
0.0456 TSLP;EREG 
positive regulation of signal transduction 
(GO:0009967) 
0.0456 XBP1;TSLP 
long-term memory (GO:0007616) 0.0472 LDLR 
positive regulation of interleukin-6 secretion 
(GO:2000778) 
0.0472 XBP1 
positive regulation of STAT cascade 
(GO:1904894) 
0.0478 TSLP 
positive regulation of immunoglobulin 
production (GO:0002639) 
0.0478 XBP1 
regulation of chemokine production 
(GO:0032642) 
0.0478 TSLP 
regulation of myotube differentiation 
(GO:0010830) 
0.0478 XBP1 
anion homeostasis (GO:0055081) 0.0478 XBP1 
regulation of platelet activation (GO:0010543) 0.0478 THBD 
cellular response to interleukin-7 
(GO:0098761) 
0.0478 TSLP 
positive regulation of blood coagulation 
(GO:0030194) 
0.0478 THBD 
interleukin-7-mediated signaling pathway 
(GO:0038111) 
0.0478 TSLP 
dopaminergic neuron differentiation 
(GO:0071542) 
0.0488 MANF 
regulation of endoplasmic reticulum stress-
induced intrinsic apoptotic signaling pathway 
(GO:1902235) 
0.0488 XBP1 
heparan sulfate proteoglycan metabolic 
process (GO:0030201) 
0.0488 EXTL3 
mRNA transcription (GO:0009299) 0.0488 EREG 
positive regulation of transcription from RNA 0.0488 XBP1 
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polymerase II promoter involved in cellular 
response to chemical stimulus (GO:1901522) 
hepaticobiliary system development 
(GO:0061008) 
0.0488 XBP1 
sterol transport (GO:0015918) 0.0488 LDLR 
cellular response to hexose stimulus 
(GO:0071331) 
0.0488 XBP1 
positive regulation of interleukin-10 production 
(GO:0032733) 
0.0496 TSLP 
regulation of ERBB signaling pathway 
(GO:1901184) 
0.0496 EREG 
negative regulation of response to 
endoplasmic reticulum stress (GO:1903573) 
0.0496 XBP1 
This table shows the biological process gene ontologies that were calculated to be 
significantly (p<0.05) differentially regulated by the software EnrichR from a list of 
gene differentially regulated by antecedent RLG compared to acute low glucose 
treatment. 
Supplementary table 6. Significantly affected molecular function gene 
ontologies caused by 0.1 mM glucose treatment compared to 2.5 mM glucose 
Term 
Adjusted 
P-value 
Genes 
phosphate ion binding (GO:0042301) 0.011 MTHFD2;RELA 
purine ribonucleoside triphosphate binding 
(GO:0035639) 
0.011 
TUBA1A;ABL1;TUBE1;
PEX1;TUBB4B;RND3;
TUBA4A;HSPA1A 
guanyl ribonucleotide binding (GO:0032561) 0.011 
TUBA1A;TUBE1;TUBB
4B;RND3;TUBA4A 
NADH dehydrogenase (ubiquinone) activity 
(GO:0008137) 
0.011 
MT-ND4L;MT-ND4;MT-
ND2 
NADH dehydrogenase (quinone) activity 
(GO:0050136) 
0.011 
MT-ND4L;MT-ND4;MT-
ND2 
GTP binding (GO:0005525) 0.011 
TUBA1A;TUBE1;TUBB
4B;RND3;TUBA4A 
purine ribonucleoside binding (GO:0032550) 0.011 
TUBA1A;TUBE1;TUBB
4B;RND3;TUBA4A 
cadherin binding (GO:0045296) 0.017 
EHD1;EIF5;BAG3;PLIN
3;DBN1;HSPA1A 
transcriptional activator activity, RNA 
polymerase II distal enhancer sequence-
specific binding (GO:0001205) 
0.033 SRF;RELA 
transcription factor activity, RNA polymerase II 
core promoter sequence-specific 
0.036 SRF;RELA 
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(GO:0000983) 
ubiquitin protein ligase binding (GO:0031625) 0.044 
FBXW7;WFS1;TXNIP;
RELA;HSPA1A 
histone deacetylase binding (GO:0042826) 0.044 SRF;RELA;HSPA1A 
ubiquitin-like protein ligase binding 
(GO:0044389) 
0.049 
FBXW7;WFS1;TXNIP;
RELA;HSPA1A 
This table shows the molecular function gene ontologies that were calculated to be 
significantly (p<0.05) differentially regulated by the software EnrichR from a list of 
gene differentially regulated by 0.1 mM glucose compared to 2.5 mM glucose HPA 
cells. 
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